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Gewichtszunahme, Glukoseintoleranz und vaskulären Dysfunktion führen kann. Das Ziel der vorliegen-
den Dissertation war es, Gene zu identifizieren, deren Expression sich aufgrund einer Diät hohen Fettge-
halts ändert und diese Änderung bestehen bleibt nachdem der Fettgehalt der Diät reduziert wurde. In
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sionsunterschieden (< 2.5 fach). Auf Genebene wurden 37 Gene und 46 auf Exonebene gefunden. Die
meisten der identifizierten Gene sind an der Regulation der vaskulären Funktion beteiligt. Die Validierung
der Gene carbonic anhydrase 3 (Car3, Car3) und cytochrome P450, family 2, subfamily E, polypeptide 1
(Cyp2E1, Cyp2E1) mittels quantitativer RT-PCR und Western Blot zeigte, dass die Gen- und Proteinex-
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Die Genexpression des Gens celldeath- inducing DFFA-like effector c (Cidec) ist durch die Diät hohen
Fettgehalts als auch die Verfütterung beider Diäten herunterrguliert wohingegen die Proteinexpression
hochreguliert ist. Für das Gen Dipeptidylpeptidase 10 (Dpp10) konnte nur gezeigt werden, dass die Gen-
expression durch die Diät hohen Fettgehalts als auch die Verfütterung beider Diäten, hochreguliert ist.
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sowohl eine Rolle in der Regulation der 5-Hydroxytryptamin-induzierten Vasokontraktion als auch in
der Vasorelaxation und Vasokontraktion durch Acetylcholin, spielt. Es scheint, dass reaktive Sauerstof-
fverbindungen und Stickstoffmonoxid zur Regulation beitragen. Zusammenfassend zeigen die Ergebnisse,
dass die Verfütterung einer Diät hohen Fettgehalts zu einer Gewichtszunahme, einer Glukoseintoler-
anz und zu einer Veränderung der Gefässreaktivität führen kann. Zum Teil konnten Veränderungen der
Gefässfunktion, die durch die Verabreichung einer Diät hohen Fettgehalts verursacht wurden, nicht durch
eine Reduktion des Fettgehalts rückgängig gemacht werden. Zusätzlich legen die Ergebnisse den Schluss
nahe, dass Cyp2E1 Spleissformen, die aufgrund der verschiedenen Diäten unterschiedlich exprimiert sind,
an der Regulation der vaskulären Funktion beteiligt sein könnten. Zusammenfassend deuten die Resultate
darauf hin, dass Cyp2E1 eine zentrale Rolle in der Entstehung von Gefässkrankheiten beim Menschen
übernehmen könnte.
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Zusammenfassung 
Die Prävalenz für Fettleibigkeit ist weltweit gestiegen. Neueste Studien zeigen, dass 
sogar nach einer Gewichtsreduktion ein erhöhtes Risiko zur Entstehung 
kardiovaskulärer Erkrankungen besteht. Die Hauptursache für die Entstehung von 
Fettleibigkeit ist eine fettreiche Ernährung, welche zu einer Gewichtszunahme, 
Glukoseintoleranz und vaskulären Dysfunktion führen kann. Das Ziel der vorliegenden 
Dissertation war es, Gene zu identifizieren, deren Expression sich aufgrund einer Diät 
hohen Fettgehalts ändert und diese Änderung bestehen bleibt nachdem der Fettgehalt 
der Diät reduziert wurde. In dieser Arbeit wurde ein etabliertes Mausmodell für Diät-
induzierte Fettleibigkeit verwendet: Vier Wochen alte, männliche Mäuse des Stammes 
C57BL/6J wurden entweder für 30 Wochen mit einer Kontrolldiät gefüttert oder mit 
einer Diät hohen Fettgehalts oder die Mäuse wurden zunächst für 15 Wochen mit der 
Diät hohen Fettgehalts und abschliessend für 15 Wochen mit der Kontrolldiät gefüttert. 
Die Verfütterung der Diät hohen Fettgehalts führte nach 30 Wochen zu einer 
Gewichtszunahme und zu einer verminderten Glukosetoleranz. Es wurden 
unterschiedliche Auswirkungen auf die durch Phenylephrin-, 5-Hydroxytryptamin und 
Acetlycholin-induzierte Vasokontraktion in der Thorakalaorta der Mäuse, die mit der 
Diät hohen Fettgehalts gefüttert wurden als auch in den Mäusen, die beide Diäten 
erhielten, festgestellt. Eine DNA Exon Microarray Analyse, die mit Aortengewebe (n=3 
Replikate pro Gruppe) der drei Mausgruppen durchgeführt wurde, identifizierte nur 
wenige Gene mit relativ geringen Expressionsunterschieden (< 2.5 fach). Auf Genebene 
wurden 37 Gene und 46 auf Exonebene gefunden. Die meisten der identifizierten Gene 
sind an der Regulation der vaskulären Funktion beteiligt. Die Validierung der Gene 
carbonic anhydrase 3 (Car3, Car3) und cytochrome P450, family 2, subfamily E, 
polypeptide 1 (Cyp2E1, Cyp2E1) mittels quantitativer RT-PCR und Western Blot 
zeigte, dass die Gen- und Proteinexpression durch die Diät hohen Fettgehalts als auch 
die Verfütterung beider Diäten, herunterreguliert ist. Die Genexpression des Gens cell-
death-inducing DFFA-like effector c (Cidec) ist durch die Diät hohen Fettgehalts als 
auch die Verfütterung beider Diäten herunterrguliert wohingegen die Proteinexpression 
hochreguliert ist. Für das Gen Dipeptidylpeptidase 10 (Dpp10) konnte nur gezeigt 
werden, dass die Genexpression durch die Diät hohen Fettgehalts als auch die 
Verfütterung beider Diäten, hochreguliert ist. Da Cyp2E1 die grössten  und 
signifikantesten Expressionsunterschiede (2.2 fach, p<0.002) zeigte, wurde es 
ausführlicher charakterisiert. Auf der Ebene der mRNA Transkripte wurden neben dem 
vollständigen Transkript zwei neue Cyp2E1 Spleissformen in der Aorta der 
Kontrolltiere identifiziert. Die erste Spleissform enthält möglicherweise bis auf einen 
verkürzten 3`untranslatierten Bereich im Exon 9 die vollständige Cyp2E1 
Nukleotidsequenz. Der zweiten Spleissform fehlen Exon 4-6. Auf der Proteinebene 
konnte das vollständige Cyp2E1 Protein nicht detektiert werden, aber stattdessen 
wurden zwei neue Proteinisoformen von Cyp2E1 mit einer Molekulargrösse von 39 und 
 XIV 
45 kDa identifiziert. Zudem zeigte die Untersuchung der Gefässreaktivität der 
Thorakalaorta von Wildtyp und Cyp2E1-defizienten Mäusen, dass Cyp2E1 sowohl eine 
Rolle in der Regulation der 5-Hydroxytryptamin-induzierten Vasokontraktion als auch 
in der Vasorelaxation und Vasokontraktion durch Acetylcholin, spielt. Es scheint, dass 
reaktive Sauerstoffverbindungen und Stickstoffmonoxid zur Regulation beitragen. 
Zusammenfassend zeigen die Ergebnisse, dass die Verfütterung einer Diät hohen 
Fettgehalts zu einer Gewichtszunahme, einer Glukoseintoleranz und zu einer 
Veränderung der Gefässreaktivität führen kann. Zum Teil konnten Veränderungen der 
Gefässfunktion, die durch die Verabreichung einer Diät hohen Fettgehalts verursacht 
wurden, nicht durch eine Reduktion des Fettgehalts rückgängig gemacht werden. 
Zusätzlich legen die Ergebnisse den Schluss nahe, dass Cyp2E1 Spleissformen, die 
aufgrund der verschiedenen Diäten unterschiedlich exprimiert sind, an der Regulation 
der vaskulären Funktion beteiligt sein könnten. Zusammenfassend deuten die Resultate 
darauf hin, dass Cyp2E1 eine zentrale Rolle in der Entstehung von Gefässkrankheiten 
beim Menschen übernehmen könnte.  
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Summary 
The prevalence of obesity has risen worldwide. Main reason responsible for the 
development of obesity is intake of nutrition rich in fat. Recent studies suggest that 
obesity is associated with an increased risk of cardiovascular diseases even after 
reduction of body weight. Elevated body weight is frequently associated with glucose 
intolerance and vascular dysfunction. The aim of the present study was to investigate 
whether alterations in vascular reactivity are associated with changes in steady state 
mRNA expression levels and gene splicing due to high-dietary fat content and whether 
these changes sustain after high-dietary fat content is reduced. A well-established mouse 
model of diet-induced obesity was used. 4 weeks old, male C57BL/6J mice were either 
fed with a control diet (CD) or a high-fat diet (HFD) for 30 weeks or with a HFD for 15 
week followed by a CD for 15 weeks (HFD/CD). Only feeding with HFD increased 
body weight and led to an impaired glucose tolerance in mice. HFD and HFD/CD 
showed hetergenous effects on contractile responses induced by phenylephrine, 5-
hydroxytryptamine and acetylcholine in thoracic aorta of mice. Subsequent DNA exon 
microarray analysis using aortic tissue (n=3 replicates/group) from these mice revealed 
very few genes with relatively small expression changes (<2.5 fold change). At a whole 
gene level 37 genes and 46 at an exon-specific level were identified. Gene Ontology 
classification showed that most of the genes are assigned to biological processes 
involved in regulation of vascular function. mRNA and protein expression levels of the 
genes carbonic anhydrase 3 (Car3, Car3) and cytochrome P450, family 2, subfamily E, 
polypeptide 1 (Cyp2E1, Cyp2E1) were confirmed to be downregulated by HFD and 
HFD/CD using quantitative RT-PCR and Western Blot, respectively. mRNA expression 
level of cell-death-inducing DFFA-like effector c (Cidec) was downregulated whereas 
protein expression level was upregulated by HFD and HFD/CD. Dipeptidylpeptidase 10 
(Dpp10) was confirmed to be upregulated by HFD and HFD/CD only by quantitative 
RT-PCR. Cyp2E1 showed highest (fold change of 2.2) and most significant changes 
(p<0.002) in gene expression and therefore was characterized in more detail. On mRNA 
transcript level, two novel aortic Cyp2E1 mRNA transcripts were identified in the CD 
group in addition to full-length Cyp2E1. The first transcript possibly consists of the full-
length nucleotide sequence with truncated 3`untranslated region in exon 9, while the 
second transcript lacks exons 4, 5 and 6. On protein level no full-length Cyp2E1 was 
detectable but two novel aortic Cyp2E1 isoforms at 39 and 45 kDa were identified in all 
dietary treatment groups. Furthermore, vascular function experiments using thoracic 
aorta of wild type and Cyp2E1-deficient mice suggest that Cyp2E1 regulates 5-
hydroxytryptamine-induced contractions but also acetylcholine-induced relaxation and 
contraction. Possible mechanisms involve contribution of reactive oxygen species and 
nitric oxide. In conclusion, the present data show that dietary fat affects body weight, 
glucose tolerance and vascular reactivity. Some changes in vascular reactivity remained 
after dietary fat was reduced. Differential expression levels of aortic Cyp2E1 splice 
 XVI 
variants during dietary interventions and its role in the regulation of vascular function 
suggest that this molecule is a novel player in obesity-associated vascular diseases even 
after fat intake is reduced.  
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1 Introduction 
1.1 Obesity 
1.1.1 Statistical data on obesity worldwide 
Obesity has become an epidemic and over the last 30 years the prevalence of obesity 
has steadily increased worldwide (Eckel et al., 2004; Dixon, 2010). The World Health 
Organization (WHO) monitors the prevalence for obesity worldwide through the Global 
Database on Body Mass Index (BMI) (Nguyen & El-Serag, 2010). This database 
contains data of national representative surveys on obesity from countries all over the 
world. Based on these surveys, a rising trend in obesity is observed in most of the 
countries despite Denmark and Saudi Arabia in which a decreasing trend was shown 
(Nguyen & El-Serag, 2010). Data of the WHO showed that in 2005 approximately 1.6 
billion people all over the world were overweight and roughly 400 million people were 
obese (World Health Organization). Prognostic data suggest that by 2015 around 2.3 
billion people will be overweight and 700 million will be obese worldwide (Nguyen & 
El-Serag, 2010). In the USA, 149.3 million people (≥ 20 years of age) were overweight 
and obese in 2008, which is about 68 % of the population (Roger et al., 2011). In 
Switzerland, the prevalence for obesity increased from 1992-2007 from 5.4-7.2 % in 
women and from 8.6-9.7 % in men (Faeh et al., 2011). 
1.1.2 Classification of obesity 
Increased body fat mass is the main characteristic of obesity (Ogden et al., 2007). 
According to the WHO, adult overweight and obesity are defined by the BMI which is 
calculated as weight in kilograms divided by the square of height in meters (kg/m2) 
(National Institute of Health (NIH), 1998; Wyatt et al., 2006). A BMI < 18.5 is 
considered as underweight, a BMI between 18.5 to 24.9 as normal. Persons with a BMI 
of 25.0 to 29.9 are classified as overweight and with a BMI ≥ 30 as obese. Obesity is 
further divided into stage I (BMI 30.0-34.9), stage II (BMI 35.0-39.9) or stage III (BMI 
≥ 40) obesity (Figure 1-1). 
A disadvantage of this method is that it does not include factors such as gender, age, 
ethnicity or composition of the body which can have an impact on accumulation of 
body fat (Deurenberg et al., 1998). In addition to the BMI measure several other, more 
direct measures of body fat content exist, namely dual energy x-ray absorptiometry, 
skinfold thickness, bioelectrical impendance analysis, and underwater weighing 
(Deurenberg et al., 1998). 
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1.1.3 Overweight and obesity in children and adolescents 
The prevalence for childhood and adolescence overweight and obesity has increased 
enormously in the USA, but also worldwide (Ogden et al., 2002; Jolliffe & Janssen, 
2006; Ogden et al., 2010a). Janssen et al. determined the percentage of overweight and 
obese children and adolescents aged 10-16 years in 34 countries including the United 
States and several European countries in 2001-2002 (Janssen et al., 2005). The study 
demonstrated that in 26 out of 34 evaluated countries at least 10 % of children and 
adolescents were overweight and in 7 out of 34 countries, 3 % were obese. Highest 
prevalence for overweight and obesity was observed in the United States, Great Britain, 
Greece, Italy, Spain and Malta whereas lowest prevalence was found in Russia and in 
the Baltic States (Janssen et al., 2005).  
BMI in children and adolescents is an age-and gender-dependent BMI (Jolliffe & 
Janssen, 2006), also referred to as the BMI-for-age, because BMI and waist 
circumferences change in children and adolescents with growth and maturation (Guo et 
al., 1997) and varies between girls and boys (Biro et al., 2010). It is calculated as for 
adults but then compared to reference values in form of percentiles typical for children 
of same age and gender. A BMI-for-age < 5th percentile defines underweight, 5th-84th 
percentile is due to normal weight, ≥ 85th percentile but < 95th percentile defines 
overweight and a BMI-for-age of ≥ 95th percentile reflects obesity (Barlow, 2007). It is 
widely known that childhood and adolescent obesity is associated with several different 
cardiovascular risk factors mainly type 2 diabetes (Fagot-Campagna et al., 2000), 
Figure 1-1 Determination of adult Body Mass Index  
The Body Mass Index increases with gain in weight and is divided into 5 different classes. Figure adapted 
from (WebMD). 
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hypertension (Genovesi et al., 2005), and the metabolic syndrome (Cook et al., 2003). 
Additionally, obesity in children and adolescents is a predictor for the development of 
cardiovascular diseases in adulthood (Baker et al., 2007). The probability that 
overweight children and adolescents become obese in adulthood is high, particularly 
with increasing BMI (Guo & Chumlea, 1999) or if their parents are obese as well 
(Whitaker et al., 1997). Must and colleagues showed that children and adolescents who 
were obese had a high risk to develop cardiovascular diseases as adults even if they lost 
weight during adulthood (Must et al., 1992). Therefore, a lot of effort should be put in 
prevention of childhood and adolescent obesity to decrease the risk for cardiovascular 
illnesses in adulthood. Most important preventive steps include regular physical activity 
and a healthy nutrition in everyday life of young people. Fat intake, carbohydrate, 
protein intake, and the amount of food eaten every day should be adapted to the age 
(Daniels et al., 2005). Family, schools and the community should be involved in 
preventive steps.  
1.2 Health burden of obesity: Causes, consequences, and costs 
1.2.1 Causes of obesity  
Factors contributing to the development of obesity are diverse and complex. 
Common causes are increased energy intake by nutrition high in fat content, sedentary 
lifestyle, as well as genetic, social and environmental factors (Wyatt et al., 2006; 
Nguyen & El-Serag, 2010). Not only in the United States high energy intake is 
promoted in terms of cheap, high energy-dense food (“fast food”), soft drinks and 
availability in huge amounts (Hill et al., 2003), but also in many developing countries a 
trend in this direction is observed (Popkin, 2001). Urbanization and westernization more 
and more replace food high in complex carbohydrates and fibres by food high in sugar 
and fat (Drewnowski, 2000; Popkin, 2001). One major problem is that energy intake in 
terms of excess in food increases but energy expenditure in form of physical activity 
decreases. Sedentary activities as watching television and surfing in the internet increase 
(Hill et al., 2003; Nguyen & El-Serag, 2010). Dietz and Gortmaker showed that each 
additional hour of watching television per day increases the prevalence of obesity about 
2 % (Dietz & Gortmaker, 1985). Genetic predisposition is an additional factor involved 
in the development of obesity, but not many genes are known until now that can be 
associated with obesity. Single gene mutations in the leptin receptor, melanocortin-4-
receptor, pro-opiomelanocortin, and leptin gene play a role in the development of 
obesity (Andreasen & Andersen, 2009). Frayling et al. showed that single nucleotide 
polymorphisms in the fat mass and obesity gene are associated with increased BMI and 
type 2 diabetes (Frayling et al., 2007). Several other research laboratories confirmed 
this finding (Andreasen et al., 2008; Haupt et al., 2008; Hunt et al., 2008). Social 
aspects in terms of obesity are important to consider, too. Obese people often have less 
social networks and are discriminated by society (Puhl & Brownell, 2001). With lower 
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educational classifications and social status higher prevalence of obesity is observed 
(Ogden et al., 2010b). Studies showed that a higher household income improves the 
quality of food (Drewnowski & Specter, 2004). Environmental factors such as 
industrialization of countries, more jobs in which less physical activities are needed, the 
food industry which advertises unhealthy eating habits increased the prevalence for 
obesity in the society. People are not willing anymore to invest much effort and time to 
cook because convenient food is relatively cheap and easily accessible (Wyatt et al., 
2006). Other data indicate that the average caloric intake per day/per person has risen 
over the years (Nestle & Jacobson, 2000). All those different factors can have a 
significant impact on a person’s risk to become obese. 
1.2.2 Consequences of obesity 
Obesity is associated with risk of mortality. People with a BMI greater than 30 are 
highly endangered to die earlier than non obese people (Calle et al., 1999; Dixon, 
2010). Annual number of deaths related to obesity range between 110000 and 400000 
(Flegal et al., 2005; Olshansky et al., 2005). Other consequences of obesity include the 
metabolic syndrome, type 2 diabetes, and hypertension, which can lead to 
cardiovascular diseases (Field et al., 2001; Klein et al., 2004a).  
1.2.2.1 Obesity and cardiovascular disease 
One of the major risk factors for cardiovascular diseases is obesity (Abate, 2000; 
Yusuf et al., 2004). Cardiovascular diseases kill approximately 17 million people per 
year worldwide (World Health Organization). These diseases affect the heart and blood 
vessels. The most important known cardiovascular diseases are atherosclerosis, angina 
pectoris, cerebrovascular disease (main cause of stroke), coronary artery disease, 
peripheral arterial disease, and congestive heart failure (Poirier et al., 2006). The risk 
for cardiovascular morbidities is higher in obese people compared to lean individuals 
(Van Gaal et al., 2006). Since obesity is associated with promoting the development of 
insulin resistance, type 2 diabetes, metabolic syndrome and hypertension, the interaction 
of all these metabolic alterations and abnormalities contribute to the progression of 
cardiovascular diseases. The molecular mechanisms by which obesity causes 
cardiovascular diseases are still not completely understood and are therefore 
investigated intensely by researchers all over the world. A main characteristic of obesity 
is an increased waist circumference indicative of accumulation of abdominal or visceral 
fat. Visceral fat is mainly composed of adipocytes (Ibrahim, 2010) which synthesize 
and secrete several pro-inflammatory cytokines such as tumor necrosis factor alpha 
(TNF-α), interleukin-1 (IL-1), IL-6, and acute-phase protein C-reactive protein (CRP). 
Levels of inflammatory cytokines are frequently increased in obese people (Grundy, 
2004). Adipocyte-derived hormones (adipokines) such as adiponectin, leptin and 
resistin, plasminogen activation inhibitor-1 (PAI-1), and nonesterified fatty acids 
(NEFAs) (Heptulla et al., 2001; Scherer, 2006; Shoelson et al., 2006) are additional 
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molecules secreted by adipocytes (Ritchie & Connell, 2007). Adiponectin is a hormone 
exclusively secreted by adipose tissue which regulates glucose and fatty acid 
metabolism. It is known to be anti-inflammatory and anti-diabetic. In obese patients, 
levels of adiponectin are usually low. Leptin on the other hand is a hormone also 
released from adipose tissue which suppresses food intake (Friedman & Halaas, 1998) 
by binding to receptors in the hypothalamus (Elmquist et al., 1999). However, leptin 
levels are elevated in obesity which can be due to leptin resistance caused by binding of 
CRP to leptin resulting in an inhibition of leptin receptor signaling (Chen et al., 2006). 
CRP is increased and secreted by the liver in response to adipokines (Pepys & 
Hirschfield, 2003). Furthermore, serum resistin, a cysteine-rich protein, is elevated in 
obesity. It is known to be highly expressed in adipocytes and is strongly associated with 
insulin resistance (Degawa-Yamauchi et al., 2003). PAI-1 inhibits fibrinolysis which is 
usually increased in obesity and is associated with an increased risk for thrombosis 
(Grundy, 2004). It can be secreted by liver, vascular endothelium, and adipose tissue. 
An accepted explanation is that PAI-1 derived from adipose tissue is activated via 
inflammatory cytokines such as TNF- α (De Taeye et al., 2005). Obesity increases 
accumulation of triglycerides in visceral fat. Triglycerides can be cleaved to glycerol 
and NEFAs by the hormone sensitive lipase, a process called as lipolysis (Macfarlane et 
al., 2008) leading to an increase of NEFAs in the blood (Heptulla et al., 2001). 
Furthermore, these elevated levels of NEFAs increase triglyceride storage in the liver 
(Grundy, 2000) promoting the development of atherogenic dyslipidemia. It is 
characterized by high levels of triglycerides and hypercholesterolemia (elevated levels 
of low density lipoprotein (LDL) and low high density lipoprotein (HDL) cholesterol 
levels). Atherogenic dyslipidemia is a metabolic risk factor strongly correlated with the 
metabolic syndrome which is linked to the development of cardiovascular diseases 
(Ritchie & Connell, 2007). Taken together, obesity increases the amount of visceral fat 
mass which leads to alterations in the production of adipocyte-derived inflammatory 
markers, adipokines and nonesterified free fatty acids. These changes can either 
independently affect the vasculature or lead to insulin resistance resulting in type 2 
diabetes and hypertension or other diseases thereby causing an impact on the 
vasculature by decreasing nitric oxide (NO) availability and increasing the generation of 
reactive oxygen species (ROS). This leads to endothelial dysfunction, a pre-stage for the 
development of cardiovascular diseases such as atherosclerosis (Figure 1-2). Obesity 
promotes the onset of atherosclerosis, a chronic inflammatory disease of arteries in 
which accumulation of fat deposits (plaques) leads to thickening of the arterial wall. 
This consequence can disturb normal blood flow and sudden rupture of plaques can lead 
to atherothrombosis occluding the whole vessel lumen (Thim et al., 2008). 
Consequences are heart attacks (myocardial infarction) (Kubo et al., 2007) and strokes 
in the brain (ischemic stroke) (Spagnoli et al., 2004). 
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1.2.2.2 Obesity-associated burden and costs on economy  
Obesity is not only a risk factor for several diseases and death, but is an increasing 
financial burden for the economy (Nguyen & El-Serag, 2010). Costs for obesity-related 
health problems are immense due to treatments and increase in professional nursing 
staff (Friedman & Fanning, 2004). Obesity-associated expenses by health programs in 
the USA increased from 6.5 % in 1998 to 9.1 % in 2008 (Finkelstein et al., 2009). Half 
of these costs are paid by Medicaid and Medicare, which are American governmental 
health-programs covering health and medical services for disabled people and families 
with low income (Friedman & Fanning, 2004). Over the last 35 years, costs for annual 
health care have risen dramatically for aged obese patients (Wyatt et al., 2006). Thorpe 
Figure 1-2 Mechanism linking obesity to cardiovascular diseases 
TNF-α, tumor-necrosis factor-alpha; IL-1, interleukin-1; IL-6, interleukin-6; CRP, C-reactive protein; 
PAI-1, plasminogen activation inhibitor-1; NEFAs, nonesterified free fatty acids; NO, nitric oxide; ROS, 
reactive oxygen species; ↑ increase; ↓ decrease. Adapted from (Ritchie & Connell, 2007). 
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et al. investigated how obesity-associated diseases influence private health care 
expenditures between 1987 and 2002. The results showed that private health care costs 
enhanced from 2 % to 11.6 % which accounts for a rise from $3.6 billion to $36.5 
billion US dollars indicating an increase of privately insured obese people (Thorpe et 
al., 2005). In Switzerland about 7.3 % of total health care expenses were spend on 
overweight-or obesity-related diseases in 2006. Expenses on only obesity-related costs 
were approximately 0.38 % of the total gross domestic product in 2006 
(Eidgenössisches Bundesamt für Gesundheit, 2009). 
1.2.3 Treatment of obesity 
Moderate reduction of weight (mainly reduction in visceral adipose tissue) has 
beneficial effects on cardiovascular diseases (Orzano & Scott, 2004). Weight loss 
reduces the risk for type 2 diabetes (Laaksonen et al., 2005), hypertension (Mertens & 
Van Gaal, 2000), the metabolic syndrome (Gill & Malkova, 2006), and improves 
endothelial dysfunction (Ziccardi et al., 2002). Main approaches to achieve weight loss 
are physical activity, changing of food habits, pharmacological and surgical treatments 
(Ritchie & Connell, 2007). Already changes in life style can reduce the risk of 
development of type 2 diabetes up to 60 % and the metabolic syndrome up to 37 % 
(1998). Furthermore, LDL cholesterol and triglycerides are decreased and HDL 
cholesterol increases (Van Gaal et al., 1997). Commonly used drugs in the treatment of 
obesity are sibutramine (Filippatos et al., 2005), orlistat (Sjostrom et al., 1998), and 
rimonabat (Van Gaal et al., 2005). Treatment with all three drugs results in weight 
reduction and improvement of cardiovascular risk factors. Sibutramine stimulates 
noradrenergic and serotonergic activity by reducing appetite (Van Gaal et al., 1998). It 
increases HDL-cholesterol levels, but side effects such as increase in blood pressure 
(Atkinson, 1997) and heart rate (Zannad et al., 2002) can occur. Orlistat inhibits lipase 
thereby reducing fat absorption. It decreases mostly LDL-cholesterol, improves insulin 
sensitivity and fasting glucose (Swinburn et al., 2005). Orlistat is not only approved in 
the treatment of adult obesity but also in childhood obesity (Norgren et al., 2003). 
Rimonabat, a cannaboid receptor-1 inhibitor, is effectively used in the reduction of 
weight in obese patients resulting in increased HDL-cholesterol and insulin sensitivity 
(Van Gaal et al., 2005). Extreme obesity with a BMI > 40 kg/m2 is treated by bariatric 
surgery in which the stomach of obese patients is reduced by implanting a gastric band. 
It is a very efficient method to reduce weight and visceral adipose fat combined with 
improvements in cardiovascular risk factors (Hanusch-Enserer et al., 2004). This is 
controversial since studies have shown that in extreme obese individuals, who lost 
weight after gastric banding, the risk for cardiovascular diseases did not decrease 
(Busetto et al., 2004; Klein et al., 2004b). The duration of fat intake over a long period 
has negative effects on the body metabolism and often the body is not able to reverse 
these effects (Murphy et al., 2006). Brook et al. showed that weight loss over 3 months 
reduced some metabolic factors but conduit artery function did not improve (Brook et 
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al., 2004). Additionally, Skilton and coworkers confirmed that short-term weight loss is 
associated with improvements in some metabolic mediators but did not improve cardiac 
and vascular functions (Skilton et al., 2008). Maintaning weight is an important 
criterion to improve cardiovascular risk factors (Wadden et al., 1999). Regaining of 
weight after weight reduction is associated with an increase in cardiovascular risk 
factors (Hensrud et al., 1995). Important to note is that pharmacological and surgical 
approaches should only be considered if changes in nutrition and physical activity have 
failed (Flodmark et al., 2004).  
1.3 The circulatory system 
1.3.1 Organization and function of the circulatory system 
The circulatory system transports blood cells, oxygen and carbon dioxide, nutrients, 
hormones, and waste products through the body via the vascular system which is 
composed of several types of blood vessels. This system is needed to maintain body 
homeostasis. It can be further divided into the cardiovascular and lymphatic systems. 
The cardiovascular system includes the heart, a network of vessels (arteries, veins and 
capillaries) and blood whereas the lymphatic system is composed of lymph nodes, 
lymph vessels and lymph (Pugsley & Tabrizchi, 2000). The cardiovascular system will 
be discussed in more detail. The pulmonary circulation and the systemic circulation 
form the cardiovascular system. Part of the pulmonary circulation are the right heart 
(right atrium and ventricle), the lungs and deoxygenated blood. The systemic circulation 
is composed of the left heart (left atrium and ventricle), systemic organs, and 
oxygenated blood. The heart is the main organ responsible to pump the blood into the 
arterial system via the aorta, arterioles, and capillaries to provide organs with 
oxygenated blood as well as returning deoxygenated blood through the venous system 
via venules and veins back to the heart (Mohrman & Heller, 2010). This process is 
repeated and called the circulation cycle. Figure 1-3 summarizes the circulation cycle. 
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1.3.2 Types of blood vessels  
Blood vessels are divided into arteries (aorta, arterioles, and capillaries) and veins 
(venules, vein). Their main function is to transport oxygenated blood from the left heart 
to organs of the body and to return deoxygenated blood back to the heart. These vessels 
differ in vessel diameter and wall thickness. The aorta is the largest artery and consists 
of an internal diameter of 25 mm in men. It is divided into five sections: aortic root, 
ascending aorta, aortic arch, descending thoracic aorta, and abdominal aorta (Figure 
1-4). It is often referred to as conduit artery because its resistance to blood flow is low 
(Greenwald, 2007). Smaller vessels are arterioles with an internal diameter of 30 µm. 
They are referred to as resistance arteries because resistance to blood flow is very 
variable. Capillaries, with an internal vessel diameter of 5 µm, build the smallest group 
of vessels in the arterial system. Total surface of capillaries in the human body is around 
1000 m2. When blood flows through capillaries, an exchange of nutrients and oxygen 
between organs and blood happens. Therefore, these vessels are often called as 
exchange vessels. After the blood has flown through capillaries, it enters venules and 
veins to be returned back to the heart. They are involved in pumping back deoxygenated 
blood upwards of the body into the right heart. For this purpose, venules and veins 
 
Figure 1-3 The circulation cycle of the human cardiovascular system 
The cycle begins with the blood (deoxygenated) coming back from the organs and entering the right 
atrium of the heart. Then, it passes into the right ventricle followed by pumping the blood into the lungs 
in which the blood is oxygenated (pulmonary circulation). Oxygenated blood flows from the lungs into 
the left atrium of the heart to be further pumped into the left ventricle. From there, blood passes into the 
aorta which supplies the periphery of the body with oxygenated blood (Systemic circulation). Oxygenated 
and deoxygenated blood is illustrated in red and blue, respectively. Arrows indicate the direction of the 
blood flow. Figure adapted from (UrgoMedical). 
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contain one-way valves which avoid the back flow of the blood (Borysenko & Beringer, 
1984; Mohrman & Heller, 2010).  
Arteries are classified in elastic (conducting) and muscular (distributing) arteries 
(Borysenko & Beringer, 1984). Aorta, carotid artery, and renal artery are elastic arteries 
because of the huge amount of elastic fibres. This is an important feature to transport 
large blood volumes forward. Most arteries and veins are of muscular nature. These 
arteries consist of large layers of vascular smooth muscle cells (VSMCs) and less elastic 
fibres. (Pugsley & Tabrizchi, 2000) Arterioles, capillaries, venules and veins belong to 
this type of arteries. Muscular arteries play a crucial role in distributing the blood to the 
periphery (Golenhofen, 2000; Mohrman & Heller, 2010). 
1.3.3 Structure of the blood vessel wall   
Blood vessels are histological divided into three different layers termed tunica 
intima, tunica media and tunica adventitia (Pugsley & Tabrizchi, 2000). The tunica 
intima is the innermost layer containing a single layer of endothelial cells (ECs) which 
are exposed to the blood flowing through the lumen of the vessel. Additional layers are 
the subendothelium with fibro-elastic connective tissue and a layer of elastic lamina that 
stabilizes endothelial cells and provide flexibility. The tunica media consists of multiple 
layers of VSMCs, elastin fibres and external elastic lamina. The third layer, called 
tunica adventitia, is the outermost mainly containing fibro-elastic connective tissue 
(collagen) and fibroblasts (Figure 1-5). Usually, big arteries and veins are surrounded 
 
Figure 1-4 Anatomical structure of the aorta 
The aorta is divided into five distinct regions: aortic root, ascending aorta, aortic arch, descending 
thoracic aorta, and abdominal aorta. Figure adapted from (MayoClinic). 
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by the vasa vasorum, a network of small vessels, supplying large vessels with oxygen 
and nutrients (Borysenko & Beringer, 1984; Mohrman & Heller, 2010). 
One common characteristic of all types of vessels is the single layer of endothelial 
cells. Arteries have a “thick” wall because the tunica media contains besides multiple 
layers of VSMCs, a lot of elastin and collagen fibres. The tunica media of venules and 
veins is “thinner” than in arteries, because of fewer amounts of VSMCs and elastic 
fibres. Veins are more distensible, because of their “thinner” walls.   
1.3.3.1 Endothelial cells 
ECs form a tight monolayer called endothelium. It represents the interface between 
lumen and the rest of the vessel wall. ECs are involved in diverse functions. The 
endothelium is permeable for different nutrients, biological active macromolecules, and 
blood cells such as leukocytes. Additionally, ECs play an important role in 
vasculogenesis, angiogenesis, regulation of vascular tone, pro-and anti coagulation, and 
inflammation (Cines et al., 1998). Development of vascular ECs is termed 
vasculogenesis (Risau & Flamme, 1995) which begins in the embryonic state. 
Angiogenesis is defined as sprouting of ECs to expand the vascular network from 
already existing vessels (Sato et al., 1995). Regulation of vascular tone is mediated by 
ECs via the release of various vasoactive molecules having vasodilator or 
vasoconstrictor functions (Cines et al., 1998). NO is a potent vasodilator secreted from 
ECs(Mulvany, 1993). Other functions of NO include inhibition of VSMC migration 
(Marks et al., 1995) and proliferation (Garg & Hassid, 1989), platelet aggregation, 
expression of adhesion molecules on ECs, endothelin-1 production, oxidation of LDL, 
and adhesion of monocytes and platelets (Michel & Vanhoutte, 2010). An additional 
Figure 1-5 Anatomy of a blood vessel wall 
An artery is structured into three distinct layers: The tunica intima, tunica media, and tunica adventitia. 
The tunica intima contains endothelial cells (ECs). The subendothelium with the interna elastic lamina 
and elastic fibres also is referred to the tunica intima. Mainly vascular smooth muscle cells (VSMCs) and 
elastin fibres are present in the tunica media. The third layer named tunica adventitia consists of fibro-
elastic connective tissue in which fibroblasts are embedded. 
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important function of ECs is to keep a balance between antithrombotic and 
prothrombotic mechanisms. Under normal conditions an antithrombotic state is present 
in ECs whereas during injury of ECs prothrombotic properties take over (Cines et al., 
1998). The role of ECs in inflammation is pivotal. The expression of endothelial cellular 
adhesion molecules stimulate leukocytes and macrophages to roll, adhere and migrate 
through them to reach the inflammatory source (Cines et al., 1998).  
1.3.3.2 Vascular smooth muscle cells  
The flexibility of VSMCs to modify their phenotype depending on normal 
physiological and pathological conditions is essential to keep vascular homeostasis 
(Owens, 1995). Under normal condition, VSMCs are in a differentiated state and mainly 
located in the medial layer. These cells express receptors, channels, regulatory and 
contractile proteins important for the regulation of vascular tone. This is crucial to 
regulate blood vessel diameter by contraction and dilation to maintain blood flow and 
blood pressure (Owens et al., 2004). Migratory and proliferative properties as well as 
the generation of extracellular matrix are decreased in differentiated VSMCs (Owens, 
1995). The most important differentiation or maturation markers are smooth muscle α-
actin (Fatigati & Murphy, 1984), smooth muscle myosin heavy chain (Aikawa et al., 
1993), calponin (Nishida et al., 1993), smooth muscle-22 α (Nishida et al., 1993), 
caldesmon (Sobue & Sellers, 1991), and smooth muscle α-tropomyosin (Ruiz-Opazo & 
Nadal-Ginard, 1987). VSMCs are dynamic cells able to switch phenotype from a 
differentiated to a dedifferentiated state which is associated with changes in structure 
and function of the cells. This often occurs during different developmental stages of the 
vessel, vascular injury and is often found in vascular diseases such as atherosclerosis 
(Owens et al., 2004) and hypertension. An early step of atherosclerosis development is 
phenotypic switching of VSMCs from a differentiated into a dedifferentiated state in 
which the cells loose their contractile properties and which allows the cells to migrate 
from the tunica media into the tunica intima where VSMCs produce and secrete for 
example inflammatory cytokines (Campbell & Campbell, 1994; Owens et al., 2004). In 
a dedifferentiated state, VSMCs are highly migratory, proliferative and synthesis of 
extracellular matrix is increased (Owens et al., 2004). 
1.3.4 Mechanisms of vasodilatation 
ECs in the blood vessel wall are exposed to blood flow and play a pivotal role in 
regulating vascular tone by mediating vascular relaxation or contraction of VSMCs 
(Vanhoutte et al., 2009).  
One of the most important mechanisms how vasodilatation is mediated was 
described by Furchgott and Zawadzki in 1980. These authors showed that acetylcholine 
causes endothelium-dependent relaxation by release of a vasodilator molecule termed 
endothelium-dependent relaxing factor (EDRF) (Furchgott & Zawadzki, 1980). This 
important EDRF was later found to be NO (Ignarro et al., 1987). Robert F. Furchgott, 
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together with Louis J. Ignarro and Ferid Murad, received the Noble price in Medicine 
for “NO as a signaling molecule in the cardiovascular system” in 1998 (The Official 
Web Site of the Nobel Prize). Acetylcholine causes endothelium-dependent relaxation 
by stimulating the release of NO but also other substances such as adenosine 
diphosphate (ADP), bradykinin, thrombin, and prostacyclin (PGI2) bind to specific 
receptors on endothelial cells triggering relaxation of VSMCs (Lüscher & Vanhoutte, 
1990). NO is the most potent vasodilator and has a protective role against endothelial 
dysfunction and vascular diseases (Li & Forstermann, 2000). NO and L-citrulline are 
produced by converting L-arginine via endothelial NO synthase (eNOS or NOS III). 
eNOS activity is dependent on calcium (Ca2+), calmodulin, nicotinamide adenine 
dinucleotide phosphate (NADPH), oxygen (O2), and the important cofactor (6R) 5, 6, 7, 
8-tetrahydro-L-biopterine (BH4) (Forstermann & Munzel, 2006). Besides eNOS which 
is exclusively expressed in ECs, two other NO synthases are described called neuronal 
NOS (nNOS or NOS I) expressed in central and peripheral neuronal cells and inducible 
NOS (iNOS or NOS II) first found in macrophages of mice. eNOS is the most important 
enzyme amongst the other two in the vasculature, but nNOS and iNOS can also act on 
the vasculature, mainly in pathophysiological conditions (Li & Forstermann, 2000). 
Activation of eNOS begins with binding of acetylcholine to M3-muscarinic receptors 
stimulating phospholipase C (PLC) which leads to the formation of inositol 1, 4, 5-
triphosphate (IP3) and diacylglycerol (DAG) from phosphatidylinositol 4, 5-
bisphosphate (PIP2). IP3 enhances Ca2+ influx through Ca2+ channels leading to an 
increase in intracellular Ca2+. Further, Ca2+ induces activation of calmodulin which 
binds to eNOS resulting in eNOS activity and thus generation of NO and citrulline from 
L-arginine. NO diffuses from ECs to VSMCs and activates soluble guanylate cyclase 
(sGC) leading to production of cyclic guanosine 3`, 5`-monophosphate (cGMP) from 
guanosine-5'-triphosphate (GTP). Protein kinase G (PKG) is activated by cGMP 
decreasing intracellular Ca2+ in VSMCs which causes vasodilatation (Figure 1-6) 
(Avogaro & de Kreutzenberg, 2005). Besides NO, PGI2, belonging to the group of 
vasodilator prostaglandins, can be released by ECs leading to NO generation and 
relaxation of VSMCs by increase in cyclic 3`, 5`-adenosine monophosphate (cAMP). 
Increase of eNOS activity and thus release of NO leading to vasorelaxation can be 
initiated by several, different factors such as shear stress (Yan et al., 2007), estrogens 
(Scott et al., 2007), adiponectin (Zhu et al., 2008), insulin (Fisslthaler et al., 2003), and 
aldosterone. A decrease in eNOS activity reduces NO bioavailability leading to 
impairment of vasodilatation which can be caused by oxygen-derived free radicals 
(Vanhoutte et al., 2009), ageing (Bulckaen et al., 2008), obesity (Avogaro & de 
Kreutzenberg, 2005), hypercholesterolaemia (Aubin et al., 2008), hypertension 
(Damjanovic & Barton, 2008), and diabetes (Vanhoutte et al., 2009) 
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Endothelium-dependent relaxation is not only mediated by NO and PGI2 by 
activating cGMP and cAMP, respectively but also by endothelium-dependent 
hyperpolarizing factors (EDHFs) which initiate relaxation by hyperpolarization of 
VSMCs (Feletou & Vanhoutte, 2009). Known EDHFs are carbonic monoxide (CO), 
hydrogen sulfide, hydrogen peroxide (H2O2), and cyclooxygenase (COX), 
lipooxygenase (LOX) or cytochrome P450 mono-oxygenases-derived metabolites. 
Hyperpolarization of the underlying VSMCs is mediated by activation of potassium 
(K+) channels through these factors resulting in vasodilatation (Feletou & Vanhoutte, 
2009). Interestingly, in some arteries, NO and PGI2 act as EDHFs by directly 
hyperpolarizing VSMCs through activation of K+ channels (Bolotina et al., 1994; 
Parkington et al., 2004). Furthermore, vasodilator responses to NO occur more 
frequently in larger vessels whereas EDHFs are released in smaller vessels (Avogaro & 
de Kreutzenberg, 2005).  
 
Figure 1-6 Endothelium-dependent relaxation 
Activation of M3-muscarinic receptor on endothelial cells by acetylcholine activates PLC leading to 
formation of DAG and IP3 from PIP2. IP3 increases intracellular Ca2+ which activates eNOS to generate 
NO. NO diffuses from endothelial cells to vascular smooth muscle cells activating sGC which leads to an 
increase in cGMP. Then, PKG is stimulated decreasing intracellular Ca2+ resulting in vasorelaxation of 
VSMCs. EC, endothelial cell; VSMC, vascular smooth muscle cell; M3, muscarinic receptor; PLC, 
phospholipase C; PIP2, phosphatidylinositol 4, 5-bisphosphate; DAG, diacylglycerol, IP3, inositol 1, 4, 5-
triphosphate; L-Arg, L-arginine; eNOS, endothelial nitric oxide synthase, NO, nitric oxide; GTP, 
guanosine-5'-triphosphate; sGC, soluble guanylate cyclase; cGMP, cyclic guanosine 3`, 5`-
monophosphate; PKG, protein kinase G. Adapted from (Avogaro & de Kreutzenberg, 2005). 
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1.3.5 Mechanisms of vasoconstriction 
ECs can also release contractile factors, called endothelium-derived contracting 
factors (EDCFs) causing vasoconstriction of VSMCs (Vanhoutte & Tang, 2008). 
Mainly, prostanoids generated by endothelial COX are responsible for endothelium-
dependent contractions. Two COX isoforms, COX-1 and COX-2, exist. Experiments 
with COX-1-deficient and COX-2-deficient mice revealed that mainly COX-1 mediates 
prostanoid-evoked endothelium-dependent contractions (Tang et al., 2005). Other 
studies showed that endothelium-dependent contractions can also be mediated by COX-
2 (Shi et al., 2008). These contractions can be blocked by addition of non-selective 
COX inhibitors, such as meclofenamate and indomethacin (Sanchez-Ferrer & Marin, 
1990; Woods et al., 2001; Traupe et al., 2002). A reduction in NO availability either 
through inhibition of NO synthase or pathophysiological conditions such as obesity or 
hypertension favor endothelium-dependent contrations (Vanhoutte, 2009; Vanhoutte et 
al., 2009). Production of prostanoids or EDCFs is mediated by acetylcholine or ADP 
which binds to M3-muscarinic receptors or P2y purinoceptors on ECs, respectively 
(Vanhoutte, 2009). This leads to an increase in intracellular Ca2+ and activation of 
phospholipase A2 (PLA2) which acts on arachidonic acid (AA) in a way that COX 
metabolizes it to produce endoperoxides (Vanhoutte & Tang, 2008). These 
endoperoxides can cause vasoconstriction by activation of VSMCs (Vanhoutte et al., 
2005) or they are converted further into prostanoids such as PGI2, thromboxane A2 
(TXA2), prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), and prostaglandin 
F2alpha (PGF2α) (Bos et al., 2004; Norel, 2007) involved in evoking endothelium-
dependent contractions (Figure 1-7). Inhibition of TXA2 prostanoid receptors (TP) on 
VSMCs showed that cyclooxygenase-dependent prostanoids bind to these receptors 
leading to endothelium-dependent contractions(Yang et al., 2003; Vanhoutte & Tang, 
2008). 
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Another important vasoconstrictor is 5-hydroxytryptamine. It is a neurotransmitter 
and monoamine derived from tryptophan (Horn, 2003) which is known to play an 
important role in cardiovascular function since decades (Page, 1958). It has 
vasoconstrictor as well as vasodilator properties in vivo, whereas in vitro it causes 
vasoconstriction in most isolated large blood vessels (Van Nueten et al., 1985). 5-
hydroxytryptamine-induced contractions are mainly mediated by activation of 
serotonergic (S2) receptors on VSMCs (Vanhoutte et al., 1984) which can be inhibited 
by serotonergic antagonists such as ketanserin, spiperone, or methysergide (Van Nueten 
et al., 1985). Whether 5-hydroxytryptamine leads to vasoconstriction or vasodilatation 
depends on the balancing effect of various factors. Additionally, sensitivity of 5-
hydroxytryptamine differs between various vascular beds (Vanhoutte et al., 1984). 
Russel et al. showed that the EC50 (concentration at which a drug causes a half-
 
Figure 1-7 Endothelium-dependent contraction 
Acetylcholine binds to the muscarinic receptor on endothelial cells and activates PLC leading to 
formation of DAG and IP3 from PIP2. IP3 increases intracellular Ca2+ which stimulates PLA2 to activate 
the release of AA from PLs. Then AA is metabolized by COX-1 to endoperoxides which itself can cause 
endothelium-dependent contraction by binding to TP receptors on VSMCs or by conversion to other 
vasoconstrictor prostaglandins (PGI2, TXA2, PGD2, PGE2, PGF2α). EC, endothelial cell; VSMC, vascular 
smooth muscle cell; M3, muscarinic receptor; PLC, phospholipase C; PIP2, phosphatidylinositol 4, 5-
bisphosphate; DAG, diacylglycerol, IP3, inositol 1, 4, 5-triphosphate; PLs, phospholipids, PLA2, 
phospholipase A2, AA, arachidonic acid, COX-1, cyclooxygenase-1; PGI2 prostacyclin; PGI2, TXA2,
thromboxane A2; PGD2, prostaglandin D2; PGE2, prostaglandin E2; PGF2α, prostaglandin F2α; TP, TXA2 -
selective prostanoid receptor. Adapted from (Vanhoutte & Tang, 2008). 
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maximal effect) for 5-hydroxytryptamine in thoracic aorta of C57BL/6J mice is ~ 0.1 
µM (Russell & Watts, 2000) whereas in several different canine arteries EC50 values 
for 5-hydroxytryptamine varied from ~ 0.01 µM-1 µM (Van Nueten et al., 1985). 
Contractions are dependent on the influx of intracellular or extracellular Ca2+ depending 
on the blood vessel (Bolton, 1979; Van Nueten et al., 1985). An interesting feature of 5-
hydroxytryptamine is that it potentiates contractile responses to other vasoconstrictors 
such as angiotensin II (AngII), norepinephrine, prostaglandins, and histamine 
(Vanhoutte et al., 1984). 5-hydroxytryptamine-induced contractions in isolated arteries 
are augmented by hypoxia (Vanhoutte et al., 1984; Van Nueten, 1985) hypertension 
(Watts, 2002), and diet-induced obesity (Boustany-Kari et al., 2007). An intact 
endothelium can protect from 5-hydroxytryptamine-induced contractions either by 
relaxant agonist or by degrading 5-hydroxytryptamine by endothelial 
monoamineoxidase. When the endothelium is damaged, vasoconstrictor responses to 5-
hydroxytryptamine can be enhanced (Van Nueten, 1985). 
Phenylephrine is a synthetic drug structurally similar to epinephrine (Aschenbrenner 
& Venable, 2009) and a well-known vasoconstrictor (Chen et al., 1994) by acting 
through alpha1(α1)-adrenergic receptors in blood vessels, mainly located on vascular 
smooth muscle cells (Langer & Schoemaker, 1989; Piascik & Perez, 2001). Adrenergic 
receptors belong to the family of G-protein coupled receptors. Several different receptor 
subtypes exist: α1, α2, β1, β2, β3. (Piascik & Perez, 2001) α1 and α2 adrenergic receptors 
mainly regulate vascular contraction (Piascik et al., 1996). Phenylephrine causes 
vascular contraction by binding to the G-protein coupled α1-adrenergic receptor. 
Activation of this receptor leads to stimulation of PLC which is involved in the 
production of IP3 and DAG from PIP2. Then, IP3 increases intracellular Ca2+ by 
activation of Ca2+ channels and protein kinase C (PKC), leading to vasoconstriction 
(Figure 1-8) (Hein & Kobilka, 1995; Piascik et al., 1996; Guimaraes & Moura, 2001). 
Introduction 
18 
1.4 Obesity, oxidative stress, and vascular dysfunction   
ECs produce low amounts of reactive oxygen species (ROS) under normal conditions 
but these amounts increase under pathological conditions such as obesity (Traupe et al., 
2002; Taniyama & Griendling, 2003; Faraci & Didion, 2004; Mundy et al., 2007b). 
Accumulation of fat increases oxidative stress in humans and mice (Urakawa et al., 
2003) by up-regulation of NADPH oxidase and downregulation of antioxidant enzymes 
(Furukawa et al., 2004). Most important ROS in the vasculature are superoxide anion 
(O2-), H2O2, and hydroxyl radical (•OH). O2- is generated by several different enzymes 
such as NADPH oxidase, xanthine oxidase, and also eNOS. Enhanced oxidative stress 
decreases NO bioavailability (Schulz et al., 2008). Under certain conditions, mainly 
during pathophysiological conditions, eNOS produces O2- and NO when it is uncoupled 
which happens, if either L-arginine or the important cofactor BH4 is not available 
sufficiently (Kojda & Harrison, 1999). O2- can scavenge NO leading to peroxynitrite 
(ONOO-) which further lowers NO availability and thereby reducing endothelium-
dependent relaxation and favoring endothelium-dependent contractions (Vanhoutte et 
al., 2009). Expression of the important inflammatory cytokine TNFα is increased by 
high-fat diet and has been associated with obesity-related endothelial dysfunction by 
stimulating the production of O2- thereby reducing NO availability (Zhang et al., 2009). 
However, O2- can also be dismutated by the antioxidant enzyme superoxide dismutase 
(SOD) to H2O2 which acts as an EDHF causing endothelium-dependent relaxation 
 
Figure 1-8 Phenylephrine-mediated contraction of vascular smooth muscle cells 
Phenylephrine binds to α1 adrenergic receptors on VSMCs activating PLC to produce IP3 and DAG from 
PIP2. IP3 activates the release of intracellular Ca2+ and activates PKC which causes vasoconstriction of 
VSMCs. EC, endothelial cell; VSMC, vascular smooth muscle cell; α1, α1 adrenergic receptor; PIP2
phosphatidylinositol 4, 5-bisphosphate; PLC, phospholipase C; IP3, inositol 1, 4, 5-triphosphate; DAG, 
diacylglycerol; PKC, protein kinase C (Ponnuchamy & Khalil, 2009). 
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(Shimokawa, 2010). On the other hand, H2O2 can be further converted by catalase to 
H2O and O2 or to •OH by the Fenton reaction (Dikalova et al., 2001) or Haber-Weiss 
reaction (Ingelman-Sundberg & Johansson, 1984; Taniyama & Griendling, 2003; Kyaw 
et al., 2004). Interestingly, •OH enhanced endothelium-dependent relaxation in mice fed 
a high-fat diet (Mundy et al., 2007b). Furthermore, in mice high-fat diet feeding leads to 
an increase in endothelium-dependent contractions due to ROS, insulin resistance and 
increased expression of TP receptors (Gollasch, 2002; Traupe et al., 2002; Mundy et al., 
2007b).  
1.5 Mouse models of obesity 
Nutrition rich in fat causes obesity in humans and is correlating with an elevation in 
body fat resulting in increased body fat mass (Klesges et al., 1992; Tucker & Kano, 
1992). Animal experiments with monkeys, pigs, dogs, hamsters, squirrels, rats, and 
mice have shown that diets rich in fat content cause obesity, too (West & York, 1998). 
First studies, in which rodents were fed with a high-fat diet, are based on rat studies in 
which rats were fed with a so called “cafeteria” diet (Rothwell & Stock, 1982). Rats 
were exposed to food which is eaten by humans such as chocolate, biscuits, bread, ham, 
cheese etc. One disadvantage of the “cafeteria” diet is that the quantification and 
analysis of diet intake is difficult to determine. Therefore, rodent-suitable, pelleted high-
fat diets were introduced. It is important to note that high-fat diet feeding in animals not 
necessarily results in obesity. It is evident that some strains or species within one family 
are prone to become obese and some others not. In squirrel monkeys, high-fat diet 
feeding results in obesity whereas cebus monkeys do not become obese upon feeding 
with high-fat diet (Ausman et al., 1981). This phenomenon is also observed in some 
dog, hamster, and mice species and strains (West et al., 1992). West et al. investigated 
in nine inbred mouse strains which of these strains is suitable to study diet-induced 
obesity. Their results showed that the AKR/J mouse strain is the most obesity-sensitive 
strain whereas the SWR/J is rather resistant to diet-induced obesity (DIO) (West et al., 
1992). Other studies by York and colleagues demonstrated that the C57BL/6J mouse 
strain is prone to develop obesity during high-fat diet whereas the CAST/Ei strain is not 
(York et al., 1996). These researchers identified a locus on chromosome 15 which is 
probably responsible to regulate fat content in the body (York et al., 1996). These 
findings could explain that chromosomal variations play a role and that some mouse 
strains are more sensitive for the development of obesity than others. Interestingly, 
Rabot et al. showed that germ-free C57BL/6J mice are resistant to DIO and insulin 
resistance when fed with a high-fat diet compared to conventional mice (Rabot et al., 
2010). Nevertheless, the C57BL/6J mouse strain is a well tolerated model to study DIO 
because it develops severe obesity, hyperglycemia, hyperinsulinemia, and hypertension 
when fed with a high-fat diet (Surwit et al., 1988), even though mice in general have 
high HDL levels and low LDL levels in their plasma compared to humans (Fox et al., 
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2006) in which obesity can lead to the development of hypercholesterolemia (high LDL 
levels and low HDL levels) (Tershakovec et al., 2002). Additionally, this strain is of 
particular interest because it develops metabolic changes similar to humans (Collins et 
al., 2004). On the other hand, this strain remains physically and metabolically normal 
when held on a low-fat diet (Surwit et al., 1988). Several different mouse models 
despite DIO mouse models also known as environmentally-induced obesity mouse 
models (Surwit et al., 1988) exist to study obesity (Brownlow et al., 1996). These are 
models in which spontaneous mutations occur leading to an obese phenotype (Chua et 
al., 1996; Tschop & Heiman, 2001), transgenic mouse models in which a specific gene 
is overexpressed resulting in obesity (Shepherd et al., 1993; Ludwig et al., 2001), 
mouse models of gene disruption (Huszar et al., 1997) and models in which a chemical 
or surgical manipulation is carried out (Tokunaga et al., 1989). Most important mouse 
models of each different type are summarized in Table 1-1. Important to note is that 
weight loss in humans is caused by diets low in fat (Schaefer et al., 1995) which is 
associated with many metabolic improvements. In animals, reduced dietary fat content 
can reverse obesity (Bartness et al., 1992; Bell et al., 1995), but also evidence exists 
that obesity is not reversed when animals are fed with a low-fat diet (Hill et al., 1989). 
Interestingly, in C57BL/6J mice fed for 4 months with a high-fat diet followed by 4 
months of a low-fat diet obesity and diabetes were reversible (Parekh et al., 1998). 
Based on these findings, C57BL/6J mice are ideal to study high-fat diet-induced obesity 
as well as low-fat diet-induced weight loss. Even though the mentioned mouse models 
in Table 1-1 are ideal to study DIO, extrapolation of the results from DIO studies to 
obesity in humans has to be regarded with caution. There are huge differences in body 
size, food intake, metabolic rates and body fat distribution between animals and humans 
(Hartung, 2008). Another factor to be included is that food which animals consume in 
nature is usually not composed of high fat (West & York, 1998). Other limitations are 
too small animal group sizes for statistical analysis, lethality (especially in transgenic 
mouse models) or exposure and durations of dietary treatments which do not reflect 
realistic human tolerance levels (Hartung, 2008).  
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1.6 Cytochrome P450 enzymes 
1.6.1 Cytochrome P450 enzymes: general overview  
The cytochrome P450 (Cyp450) enzymes belong to a superfamily of proteins 
containing heme, acting as monooxygenases catalyzing the oxidation of endogenous 
substrates (e.g. steroids such as testosterone and progesterone or fatty acids such as 
arachidonic acid) and exogenous compounds (e.g. xenobiotics such as drugs 
(acetaminophen), toxins (ethanol, carbon tetrachloride) and pro-carcinogens 
(nitrosamines) (Guengerich, 1987; Niwa et al., 2009). 
The monooxygense reaction is following: 
RH + O2 + 2H+ + 2e-ROH + H2O 
It means that a substrate (RH) binds to the heme iron in ferric state (Fe3+). This 
promotes the reduction of the heme group from a ferric state to a ferrous state (Fe2+) by 
an electron transfer from cytochrome P450 reductases. This ferrous hemoprotein can 
now bind O2 to form an oxycomplex which is further reduced by a second electron 
Table 1-1 Common mouse models of obesity 
Lepob/Lepob, spontaneous mutation in the leptin gene; Leprdb/Leprdb, spontaneous mutation in the leptin 
receptor; GLUT-4, glucose transporter type-4; MHC, melanin concentrating hormone; MC4-R, 
melanocortin-4 receptor; PVN, paraventricular nucleus. 
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transfer to a peroxycomplex. Protonation of the peroxycomplex leads to the cleavage of 
O-O bond producing H2O and the oxenoid complex which inserts the other oxygen 
atom into the substrate RH to result in the product (ROH) (Lewis & Pratt, 1998; 
Davydov, 2001). ROS generation will occur during P450 catalytic cycle if transfer of 
the electrons is used for the reduction of oxygen to O2- instead of Fe2+or if the 
peroxycomplex is protonated resulting in H2O2. This is known as the “decoupling 
reaction” (Figure 1-9) (Loida & Sligar, 1993). Binding of CO to reduced Cyp450 
enzymes inhibits the catalytic cycle (Fabry & Lieber, 1979). Irradiation with light at a 
wavelength of 450 nm abolishes CO inhibition (Diehl et al., 1969). The number 450 
visible in the enzymes` name represents at which wavelength Cyp450 enzymes absorb 
light. Cyp450 enzymes are present in animals, plants, fungi, bacteria and archea 
(Danielson, 2002). A nomenclature system for eukaryotic and prokaryotic Cyp450 
enzymes based on sequence homologies exist which is updated since 1995 (Nelson et 
 
Figure 1-9 Catalytic cycle of cytochrome P450 enzymes 
The substrate (RH) binds to the active site of Cyp450 enzymes containing a heme iron in ferric state 
(Fe3+) with H2O at one coordination position and a cystein residue at the other coordination position (A).
Binding of the substrate RH leads to a conformational change of the active site displacing H2O and 
promoting the reduction of the heme group from a Fe3+ (B) to a ferrous state (Fe2+) by an electron transfer 
from NAD(P)H via NADPH-cytochrome P450 reductase or other reductases (C). O2 can now bind to 
heme iron of the intermediate to form an oxycomplex (D) which is further reduced by a second electron 
transfer to a negatively charged peroxycomplex (E). Then, this peroxycomplex is immediately protonated 
(2H+) leading to the cleavage of O-O bond thereby releasing one oxygen atom in form of H2O and 
producing the oxenoid complex (F) which inserts the other oxygen atom into RH to result in the product
(ROH). ROS generation will occur during P450 catalytic cycle if transfer of the electrons is used for the
reduction of oxygen to O2- instead of Fe2+or if the peroxycomplex is protonated resulting in H2O2
(reactions indicated by red arrows) This is known as the “decoupling reaction” (G). Adapted from 
(Fleming, 2001). 
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al., 1996; Nelson, 2009). The nomenclature is as follows: Cyp stands for cytochrome 
P450, followed by an arabic number which represents the family, the capital letter 
indicates the subfamily and the last Arabic number describes the individual gene within 
the subfamily. The number of Cyp450 genes varies between humans and mice. In 
humans, 57 Cyp450 genes with annotated function and 58 pseudogenes are known, 
whereas mice have 102 functional Cyp450 genes and 88 pseudogenes (Nelson et al., 
2004). The mammalian expression of Cyp450 enzymes is diverse and is reported in 
several different tissues including liver, kidney, adrenal, lung, gonads, brain, and 
cardiovascular tissue (Elbekai & El-Kadi, 2006; Seliskar & Rozman, 2007). All Cyp450 
enzymes in mammals are membrane bound either to the endoplasmic reticulum (ER) 
membrane (representing 90 %) or the inner mitochondrial membrane (Bar-Nun et al., 
1980; Nelson et al., 2004; Seliskar & Rozman, 2007). 
1.6.2 Cytochrome P450 enzymes in the regulation of vasomotion 
Many Cyp450 enzymes as well as their metabolites are implicated to regulate 
cardiovascular function and diseases (Fleming, 2001; Roman, 2002). Several different 
Cyp families including Cyp1, Cyp2, Cyp3, Cyp4, Cyp8, Cyp11 and Cyp19 were found 
to be expressed in cardiovascular tissue (Elbekai & El-Kadi, 2006). Cyp450 enzymes 
belonging to the Cyp2 family are found to be expressed in vascular endothelial cells 
(e.g. Cyp2B, Cyp2C, Cyp2J) (Roman, 2002; Elbekai & El-Kadi, 2006) whereas 
Cyp2E1 was identified in heart and coronary vessels in humans (Minamiyama et al., 
1999), but also in aorta (Irizar & Ioannides, 1995; Elbekai & El-Kadi, 2006). The most 
important endogenous substrate of Cyp450 enzymes is the unsaturated fatty acid AA 
which is metabolized either to epoxyeicosatetraenoic acids (EETs) and 
dihydroxyeicosatetraenoic acids in liver but in vascular tissue predominantly EETs and 
hydroxyeicosatetraenoic acids (HETEs) are formed (Roman, 2002). AA can also be 
metabolized by COX to prostaglandins or by LOX to leukotrienes known to have 
vasoactive functions. Figure 1-10 summarizes the metabolism of AA. EETs are 
important vasodilators generated by epoxygenases such as by Cyp2B, Cyp2C, Cyp2J. 
They are also known as EDHFs because vasodilator responses by EETs are mediated 
through NO and PGI2-independent vasodilatation by the activation of large conductance 
Ca2+-activated K+ channels (BKca) on VSMCs leading to hyperpolarization and 
relaxation (Michaelis & Fleming, 2006). An important HETE, known to act as a 
vasoconstrictor, is 20-HETE which is metabolized from AA by enzymes of the Cyp4 
family, mainly the ω- hydroxylase Cyp4A (Fleming, 2001). 20-HETE-mediated 
vasoconstriction can be initiated by stretch of the membrane or in response to AngII or 
norepinephrine (Uddin et al., 1998; Muthalif et al., 2000; Roman, 2002). This leads to 
the activation of PLC releasing IP3 and DAG. IP3 activates the release of intracellular 
Ca2+ which leads to stimulation of PLA2 and DAG lipase releasing AA from membrane 
PLs in VSMCs and consequently to the generation of 20-HETE. Then, 20-HETE 
inhibits BKca in VSMCs leading to depolarization of VSMCs which activates influx of 
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Ca2+ by L-type, voltage sensitive Ca2+ channels resulting in vasoconstriction (Roman, 
2002). 
1.6.3 Cyp2E1 in liver 
Cyp2E1 plays a pivotal role in ethanol oxidation in liver and liver injury (Cederbaum 
et al., 2009). Many years it was believed that alcohol dehydrogenase alone catalyzes the 
conversion of ethanol to acetaldehyde in vivo (Lieber, 1992). In vitro, catalase can 
convert ethanol to acetaldehyde via an H2O2 generating system (Crabb & 
Liangpunsakul, 2007). Lieber and collegues demonstrated that in chronic ethanol 
consumption ethanol is metabolized by the microsomal ethanol-oxidizing system. 
Cyp2E1 was found to be the regulatory enzyme oxidizing ethanol to acetaldehyde 
(Lieber, 1999; 2004). Chronic ethanol consumption increases Cyp2E1 levels, ROS 
generation, and lipid peroxidation in the liver (Lu & Cederbaum, 2008). It can produce 
ROS during the catalytic cycle which plays a role in liver injury (Cederbaum et al., 
2009). It is mainly expressed in liver, specifically in the centrilobular zone (also known 
as zone 3) of liver lobules (Ingelman-Sundberg et al., 1988). Liver hepatocytes and 
Kupffer cells also express Cyp2E1, and its expression is inducible by ethanol (Koivisto 
et al., 1996; Lieber, 1997) but also by pyrazole, 4-methylpyrazole, acetone (Jimenez-
Lopez & Cederbaum, 2005). Pathophysiological conditions such as obesity (Dey & 
Cederbaum, 2007), diabetes (Schafer et al., 2010), and starvation (Lieber, 1997) can 
influence its expression. Cyp2E1 expression is regulated on transcriptional, 
posttranscriptional, and posttranslational levels (Lieber, 1997). In obese (Salazar et al., 
 
Figure 1-10 Metabolism of arachidonic acid 
The metabolism of arachidonic acid (AA) includes three different enzyme classes such as Cytochrome P 
(Cyp) 450 enzymes, cyclooxygenase and lipooxygenase. Several different vasoactive metabolites are 
formed. Epoxyeicosattrienoic acids (EETs), dihydroxyeicosatetraenoic acids (DiHETEs), 
hydroxyeicosatetraenoic acids (HETEs), Prostacylin (PGI2), prostaglandin E2 (PGE2), prostaglandin F2α
(PGF2α), prostaglandin D2 (PGD2), thromboxane A2 (TXA2) (Roman, 2002). 
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1988; Raucy et al., 1991) and diabetic rats (Sindhu et al., 2006) Cyp2E1 expression in 
liver is increased. Interestingly, in Lepob/Lepob mice hepatic Cyp2E1 expression is 
reduced compared to control mice, (Enriquez et al., 1999; Leclercq et al., 2000; Sindhu 
et al., 2006) indicating that leptin regulates the expression of Cyp2E1. As described 
above, most of Cyp450 enzymes are located in the membrane of the ER, which is also 
the case for Cyp2E1. It is tethered with its hydrophobic NH2-terminus to the membrane 
while the C-terminus with the catalytic active site is directed to the cytosol (Jimenez-
Lopez & Cederbaum, 2005). Interestingly, lack of Cyp2E1-containing hydrophobic 
NH2-terminus leads to a transport of Cyp2E1 to the mitochondria (Neve & Ingelman-
Sundberg, 1999; 2001). Additionally, a phosphorylated form of Cyp2E1 at serine129 in 
mitochondria is described which is inducible by pyrazole (Robin et al., 2001). Cyp2E1 
catalyzes the oxidation of several different endogenous and exogenous substrates. 
Important endogenous substrates are acetone and fatty acids such as AA. Acetone is 
metabolized by Cyp2E1 to acetol and methylglyoxal (Bondoc et al., 1999). Exogenous 
substrates of Cyp2E1 are various including aromatic compounds (acetaminophen also 
known as paracetamol, chlorzoxazone, p-nitrophenol), alcohols (ethanol, methanol, 
propanol) nitrosamines (N-N Dimethylnitrosamine, N-N Diethylnitrosamine), 
halogenated alkanes and alkenes (chloroform, halothane, ethane, hexane), and reducible 
substrates (carbon tetrachloride) (Koop, 1992; Tanaka et al., 2000). Conversion of some 
exogenous substrates by Cyp2E1 can cause toxic products such as acetaminophen 
which in combination with ethanol can cause hepatoxicity (Lu & Cederbaum, 2008). 
Enzyme activity of Cyp2E1 can be determined by hydroxylation of chlorzoxazone to 6-
hydroxychlorzoxazone (Peter et al., 1990) or of p-nitrophenol to 4-nitrocatechol (Chang 
et al., 2006). A concentration of 200 µM of dietyldithiocarbamate (DETC) decreases 
hydroxylation reaction of aniline, a substrate of Cyp2E1, to aniline 4-hydroxylation. 
This effect is even more prominent at a concentration of 500 µM (Ono et al., 1996). 
Guengerich and colleagues showed that chlorzoxazone hydroxylation which is 
catalyzed by Cyp2E1 is inhibited by DETC about 80-85% indicative of a reduced 
Cyp2E1 activity (Guengerich et al., 1991).  
1.6.3.1 Cyp2E1-deficient mice 
Many Cyp450 enzymes play a very important role in metabolizing and activating 
various xenobiotics to products which are hepatotoxic. Cyp2E1 metabolizes 
acetaminophen (a worldwide known and clinically used analgesic and antipyretic) to N-
acetyl-p-benzoquinone amine (NAPQI) (Corcoran et al., 1980) which is usually 
inactivated by reacting with glutathione in the liver when low amounts are available. In 
case of a high dose of acetaminophen, NAPQI levels are increased and glutathione 
levels are decreased which may lead to an inhibition of NAPQI break-down by the liver. 
High amounts of NAPQI can act as free radicals destroying hepatocytes leading to liver 
damage and toxicity (Dahlin et al., 1984; Lee et al., 1996). To investigate whether 
Cyp2E1 plays a role in the hepatotoxicity of acetaminophen in vivo, Cyp2E1-deficient 
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(Cyp2E1-/-) mice were generated by Lee et al. by knockout of Cyp2E1 through 
homologous recombination in embryonic stem cells (Lee et al., 1996). Cyp2E1-/- mice 
are viable and phenotypically not different from wild type animals. Treatment of the 
mice with 400 mg of acetaminophen per kg ofbody weight, Cyp2E1-/- mice were 
resistant to this dose whereas 50 % of their wild type counterparts died. Very high doses 
of acetaminophen (up to 800 mg/kg body weight) were also lethal to Cyp2E1-/- mice. 
Additionally, levels of the liver enzymes aspartate aminotransferase and alanine 
aminotransferase were increased upon stimulation with acetaminophen in wild type 
mice but not in Cyp2E1-/- mice. An increase in those enzymes indicates hepatocyte cell 
death and gives an implication of how damaged the liver is. These results indicate that 
Cyp2E1 is involved in acetaminophen-induced toxicity in the liver (Lee et al., 1996). 
Until now most researchers have utilized Cyp2E1-/- mice in investigating the role of 
Cyp2E1 in liver toxicity extensively, but no data is available with these mice to 
investigate the role of Cyp2E1 in vascular reactivity.  
1.6.4 Cyp2E1 in the vasculature 
Its role in liver is extensively investigated (Lieber, 1997), but little is known about 
the role of Cyp2E1 in the regulation of vascular reactivity. Cyp2E1 acts as a ω- 
hydroxylase catalyzing the formation of 18 (R)-, 19 (R)-and 19(S)-HETEs from AA in 
the vasculature, an endogenous substrate of Cyp2E1 (Laethem et al., 1993). These 
metabolites play an important role in maintaining vascular homeostasis (Elbekai & El-
Kadi, 2006). Zhang et al. showed that Cyp2E1 expression is down regulated in 
interlobar arteries of spontaneously hypertensive rats (SHR) compared to control Wistar 
Kyoto rats (WYR) (Zhang et al., 2005). These researchers showed that 18- and 19- 
HETE levels are decreased in arteries of both rat groups by inhibition of Cyp2E1 with 
500 μM DETC. This inhibitor is reported to inhibit Cyp2E1 in rat (Brady et al., 1991) 
and human liver microsomes (Guengerich et al., 1991), but also SOD (Ghanam et al., 
1998; Karasu, 2000), and Cyp6A (Ono et al., 1996). The decrease in Cyp2E1-derived 
18-and 19-HETEs leads to an amplification of Cyp4A-derived 20-HETE-mediated 
vasoconstriction and 20-HETE also enhances phenylephrine-mediated contractions 
(Zhang et al., 2005), indicating that 18-and 19 HETE act as vasodilators. Another study 
by Escalante and coworkers showed that 20-HETE strongly contracts isolated aorta of 
rats, but also 19-HETE is able to contract this artery (Escalante et al., 1989). COX 
inhibition by indomethacin and addition of a TXA2 receptor antagonist SQ29458 
abolished 20-HETE-mediated contractions, suggesting that 20-HETE is converted by 
COX to TXA2 leading to the observed contraction (Escalante et al., 1989). 
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1.7 Aim of the study 
The prevalence of obesity has risen worldwide. Main reason responsible for the 
development of obesity is intake of nutrition rich in fat. As a consequence body weight 
is increased and is frequently associated with glucose intolerance and vascular 
dysfunction. Recent studies suggest that obesity is associated with an increased risk of 
cardiovascular diseases even after reduction of body weight. Little is known which 
genes play a role in obesity-associated vascular dysfunction even after reduction of 
body weight. To this end C57BL/6J mice were either fed with a control diet or a high-
fat diet for 30 weeks or 15 weeks with a high-fat diet followed by 15 weeks of control 
diet. 
 
Main objectives of my dissertation were: 
 
(1) To investigate the impact of high-dietary fat content and its reduction on body 
weight, glucose tolerance, and vascular reactivity in C57BL/6J mice 
 
(2) To investigate whether in aorta of these mice groups changes in steady state 
mRNA expression levels of genes (referred to as gene expression levels) and gene 
splicing occur 
 
(3) To identify and validate target genes revealing changes in gene expression that 
sustain after high-dietary fat content is reduced 
 
(4) To investigate whether the selected target gene Cyp2E1 is involved in the 
regulation of vascular reactivity in thoracic aorta of mice and characterize aortic 
Cyp2E1 splice variants 
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2 Materials and Methods 
2.1 Materials 
All chemicals were obtained from Sigma-Aldrich Chemie GmbH (Munich, 
Germany) if not it is otherwise stated. Oligonucleotide primers were obtained from 
Microsynth AG (Balgach, Switzerland), and described in Appendix Table 5-1 and 
Table 5-2. 
2.2 Methods 
2.2.1 Mice and dietary treatment 
Mice were housed at the animal facility of the University Hospital of Zurich 
(Biologisches Zentrallabor). Animals had access to tap water ad libitum and were kept 
in a 12h: 12h light-dark cycle. Housing facilities and mice experiments were approved 
by the local authorities for animal research (Kommission für Tierversuche des Kantons 
Zürich, Switzerland) and conform to the Guide for the Care and Use of Laboratory 
animals published by the US National Institutes of Health (NIH Publication No.85-23, 
revised 1996). 
An established DIO mouse model was used (West et al., 1992): Young (4 weeks 
old), male C57BL/6J (Charles River, Sulzfeld, Germany) mice were assigned to one of 
the 3 dietary protocols for 30 weeks: Control diet (CD) group was fed with standard 
chow for 30 weeks (12.3 % kcal from fat, Kliba Nafag 3430, Kaiseraugst, Switzerland), 
mice included in the high-fat diet (HFD) group were fed with a high-fat diet (41% kcal 
from fat, Research Diets D12079B, New Brunswick, NJ), for 30 weeks, and the mice in 
the high-fat diet/control diet (HFD/CD) group were fed with a high-fat diet (41% kcal 
from fat, Research Diets D12079B, New Brunswick, NJ) for 15 weeks followed by 15 
weeks of control diet (12.3 % kcal from fat, Kliba Nafag 3430, Kaiseraugst, 
Switzerland) (Table 2-1). 
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Breeding pairs of Cyp2E1-deficient (129/Sv-Cyp2e1tm1Gonz/J) mice and 
corresponding wild type (129S1/SVImJ) mice were obtained from Prof. Frank J. 
Gonzalez at the National Cancer Institute, Bethesda, Maryland, USA. Cyp2E1 gene was 
disrupted by homologous recombination in embryonic stem cells. Exon 2 of Cyp2E1 
was replaced with a neomycin resistance cassette (Lee et al., 1996). Mice were 
genotyped by PCR using isolated genomic DNA (deoxyribonucleic acid) from wild type 
and Cyp2E1-deficient mice. For genotyping wild type forward (5`-AGTGTT 
CACACTGCACCTGG-3`) and reverse (5`-CCTGGAACACAGGAATGTCC-3`) 
primer and corresponding mutant forward (5`-CTTGGGTGGAGAGGCTATTC-3`) and 
reverse (5`-AGG TGAGATGACAGGAGATC-3`) primer were used published at the 
Jackson laboratory website  to detect wild type and mutant PCR band at 125 and 280 
base pairs (bp), respectively (The Jackson Laboratory.). Following PCR program was 
used for amplification on an iCycler™ Thermal Cycler PCR machine (BioRad 
Laboratories, Hercules, CA, USA): 
 
Cycle (1x)   Denaturation at 94°C for 3 min 
Cycle (30x) Denaturation at 94°C for 20 seconds  
                    Annealing at 58°C for 30 seconds 
                    Elongation at 72°C for 35 seconds 
Cycle (1x)   Final elongation at 72 °C for 2 minutes 
 
Amplified PCR products were separated on a 1.5 % agarose gel, visualized with UV 
light, photographed using the Molecular Imager® ChemiDoc™ XRS Imaging System 
(BioRad Laboratories, Hercules, CA, USA) and sequenced (Microsynth AG, Balgach, 
Switzerland). 
Breeding of the animals was performed in the animal facilities at the Institute for 
Labortierkunde, University of Zurich. Male and female litters of wild type and Cyp2E1-
deficient mice were fed with control diet (12.3 % kcal from fat, Kliba Nafag 3430, 
Kaiseraugst, Switzerland) for 8 weeks before vascular function experiments were 
performed.  
17 %22.4 %Protein
45 %65.4 %Carbohydrate
41 %12.3 %Fat
HFDCDDiet 
constituents
 
Table 2-1 Main nutritional constituents in CD and HFD 
Values represent percent of kcal from fat, carbohydrate and protein.  
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2.2.2 Glucose tolerance test 
Body weight of DIO animals was monitored weekly during the dietary treatment of 
30 weeks. At the end of the feeding period glucose tolerance test (GTT) was performed 
with overnight fasted animals. For baseline glucose measurements (0 min) venous blood 
was taken from the tail vein. Then mice were injected with 2 mg/g of body weight D-
glucose (Riedel-de Haën, Seelze, Germany), and blood was collected at 5, 10, 15, 30, 
45, 60, 90, and 120 min. Glucose concentration in the blood was determined using an 
AccuChek Advantage glucose meter (Roche Diagnostics, Switzerland). 
2.2.3 Vascular function experiments 
2.2.3.1 Experimental set-up of organ chamber baths  
After 30 weeks of dietary treatment, fasted mice were anesthetized and 
exsanguinated via cardiac puncture. Organs were removed and immediately snap-frozen 
at -80° C. In the Appendix Figure 5-1, a schematic representation of the experimental 
set-up of organ chamber baths used for vascular function experiments is shown. The 
aorta was carefully excised and placed in 4°C Krebs Ringer bicarbonate buffer solution 
of pH 7.4 (Bhattacharya et al., 2008). Ascending aorta, aortic arch, descending aorta 
and thoracic aorta sections were carefully cleaned of adherent, connective fat and 
muscle tissue. Care was taken while cleaning of adherent tissue not to damage the 
endothelial and vascular smooth muscle cell layer. Ascending aorta, aortic arch and 
descending aorta (in one piece) were immediately snap-frozen at -80°C and stored for 
RNA isolation (for DNA exon microarray experiments). Thoracic aorta was cut into 3 
mm rings, mounted onto two tungsten wires (100 µm diameters) and transferred into 
pre-warmed water-jacketed organ baths containing warm (37°C) gassed (95 % O2, 5% 
CO2) Krebs Ringer bicarbonate buffer solution of pH 7.4 (Bhattacharya et al., 2008). 
Rings were connected to a force transducer to record isometric tension. First, a passive 
tension was induced to the rings by stretching the vessels step by step to an optimal 
weight of 3 g (Russell & Watts, 2000). After optimal passive tension was reached, rings 
were two times exposed to potassium chloride (KCl, 100 mM) until a stable contractile 
response was reached to test integrity of VSMC layer. Changes in vascular reactivity 
were recorded using a plotter (Rikadenki Elektronics GmbH, Freiburg, Germany).  
2.2.3.2 Experimental protocols  
The following protocols were used to determine vascular reactivity: 
1. To investigate vascular contraction induced by phenylephrine and relaxation 
induced by acetylcholine in thoracic aorta from different dietary treatment groups, and 
wild type (WT) and Cyp2E1-/- mice, vessel rings were treated without and with DETC 
(100 µM or 500 µM) for 30 minutes before contraction with cumulative concentrations 
of phenylephrine (0.1 nM-100 nM). The contractions were induced to 60 % (in case of 
mice from dietary treatment groups) or 50 % (in case of WT and Cyp2E1-/- mice) of 
KCl-induced contraction. After a stable contractile plateau was reached increasing 
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concentrations of acetylcholine (0.1 nM-100 µM) were added to investigate 
endothelium-dependent relaxation (Appendix Figure 5-2A).  
2. To investigate endothelium-dependent contractions and the effect of DETC on 
these contractions in thoracic aorta, vessels were incubated with the NO-synthase 
inhibitor NG-nitro-L-arginine methylester (L-NAME, 300 µM) alone or with L-NAME 
and DETC (100 µM) for 30 minutes before pre-contracting the vessels with increasing 
concentrations of phenylephrine (0.1 nM-1 μM). Inhibition of NO using L-NAME is 
needed to elicit endothelium-dependent contractions at high concentrations of 
acetylcholine (>0.1µM) (Vanhoutte & Tang, 2008). After a stable contraction with 
phenylephrine was reached, acetylcholine in cumulative concentrations (0.1 nM-100 
µM) (in case of mice from dietary treatment groups) or a single concentration (100 µM) 
(in case of WT and Cyp2E1-/- mice) was added (Appendix Figure 5-2B). To investigate 
whether endothelium-dependent contractions are mediated by COX, only vessels of 
Cyp2E1-/- mice were pre-incubated with L-NAME (300 µM) together with the non-
selective COX inhibitor, meclofenamate (1 µM) (Kretz et al., 2006) for 30 minutes 
prior to pre-contraction with phenylephrine (0.1 nM- 1 μM) followed by a single 
concentration of 100 µM of acetylcholine.  
3. To investigate 5-hydroxytryptamine-mediated contractions in thoracic aorta from 
dietary treatment groups, and WT and Cyp2E1-/- mice, vessels were incubated without 
or with DETC (100 µM or 500 µM) for 30 minutes before rings were exposed to 
additive concentrations of 5-hydroxytryptamine in a concentration-dependent manner 
(0.1 nM-10 µM) (Appendix Figure 5-2C).  
2.2.3.3 Statistical analysis of vascular function experiments 
Statistical analyis was performed using the software Statview® for Windows® 
version 5.0.1. Two-tailed paired or unpaired Student`s t-test, one-way analysis of 
variance (ANOVA) for repeated measurements followed by Bonferroni correction were 
used, when appropriate. Data are represented as means ± SEM (standard error of the 
mean). n indicates the number of animals used in the experiments. A p value < 0.05 was 
considered significant. 
2.2.4 DNA exon microarray and analysis 
2.2.4.1 RNA extraction and array hybridization 
5-10 mg aortic tissue originating from ascending aorta, aortic arch, and descending 
aorta/per mouse (3 replicates per treatment group were used) was disrupted by 
homogenization of the tissue using six borosilicate glass beads (3 mm) in the FastPrep® 
-24 System from MP Biomedicals (Solon, OH, USA). The FastPrep® -24 homogenizer 
uses a unique, vertical angular optimized motion to disrupt the tissue through a 
multidirectional, simultaneous beating to release RNA into the protective buffer very 
fast. Very fibrous tissue, such as aortic tissue, can be disrupted within seconds. The 
homogenization protocol for complete disruption of each aortic tissue/per mouse was 
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set as follows: 3 x 30 seconds at 6.5 m/s for followed by 1 x 30 seconds at 6.0 m/s. All 
other steps of RNA isolation were done as described in the RNeasy Fibrous Tissue Mini 
protocol from Qiagen AG (Hombrechtikon, Switzerland). Before cDNA synthesis, 
quality of the isolated RNA was determined using NanoDrop ND 1000 
spectrophotometer (NanoDrop Technologies Inc., Wilmington, DE, USA) and 
Bioanalyzer 2100 (Agilent Technologies, Inc., Santa Clara, CA, USA). cDNA was 
synthesized from total RNA using a primer mix and reverse transcriptase using the WT 
(Whole Transcript)-Ovation™ Pico RNA Amplification System from NuGEN 
(Bemmel, the Netherlands) which is a rapid method to amplify cDNA from low 
amounts of total RNA. The primers have a DNA portion that hybridizes either to the 
5`portion of the poly-A sequence or randomly across the transcript. SPIA® (Single 
Primer Isothermal Amplification), a linear isothermal DNA amplification process, was 
used to prepare single-stranded cDNA in antisense direction of the mRNA starting 
material. Single-stranded cDNA quality was determined using NanoDrop ND 1000 
Spectrophotometer and Bioanalyzer 2100. Single stranded cDNA quality (3 µg) was 
converted into sense target-cDNA (ST-cDNA) using WT-Ovation™ Exon Module from 
NuGen. Fragmentation and biotin-labelling of ST-cDNA were generated with the FL-
Ovation cDNA Biotin Module V2 from NuGEN. Biotin-labelled single-stranded cDNA 
targets (5µg) were mixed with a hybridization mix containing hybridization controls and 
the control oligonucleotide B2 from Affymetrix (Santa Clara, CA, USA). Samples were 
hybridized to Affymetrix Mouse Exon 1.0 ST Arrays (9 Exon Arrays were used because 
of 3 replicates per treatment group) for 18 h at 45 °C. Arrays were then washed using an 
Affymetrix GeneChip® Fluidics Station 450 FS450 0001 protocol. An Affymetrix 
GeneChip® Scanner 3000 was used to measure fluorescent intensity emitted by the 
labelled target. Transformation of Raw (Pixel) Images (DAT. file) of each array to 
signal intensity values (CEL. file) was performed using the Affymetrix® GeneChip® 
Command Console® (AGCC) software. 
2.2.4.2 Statistical analysis of Microarray data  
The microarray data provided exon-specific measurements of expressed genes in the 
3 different experimental groups. Briefly, the Affymetrix Mouse Exon 1.0 ST Array 
contains ~ 4.5 million probes corresponding to ~ 1.2 million probesets which target ~ 1 
million exons (Affymetrix Mouse Exon 1.0 ST Array). Each probe set consists of 4 
probes which cover one exon of a particular gene (Figure 2-1). 
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In general, data analysis begins with pre-processing of the Exon array data. First, 
intensity values of each individual probe on each array chip are normalized to remove 
systematic errors (biases) from the data so that multiple chips can be compared to each 
other and analyzed together. Next step includes the generation of expression summaries 
by using the robust multi-array average algorithm in which intensity values of each 
individual probe in a probe set are summarized to a single intensity value (exon 
intensity value or so called probe set intensity value representing exon expression, 
Figure 2-2), and additionally, all probe set intensity values belonging to a gene are 
integrated to a meta-probe set intensity value (Figure 2-2) representing whole gene 
expression. 
After pre-processing of the data, exonmap (Okoniewski et al., 2007), a 
BioConductor/R package for Exon array analysis was applied to (i) identify genes that 
show a whole gene expressional change (meta-probe set expressional change 
representing gene expression), and to (ii) identify genes in which least 2 exons show an 
expressional change (probe set expressional change representing exon expression) in 
arterial tissue in any of the groups using ANOVA test.  
Figure 2-1 Schematic representation of mRNA transcripts originating from a genomic locus and 
design of the Affymetrix Mouse Exon 1.0 ST Array 
A gene is a region of the genomic locus which can contain exons (yellow region) and introns (grey 
region). First, it is transcribed into pre-mRNA (precursor-messenger ribonucleic acid, still containing 
exons and introns). During Splicing, introns but also exons can be removed from the pre-mRNA leading 
to several different mRNA transcripts. This process is referred to as alternative splicing. In exon arrays 4 
probes (pink dashes) cover one exon (pink region). 4 probes are one probe set which cover one exon of a 
particular gene. Adapted from Affymetrix data sheet: GeneChip®Exon Array System for Human, Mouse, 
and Rat (Affymetrix., 2005a).  
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(i) To find out genes that show a whole gene expressional change in any of the 
groups the analysis was done as follows: 
Step 1: Differentially expressed probe sets/exons were identified by calculating the 
mean intensity value of each probe set/exon (log2 signal) of 3 replicates per treatment 
group.  
Step 2: These significantly identified probe sets/exons were further mapped to the X: 
MAP Database (Yates et al., 2008), a database of exon array annotation. Differentially 
expressed probe sets/exons can be mapped in silico to the entire genome to identify 
corresponding genes that show a whole gene expressional change in any of the groups.  
To find out those, the mean intensity value of each probe set/exon of 3 replicates per 
treatment group was summarized to a whole gene intensity value (meta-probe set 
intensity value). To generate a top list of genes showing a whole gene expressional 
change in any of the groups, only genes with a p value < 0.01 and a log2 effect (fold 
change) > 0.5 were included.  
(ii) To generate the list of genes in which at least 2 exons show a significant 
expressional change in any of the groups the analysis was done as follows: 
Step A: same as in Step1 
Figure 2-2 Summarization of probe set and meta-probe set intensities 
Intensity values of each individual probe (pink dashes) in a probe set covering one particular exon are 
summarized to generate a single exon/probe set intensity value. As during splicing several different 
mRNA transcripts or isoforms of a particular gene can be generated, the summarized single exon intensity 
value is calculated based on the signals coming from one exon occurring in different mRNA transcripts of 
a particular gene (red box). Summarization of all exon/ probe set intensity values result in a meta-probe 
set intensity value representing whole gene expression. Adapted from Affymetrix data sheet: 
GeneChip®Exon Array System for Human, Mouse, and Rat (Affymetrix., 2005a). 
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Step B: Differentially expressed probe sets were mapped to the X: MAP Database to 
identify corresponding genes where at least 2 exons show a significant expressional 
change in any of the groups. In this case, the mean intensity values of each probe 
set/exon of 3 replicates per treatment group were not averaged to a whole gene intensity 
value. Here, only genes were included in the list where at least 2 exons demonstrated 
significantly different mean intensity values of each probe set/exon (probe set intensity 
value) of 3 replicates per treatment group. Genes were included with a p value threshold 
< 0.65 and a log2 effect (fold change) > 0.3.  
The differences in intensity values between the treatment groups were visualized as 
line graphs using exonmap, by plotting each intensity value (y-axis, in log2 scale) 
against the total number of probe sets/exons of a particular gene (x-axis). 
Gene Ontology analysis was performed using the pathway analysis software 
GeneGoMetacore (GeneGo, Inc.). 
2.2.4.2.1 Tukey`s post-hoc test 
To identify specific exons and corresponding genes that are significantly changed 
between HFD or HFD/CD and CD group Tukey`s post-hoc test was applied. Tukey`s 
post-hoc test was used based on the one-way ANOVA results. The list generated 
includes identified exons and corresponding genes with a p value < 0.05 and an exon 
fold change which is at least 0.5 up or down regulated compared to the CD group.  
2.2.5 Quantitative real-time-polymerase chain reaction  
Quantitative real-time-polymerase chain reaction (qRT-PCR) was performed using 
specifically designed mouse primers for the genes of interest (Table 5-1). Briefly, iQ 
SYBR Supermix PCR kit (1X final concentration; BioRad Laboratories, Hercules, CA, 
USA), primers (20 µM final concentration) and cDNA (1 ng/µl final concentration) 
were used to perform a two-step PCR with the following PCR program on the iCycler 
iQTM real-time PCR detection system (BioRad Laboratories, Hercules, CA, USA): 
 
Cycle (1x)   Denaturation at 95°C for 3 minutes 
Cycle (40x) Denaturation at 95°C for 15 seconds                     (step 1)  
                    Annealing and Elongation at 60°C for 1 minute    (step 2) 
 
At the end of each extension step fluorescence was measured. Amplicons were 
confirmed by melting curve analysis, agarose gel electrophoresis and sequencing 
(Microsynth AG, Balgach, Switzerland). Gene expression was calculated using the 2-
ΔΔCT method (Livak & Schmittgen, 2001). The relative amount of each mRNA was 
normalized to the housekeeping gene β-actin and expressed as arbitrary units (AU).  
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2.2.6 “Exon-specific” PCR 
Briefly, to perform PCR reaction RNA from liver and aorta of mice in the CD, HFD 
and HFD/CD group was reverse transcribed to cDNA and used at a final concentration 
of 1 ng/µl. Mouse specific exon-spanning primers (Appendix Table 5-2) for each exon 
of Cyp2E1 were designed to perform PCR reactions. Following PCR program was used 
to amplify DNA fragments in an iCycler™ Thermal Cycler PCR machine (BioRad 
Laboratories, Hercules, CA, USA): 
 
Cycle (1x)   Denaturation at 94°C for 5 min 
Cycle (38x) Denaturation at 94°C for 30 seconds  
                    Annealing at 60°C for 30 seconds 
                    Elongation at 72°C for 2 minutes 
Cycle (1x)   Final elongation at 72 °C for 10 minutes 
 
Amplified PCR products were separated on a 2 % agarose gel, visualized using UV 
light, photographed using the Molecular Imager® ChemiDoc™ XRS Imaging System 
(BioRad Laboratories, Hercules, CA, USA) and sequenced (Microsynth AG, Balgach, 
Switzerland)  
2.2.7 Protein extraction and Western blot 
Total protein was extracted from mouse aorta and liver using 100 µl 
radioimmunoprecipitation assay buffer (0.25 % Na-deoxycholate, 0.05 M Tris/HCl pH 
7.4, 0.15 M NaCl, 0.001 M sodium ethylenediaminetetraacetic acid (Na-EDTA), 0.1% 
sodium dodecyl sulfate (SDS), 1 % NP-40) supplemented with a protease inhibitor 
cocktail, EDTA-free (1:7, Roche Diagnostics GmbH, Mannheim, Germany) at 4°C. 
Tissue homogenization was performed using TissueLyser (Qiagen AG, Hombrechtikon, 
Switzerland) 3 times at 30 Hz for 5 minutes. Finally, samples were centrifuged at 15700 
rcf (13000 rpm) (Centrifuge type 5415R from Vadaux-Eppendorf AG, Basel, 
Switzerland) for 10 minutes at 4°C. Supernatants were collected and protein 
concentration was measured using the Bradford protein assay. As protein standard 
bovine serum albumin was used at concentrations 0, 7.81, 15.625, 31.25, 62.5, 125, 250, 
500 and 1000 µg/ml (Kruger, 2002). Before using the samples in sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 4X sample buffer (62.5 mM 
Tris pH 6.8, 10 % glycine, 2 % SDS, 0.01 % Bromphenol blue (3',3",5',5"-
tetrabromophenolsulfonphthalein), 50 mM Dithiothreitol was added and incubated for 5 
minutes at 95°C. Equal amounts of proteins (aorta: 25 µg, liver: 5 µg) and a molecular 
weight standard (SeeBlue®Plus2 Pre-Stained Standard, Invitrogen, Basel, Switzerland) 
were loaded and separated by SDS-PAGE using NuPage® 4-12 % bis-Tris gradient gels 
(Invitrogen AG, Basel, Switzerland) in 3-(N-morpholino) propanesulfonic acid (MOPS) 
buffer (1X runnig buffer was used: 0.1 M MOPS, 0.1 M Tris-Base, 0.002 M Na-EDTA, 
0.007 M SDS, 1l distilled H2O) at 200 Volts for 50 minutes. Proteins were either blotted 
Materials and Methods 
38 
onto a Polyvinylidene fluoride membrane (Millipore AG, Zug, Switzerland) after 
wetted in methanol or onto a Hybond™-ECL™ nitrocellulose membrane (Amersham 
Biosciences, part of GE Healthcare, Glattbrugg, Switzerland), depending on the 
protocol,  using a wet tank electro blotting system (BioRad Laboratories, Hercules, 
California, USA) filled with 1X transfer buffer (25 mM Tris-Base, 0.19 M glycine, 3.47 
mM SDS, 10 % methanol, 1l distilled H2O) at 110 mV/per membrane for 2h. After 
transfer of the proteins, membranes were washed (phosphate buffered saline (PBS)-
Tween 20 (0.1 %) or PBS-Tween 20 (0.2 %) or TBS-Tween 20 (0.1 %) 3 times 5-10 
minutes before incubating the membrane in blocking buffer for 1h at room temperature 
on a shaker. Depending on the primary antibody, different dilutions and blocking 
buffers (Table 2-2) were used to incubate membranes overnight at 4°C on a shaker. 
After over night incubation with one of the primary antibodies, blots were washed 
again as mentioned above and the appropriate horseradish peroxidase (HRP)-conjugated 
anti-rabbit or anti-mouse (GE Healthcare, Zurich, Switzerland) IgG secondary 
antibodies were added, diluted 1:5000 or 1:2000, respectively in blocking buffer for 1-
1.5 h. Finally, membranes were washed as before and incubated for 5 minutes in 
enhanced chemiluminescence (ECL)™ Western Blotting detection reagents (ECL, GE 
Healthcare, Zurich, Switzerland) before bands of interest were detected and visualized 
on high performance chemiluminescence films (Amersham, GE Healthcare, Zurich, 
Switzerland). Films were developed on the developing machine Cavomat 2000 IR 
(CAWO Photochemisches Werk GmbH, Schrobenhausen, Germany). Densitometry 
quantification of Western Blots were analyzed using Image J (Image Processing and 
Analysis in Java) software (developed by Wayne Rasband, National Institutes of Health 
1X gelatine blocking buffer1:1000Santa Cruz 
Biotechnology, 
Inc., Santa 
Cruz, CA, USA
Rabbit polyclonal
antibody against Erk1/2
5% non-fat milk in 1X TBS + 
0.1% Tween 20
1:500Abnova, Taipei 
City, Taiwan
Mouse monoclonal
antibody against Cidec
3% non-fat milk in PBS + 
0.1% Tween 20 
1:100Abcam, 
Cambridge, UK
Rabbit polyclonal
antibody against N-
terminal Car3
1X gelatine blocking buffer1:250Abnova, Taipei 
City, Taiwan
Rabbit polyclonal
antibody against a 
synthetic peptide
corresponding to C-
terminal Cyp2E1
1X gelatine blocking buffer: 
0.15 M NaCl, 0.005 M EDTA 
pH 8, 0.05 M tris-HCl pH 7.5, 
0.05% Triton X-100, 1l 
distilled H2O
1:2000Abcam, 
Cambridge, UK
Rabbit polyclonal
antibody against full-
length Cyp2E1
Blocking bufferDilutionManufactureurPrimary antibody 
 
Table 2-2 Primary antibodies used for Western Blot 
 
Materials and Methods 
39 
(NIH), Bethesda, MD, USA) and determined by dividing the absolute intensity of each 
sample band per group by the absolute intensity of the loading control band per group 
resulting in a relative intensity. 
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3 Results 
3.1 Impact of diets on appearance, body weight and glucose tolerance 
in C57BL/6J mice  
Body weight of the three different treatment groups was monitored over 30 weeks. 
Initial weight at 4 weeks of age (start of the feeding period) was similar in all groups 
(initial weights of CD group: 16.1±0.7 g, HFD group: 14.5±0.6 g, HFD/CD group: 
15.8±0.8 g). After 15 weeks of feeding period body weight was similarly increased in 
the three treatment groups (CD group: 28.9±0.5 g, HFD group: 31.2±0.7 g, HFD/CD 
group: 28.7±0.7 g). At the end of 30 weeks of feeding period body weight increased in 
 
 
 
 Figure 3-1 Appearance and weight gain of mice from the CD, HFD and HFD/CD group 
(A) Representative photographs of mice from the CD, HFD and HFD/CD group. (B) Body weight was 
monitored weekly over 30 weeks in mice of the CD (open squares), HFD (black squares) and HFD/CD 
(grey squares) group. n=21-26 animals/group. Data represent means±SEM. * p<0.05 vs. weight of CD 
group (20-30 weeks), †p<0.05 vs. weight of HFD/CD group (20-30 weeks).  
Results 
42 
all the groups, but mice in the HFD group gained significantly more weight compared to 
the CD and HFD/CD group (final weight of HFD group: 37.0±1.4 g vs. CD group: 
31.6±0.6 g and HFD/CD group: 31.4±0.7 g). Interestingly, final body weight of mice in 
the HFD/CD group was at a similar level compared to the CD group (Figure3-1A,B). 
Basal glucose levels (0 min) were similar across all groups after overnight starvation 
(CD group: 5.5±0.4 mM; HFD group: 6.6±0.2 mM; HFD/CD group: 6.4±0.3 mM). 
After 15 minutes of D-glucose injection, blood glucose levels in all the groups were 
higher compared to 0 min (Figure 3-2). At 30 minutes, glucose levels peaked in the 
HFD group (24.2±1.2 mM) whereas glucose concentrations in CD (16.5±1 mM) and 
HFD/CD group (18.6±0.7 mM) started to decrease. Furthermore, glucose concentration 
in mice of the HFD group did not return to the basal glucose level even after 120 
minutes (HFD group: 13.6±1.3 mM vs CD group: 7.6±0.3 mM, and HFD/CD group: 
8±0.4 mM) whereas glucose concentrations were similar in CD and HFD/CD group 
after 120 minutes (CD group: 7.6±0.3 mM, HFD/CD group: 8±0.4 mM) (Figure 3-2). 
3.2 Effect of diets on vascular reactivity 
3.2.1 Vascular responses to vasoconstrictors phenylephrine and 5-
hydroxytryptamine  
Phenylephrine-induced contraction was investigated in thoracic aorta from mice of 
different dietary groups. HFD increased phenylephrine-induced contractions compared 
to CD (CD group: 21±3.7 %; HFD group: 46.5±5.8 %). Interestingly, contractile 
responses to phenylephrine remained even higher elevated by HFD/CD (HFD/CD 
 
Figure 3-2 Glucose tolerance measurements of mice from the CD, HFD and HFD/CD 
Concentration of blood glucose in CD (open squares), HFD (black squares) and HFD/CD (grey squares) 
group was measured over 120 minutes after peritoneal injection of 2 mg/g body weight of D-glucose. 
n=11-22 animals/group. Values represent means ± SEM.*p<0.05 vs. CD group (30-120 minutes), 
†p<0.05 vs. HFD/CD group (30-120 minutes).  
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group: 56.7±6.6 %) (Figure 3-3A). Figure 3-3B represents contractions induced by 5-
hydroxytryptamine exposure. Only HFD/CD increased 5-hydroxytryptamine-induced 
contractions, but not HFD (CD group: 58.8±5.4 %, HFD group: 53.1±4.6 %, HFD/CD 
group: 67.6±3.9 %). The effect of HFD and HFD/CD on phenylephrine-mediated 
contractions was more prominent than on contractions to 5-hydroxytryptamine. 
3.2.2 Acetylcholine-induced endothelium-dependent relaxation and contraction 
Endothelium-dependent relaxation was analyzed in rings of thoracic aorta from 
experimental groups using acetylcholine. HFD and HFD/CD had no effect on 
acetylcholine-induced vascular relaxation (CD group: -85.1±3.6 %, HFD group: -
86.0±3.0 %, HFD/CD group: -81.3±5.1 %) (Figure 3-4A) and no difference in the half 
maximal effective concentration (EC50) response to acetylcholine was observed (data 
not shown). Under NO-depleted condition using the NO-synthase inhibitor L-NAME, 
addition of acetylcholine completely blocks endothelium-dependent relaxation and 
induces endothelium-dependent contractions (Vanhoutte & Tang, 2008). HFD increased 
these contractions by 2.6 fold (HFD group: 40.3±5.1 % vs. CD group: 15.4±3.3 %) 
whereas by HFD/CD contractions were at a level similar compared to the CD group 
(HFD/CD: 11±2.8 % vs. CD group: 15.4±3.3 %) (Figure 3-4B). 
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Figure 3-3 Contractile responses to phenylephrine and 5-hydroxytryptamine in thoracic aorta of 
mice in CD, HFD and HFD/CD group 
Phenylephrine (100 nM) (A) and 5-hydroxytryptamine (10 µM)-induced contractions (B) in aortic rings 
are shown. Open bars represent CD group, black bars; HFD group, grey bars; HFD/CD group. Data are 
shown as a percentage of KCl-induced contraction. n= 4-16 animals/group. Bars represent means±SEM. 
*p<0.05 vs. CD. 
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3.3 Vascular gene expression analysis in dietary treatment groups 
3.3.1 Gene expression analysis  
Based on these physiological, metabolic and vascular functional changes induced by 
dietary fat intake in mice we speculated that these functional effects may be a result of 
changes in vascular gene expression levels and/ or formation of alternatively spliced 
transcripts in the vasculature. Data obtained from the DNA Mouse Exon 1.0 ST Array 
were compared using one-way ANOVA to identify genes that show gene expression 
change in any of the experimental groups. The analysis revealed only very few genes 
with small expressional changes within the analyzed groups. The first list (“Top 
Genes”) includes 37 genes with gene expressional changes between any of the groups 
(p< 0.01, log2 effect (fold change) > 0.5, Table 3-1. Highest fold change differences 
between any of the groups was identified for Cyp2E1. 
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Figure 3-4 Acetylcholine-induced endothelium-dependent relaxation and contraction in thoracic 
aorta of mice in the CD, HFD and HFD/CD group 
Thoracic aortic rings were treated in the absence (A) or presence (B) of L-NAME (300 µM) before rings 
were pre-contracted with cumulative concentrations of phenylephrine (0.1-100 nM) followed by 
acetylcholine treatment (0.1 nM-30 µM). Acetylcholine-induced relaxation at 30 µM (A) and contraction 
at 1 µM (B) are represented. Open bars represent CD group, black bars; HFD group, grey bars; HFD/CD
group. Data are shown as a percentage of phenylephrine-induced pre-contraction (A) or KCl-induced 
contraction (B). n= 8-15 animals/group. Bars represent means±SEM. * p<0.05 vs. CD, † p<0.05 vs. HFD. 
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3.3.2 Exon expression analysis 
Exon expression analysis was used to identify how many exons of a certain gene are 
significantly differentially expressed. The second list (“Top Genes by Exon”) generated 
with one-way ANOVA includes 46 genes in which at least 2 exons of one gene show a 
significant expressional change in any of the three groups analyzed (p <0.65, log2 effect 
(fold change) >0.3, Table 3-2. Again Cyp2E1 was identified as the top differentially 
expressed gene. 
 
Gene Symbol Gene Description pValue
ENSMUSG00000025479 Cyp2E1 cytochrome P450, family 2, subfamily E, polypeptide 1 2.194 0.001485
ENSMUSG00000046957 Spz1 spermatogenic Zip 1 1.02 0.00168
ENSMUSG00000065610 mmu-mir-29a mmu-mir-29a 0.8982 0.004114
ENSMUSG00000075096 Olfr1228 olfactory receptor 1228 0.8727 0.009427
ENSMUSG00000051503 EG625424 predicted gene, EG625424 0.8182 0.00615
ENSMUSG00000026691 Fmo3 flavin containing monooxygenase 3 0.8135 0.009777
ENSMUSG00000056706 Krtap7-1 keratin associated protein 7-1 0.7405 0.006657
ENSMUSG00000068646 Olfr1279 olfactory receptor 1279 0.7398 0.0007183
ENSMUSG00000030194 Tas2r116 taste receptor, type 2, member 116 0.7211 0.005026
ENSMUSG00000054072 Iigp1 interferon inducible GTPase 1 0.703 0.004058
ENSMUSG00000076559 IGKV4-54 Immunoglobulin Kappa light chain V gene segment 0.7024 0.00979
ENSMUSG00000004151 Etv1 ets variant gene 1 0.6987 0.008023
ENSMUSG00000061653 V1rb8 vomeronasal 1 receptor, B8 0.6987 0.007414
ENSMUSG00000052908 Olfr699 olfactory receptor 699 0.6836 0.001096
ENSMUSG00000070411 NM_001011810.1 olfactory receptor 485 (Olfr485), mRNA 0.6742 0.001378
ENSMUSG00000072892 Zkscan17 zinc finger with KRAB and SCAN domains 17 0.6631 0.0007077
ENSMUSG00000038576 Susd4 sushi domain containing 4 0.6629 0.007462
ENSMUSG00000040134 Rdh7 retinol dehydrogenase 7 0.6562 0.005386
ENSMUSG00000029255 Gnrhr gonadotropin releasing hormone receptor 0.6389 0.002552
ENSMUSG00000050772 Olfr1125 olfactory receptor 1125 0.6299 0.005434
ENSMUSG00000029088 Kcnip4 Kv channel interacting protein 4 0.6275 0.00946
ENSMUSG00000031465 Angpt2 angiopoietin 2 0.6227 0.002501
ENSMUSG00000069867 Pabpnl1 poly(A)binding protein nuclear-like 1 0.5928 0.004266
ENSMUSG00000048504 Olfr453 olfactory receptor 453 0.5918 0.0008339
ENSMUSG00000047720 4922502D21Rik RIKEN cDNA 4922502D21 gene 0.5803 0.005862
ENSMUSG00000058079 Olfr605 olfactory receptor 605 0.5799 0.008747
ENSMUSG00000030544 Mesp1 mesoderm posterior 1 0.5795 0.005686
ENSMUSG00000008686 Zfp422-rs1 zinc finger protein 422, related sequence 1 0.5785 0.006022
ENSMUSG00000002661 Alkbh7 alkB, alkylation repair homolog 7 (E. coli) 0.5529 0.006323
ENSMUSG00000010592 Dazl deleted in azoospermia-like 0.5493 0.009727
ENSMUSG00000047976 Kcna1 0.538 0.007859
ENSMUSG00000061186 Sfmbt2 Scm-like with four mbt domains 2 0.5327 0.007728
ENSMUSG00000038305 2810022L02Rik RIKEN cDNA 2810022L02 gene 0.512 0.006317
ENSMUSG00000020108 Ddit4 DNA-damage-inducible transcript 4 0.511 0.002309
ENSMUSG00000049507 4930429B21Rik RIKEN cDNA 4930429B21 gene 0.5061 0.008182
ENSMUSG00000053088 NP_001098114.1 vomeronasal receptor Vmn2r53 0.5046 0.0009767
ENSMUSG00000020642 Rnf144a ring finger protein 144A 0.5017 0.007075
potassium voltage-gated channel,                                        
shaker-related subfamily, member 1
Ensembl accession 
number
log2 Effect 
(Fold change)   
Table 3-1 “Top Genes” list including 37 genes which show gene expression differences in any of the 
groups. 
Content of the table shows Ensembl accession number, gene symbols of identified genes, gene 
description, log2 effect (fold change) and p value. Genes are ranked hierarchically based on highest log2
effect. p value and log2 effect threshold were set at < 0.01 and >0.5, respectively. 
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3.3.3 Gene Ontology classification  
The 46 identified genes from the “Top Genes by Exon” list were classified by Gene 
Ontology (GO) using GeneGO Metacore software (GeneGO, Inc.) to assign biological 
meaning. The top most 10 significant GO processes are shown in Figure 3-5. Analysis 
determined GO processes of genes with a minimum log2 effect (fold change) of 0.3 and 
a maximum p value of 0.06. Results revealed that genes cluster mainly to biological 
processes involved in regulation of vasoconstriction, circulatory system process, blood 
circulation, and positive regulation of vasodilatation. 
Gene Symbol Gene Description pValue
ENSMUSG00000025479 Cyp2E1 cytochrome P450, family 2, subfamily E, polypeptide 1 9 10 2.194 0.001485
ENSMUSG00000036815 Dpp10 dipeptidylpeptidase 10 26 19 1.681 0.01487
ENSMUSG00000027559 Car3 carbonic anhydrase 3 7 2 1.451 0.2124
ENSMUSG00000029273 Sult1d1 sulfotransferase family 1D, member 1 9 2 1.249 0.04416
ENSMUSG00000030278 Cidec cell death-inducing DFFA-like effector c 6 3 0.985 0.0579
ENSMUSG00000030787 Lyve1 lymphatic vessel endothelial hyaluronan receptor 1 6 4 0.9668 0.01168
ENSMUSG00000019577 Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4 11 5 0.9375 0.03672
ENSMUSG00000057722 Lepr leptin receptor 22 4 0.9245 0.1302
ENSMUSG00000027445 Cst9 cystatin 9 3 2 0.9238 0.09917
ENSMUSG00000020787 P2rx1 purinergic receptor P2X, ligand-gated ion channel, 1 12 2 0.9156 0.0597
ENSMUSG00000028883 Sema3a semaphorin 3A 24 4 0.9044 0.178
ENSMUSG00000019874 Fabp7 fatty acid binding protein 7, brain 4 2 0.8935 0.1164
ENSMUSG00000066687 Zbtb16 zinc finger and BTB domain containing 16 7 3 0.8728 0.1247
ENSMUSG00000003974 Grm3 glutamate receptor, metabotropic 3 8 2 0.8657 0.2918
ENSMUSG00000030790 Adm adrenomedullin 4 2 0.8562 0.023
ENSMUSG00000048337 Ppyr1 pancreatic polypeptide receptor 1 2 2 0.833 0.02239
ENSMUSG00000027513 Pck1 phosphoenolpyruvate carboxykinase 1, cytosolic 8 3 0.8217 0.04389
ENSMUSG00000024222 Fkbp5 FK506 binding protein 5 11 2 0.8148 0.1045
ENSMUSG00000026691 Fmo3 flavin containing monooxygenase 3 9 2 0.8135 0.009777
ENSMUSG00000052374 Actn2 actinin alpha 2 21 2 0.7898 0.5399
ENSMUSG00000031099 Smarca1 26 2 0.7438 0.3686
ENSMUSG00000030935 Acsm3 acyl-CoA synthetase medium-chain family member 3 16 2 0.7361 0.1175
ENSMUSG00000020493 Prr11 proline rich 11 10 2 0.7172 0.1371
ENSMUSG00000020524 Gria1 glutamate receptor, ionotropic, AMPA1 (alpha 1) 18 4 0.7043 0.06306
ENSMUSG00000062991 Nrg1 neuregulin 1 9 2 0.6886 0.2022
ENSMUSG00000061723 Tnnt3 troponin T3, skeletal, fast 19 2 0.6689 0.06842
ENSMUSG00000056004 9630031F12Rik RIKEN cDNA 9630031F12 gene 22 2 0.6327 0.415
ENSMUSG00000028033 Kcnq5 19 3 0.6209 0.01316
ENSMUSG00000011463 NP_083982.1 carboxypeptidase B1 12 2 0.6103 0.4113
ENSMUSG00000022861 Dgkg diacylglycerol kinase, gamma 25 4 0.5958 0.3253
ENSMUSG00000032254 Kif23 kinesin family member 23 24 2 0.5844 0.05934
ENSMUSG00000015879 9330182L06Rik RIKEN cDNA 9330182L06 gene 16 2 0.5512 0.1411
ENSMUSG00000033282 Rpgrip1l Rpgrip1-like 26 3 0.5448 0.1275
ENSMUSG00000038665 NP_001074675. diacylglycerol kinase, iota 39 2 0.5231 0.5855
ENSMUSG00000039783 Kmo 17 2 0.5184 0.2477
ENSMUSG00000049482 2310061F22Rik RIKEN cDNA 2310061F22 gene 8 3 0.515 0.4793
ENSMUSG00000045328 Cenpe centromere protein E 46 2 0.4955 0.3941
ENSMUSG00000040084 Bub1b 23 2 0.4751 0.1324
ENSMUSG00000019359 Gdpd2 16 2 0.4725 0.269
ENSMUSG00000027985 Lef1 lymphoid enhancer binding factor 1 13 2 0.4668 0.6247
ENSMUSG00000026141 Col19a1 collagen, type XIX, alpha 1 53 2 0.451 0.3487
ENSMUSG00000014850 Msh3 mutS homolog 3 (E. coli) 26 2 0.4494 0.1209
ENSMUSG00000033826 Dnahc8 dynein, axonemal, heavy chain 8 93 3 0.4492 0.08218
ENSMUSG00000022262 Dnahc5 dynein, axonemal, heavy chain 5 79 2 0.4163 0.333
ENSMUSG00000057378 Ryr3 ryanodine receptor 3 104 2 0.3997 0.2306
ENSMUSG00000022483 Col2a1 collagen, type II, alpha 1 56 2 0.3742 0.2631
SWI/SNF related, matrix associated,                               
actin dependent regulator of chromatin, subfamily 1
potassium voltage-gated channel,                                   
subfamily Q, member 5
kynurenine 3-monooxygenase                                         
(kynurenine 3-hydroxylase)
Ensembl accession 
number
budding uninhibited by benzimidazoles                           
1 homolog,beta (S. cerevisiae)
glycerophosphodiester phosphodiesterase                     
domain containing 2
Number of 
total exons
Significant 
probe sets 
log2 Effect 
(Fold Change)
Table 3-2 “Top Genes by Exon” list including 46 genes in which at least 2 exons show a significant 
expression difference in any of the three groups 
Content of the table shows Ensembl accession number, gene symbols of identified genes, gene 
description, number of total exons of the gene, significant probe sets (exons) of the identified genes, log2
effect (fold change) and p value. Genes are ranked hierarchically based on highest log2 effect. p value and 
log2 effect threshold was set at < 0.65 and >0.3, respectively. 
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3.3.4 Visualization of probe set expression for selected target genes 
Probe set expression as measured by intensity values of genes were visualized as line 
graphs. Figure 3-6 and Figure 3-7 show representative line graphs of 12 genes chosen 
for further validation based on the criterion to be changed by HFD and HFD/CD. The 
line graphs illustrate differences in intensity values of every probe set between the 
treatment groups. Depending on the length, an exon is covered by several probe sets. 
Short exons are not covered by a probeset (Appendix Table 5-3) 
This is the case for exons 17 and 24 of diacylglycerol kinase, gamma (Dgkg), exons 
15 and 17 of dipeptidylpeptidase (Dpp10), exon 1 of flavin containing monooxygenase 
(Fmo3), exons 14, 17, and 21 for leptin receptor (Lepr). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5 Gene Ontology Classification by GeneGO Metacore 
Identified genes from the “Top Genes by Exon” list are grouped in regard to biological processes. Top 10 
biological processes are listed sorted by the lowest p value. Longer orange bars indicate lower p value for 
genes in a GO category. Figure was generated using GeneGO Metacore software (GeneGO Inc). 
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Figure 3-6 Visualization of probe set/exon intensity values of target genes 
Each Intensity value (log2) on the y-axis is plotted against the total number of probe sets of the respective 
gene (Car3, carbonic anhydrase 3; Cidec, cell-death-inducing DFFA-like effector c; Cyp2E1, cytochrome 
P450, family 2, subfamily E, polypeptide 1; Dgkg, diacylglycerol kinase gamma; Dpp10, 
dipeptidylpeptidase 10; and Fkbp5, FK506 binding protein 5) on the x-axis. Arrow indicates 5`to 
3`direction of the gene. CD group (red line), HFD group (purple line), and HFD/CD group (green line).  
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3.4 Validation of selected target genes   
To further investigate whether the expression of the 12 chosen genes in aortic tissue 
are specifically and sustainably changed by HFD and HFD/CD, steady state mRNA 
expression levels were validated with gene specific mouse primer pairs (Appendix 
Table 5-1) using qRT-PCR. Table 5-1 also shows which exons of selected genes are 
covered by primer pairs.  
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Figure 3-7 Visualization of probe set/exon intensity values of target genes 
Each Intensity value (log2) on the y-axis is plotted against the total number of probe sets of the respective 
gene (Fmo3, flavin containing monooxygenase 3; Lepr, leptin receptor; Lyve1, lymphatic vessel 
endothelial hyaluron receptor 1; Nrg1, neuregulin 1; Pdk4, pyruvate dehydrogenase kinase, isoenzyme 4; 
and P2rx1, purigenic receptor P2X ligand-gated ion channel) on the x-axis. Arrow indicates 5`to 
3`direction of the gene. CD group (red line), HFD group (purple line), and HFD/CD group (green line).  
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3.4.1 Genes with no expressional change  
Dietary treatments had no effect on steady-state mRNA expression levels of the 
genes FK506 binding protein 5 (Fkbp5) (Figure 3-8A), Fmo3 (Figure 3-8B), 
neuregulin 1 (Nrg1) (Figure 3-8C), lymphatic vessel endothelial hyaluronan receptor 1 
(Lyve1) (Figure 3-8D), pyruvate dehydrogenase kinase, isoenzyme 4 (Pdk4) (Figure 
3-8E), and purinergic receptor P2X, ligand-gated ion channel 1 (P2rx1) (Figure 3-8F). 
3.4.2 Changes in gene expression levels induced by high-fat diet 
Steady state mRNA expression levels of Lepr (Figure 3-9A) and Dgkg (Figure 
3-9B) were upregulated approximately 2-fold by HFD and expression levels in 
HFD/CD group were similar to CD group.  
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Figure 3-8 Genes that are not changed by different diets 
mRNA expression levels of target genes Fkbp5 (A), Fmo3 (B), Nrg1 (C), Lyve1 (D), Pdk4 (E) and P2rx1
(F) induced by the different dietary treatments are represented. mRNA expression was calculated by ∆CT 
of the gene of interest and the housekeeping gene β-actin =arbitrary units (AU). Values represent means ± 
SEM. Open bars, CD; black bars, HFD; grey bars, HFD/CD. n=5-6 aortic samples/experimental group.  
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3.4.3 Expression levels of genes with “high-fat diet memory effect”  
Analysis of data of the qRT-PCR showed that steady state mRNA expression of 
Dpp10, carbonic anhydrase 3 (Car3), Cidec, and cytochrome P450, family2, subfamily 
E, polypeptide 1 (Cyp2E1) were specifically and sustainably changed by HFD and 
HFD/CD (Figure 3-10). Dpp10 gene expression was 2.4 fold upregulated in the HFD 
group and 3.4 fold in the HFD/CD group compared to the CD group (Figure 3-10A) 
Expression of Car3 and Cidec was downregulated by HFD (Car3 and Cidec: 3.8 fold) 
and HFD/CD (Car3: 3.1 fold and Cidec: 2.6 fold) (Figure 3-10B,C). Expression of 
Cyp2E1 was downregulated by 3.6 fold in the HFD group and 4.8 fold in the HFD/CD 
group (Figure 3-10D). 
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Figure 3-9 Validation of genes that are changed by HFD but not by HFD/CD 
mRNA expression levels of target genes Lepr (A) and Dgkg (B) induced by the different dietary 
treatments are represented. mRNA expression was calculated by ∆CT of the gene of interest and the 
housekeeping gene β-actin and expressed in arbitrary units (AU). Values represent means ± SEM. Open 
bars, CD; black bars, HFD; grey bars, HFD/CD. n=5-6 aortic samples/experimental group.* p<0.05 vs. 
CD, † p<0.05 vs. HFD.  
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3.4.4 Protein expression level analysis of genes with “high-fat diet memory effect” 
To determine protein expression levels of aortic Car3, Cidec and Cyp2E1 in different 
dietary treatment groups, immunoblotting was performed using specific antibodies for 
Car3, Cidec and Cyp2E1. Extracellular signal-regulated kinase 1 and 2 (Erk1/2) 
antibody was used as loading control. HFD and HFD/CD downregulated Car3 protein 
expression level which is in line with mRNA expression levels (Figure 3-11A). Protein 
expression level of Cidec was upregulated by HFD and HFD/CD whereas mRNA 
expression was downregulated (Figure 3-11B). 
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Figure 3-10 Validation of genes that are changed by HFD and HFD/CD 
mRNA expression levels of target genes Dpp10 (A), Car3 (B), Cidec (C) and Cyp2E1 (D) induced by the 
different dietary treatments are represented. mRNA expression was calculated by ∆CT of the gene of 
interest and the housekeeping gene β-actin =arbitrary units (AU). Values represent means ± SEM. Open 
bars, CD; black bars, HFD; grey bars, HFD/CD. n=5-6 aortic samples/experimental group for qRT-PCR. 
* p<0.05 vs. CD. 
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Figure 3-11 Protein expression levels of Car3, Cidec and Cyp2E1 in aortic tissue of mice 
undergoing different dietary protocols 
Car3 (A) Cidec (B) and Cyp2E1 (C) in CD, HFD and HFD/CD group were analyzed using Western blot. 
Car3 is detectable at 28 kDa (A) and Cidec (B) at 27 kDa using the respective antibodies. Erk1/2 antibody 
was used as a loading control. Total protein lysates from liver and epididymal fat were used as positive 
controls to detect full-length Cyp2E1 at 51 kDa (red arrow). Blue arrows at 39 and 45 kDa indicate the 
size of Cyp2E1 protein in aorta (C; lower panel). Densitometry quantification of aortic Cyp2E1 protein 
at 39 (C; upper, left panel) and 45 kDa (C; upper, right panel) is shown. Values represent means ± 
SEM. Open bars, CD; black bars, HFD; grey bars, HFD/CD. n=4 aortic samples for immunoblotting.* 
p<0.05 vs. CD. 
Results 
54 
Immunoblotting analysis using the anti-Cyp2E1 (rabbit polyclonal antibody against 
full-length Cyp2E1) showed that full-length Cyp2E1 is highly expressed in liver and 
epididymal fat (both tissues were used as positive controls), and is detectable at 51 kDa 
while in aorta Cyp2E1 is expressed at low level and detected at 39 and 45 kDa in all the 
groups, but not at 51 kDa (Figure 3-11C, lower panel).This expression level pattern 
was confirmed also with a different antibody (rabbit polyclonal antibody against a 
synthetic peptide corresponding to C-terminal Cyp2E1, data not shown). Densiometric 
analysis of the blots revealed that aortic Cyp2E1 variant detected at 39 kDa was 
significantly downregulated 8-fold by HFD and 4-fold by HFD/CD (Figure 3-11C, 
upper, left panel) while Cyp2E1 variant detected at 45 kDa tended to be 
downregulated by 1.4-fold by HFD (p=0.0527) and HFD/CD (p=0.0599), respectively 
(Figure 3-11C, upper, right panel). 
3.5 Motivation to select Cyp2E1 for further in depth analysis 
The statistical analysis of the DNA Exon array and validation with qRT-PCR was 
revealing Cyp2E1 to be the top most differentially expressed gene within the groups 
(2.2 fold change compared to other genes which ranged between fold changes of 0.4-
1.7). Cyp2E1 belongs to the Cyp450 enzymes, a family of heme-containing 
monooxygenases which play an important role in the metabolism of arachidonic acid 
AA to HETEs (Laethem et al., 1993). These molecules contribute to the regulation of 
vascular homeostasis (Elbekai & El-Kadi, 2006). Cyp2E1 acts as ω- hydroxylase 
catalyzing the formation of 18 (R)-, 19 (R)-and 19(S)-HETEs from AA in the 
vasculature (Laethem et al., 1993). These metabolites were shown to act as vasodilators 
(Zhang et al., 2005; Schafer et al., 2010). Furthermore, Cyp2E1 can also generate 
reactive oxygen species (Lu & Cederbaum, 2008) which affect vascular reactivity (Cai 
& Harrison, 2000). So far only little data exist on the role of Cyp2E1 in vascular 
function and to my knowledge nothing is known how different diets influence Cyp2E1 
expression in aortic tissue. Furthermore, Western blot analysis showed two shorter 
protein forms of Cyp2E1 to be expressed in aorta. It is not known whether splice 
variants of Cyp2E1 exist in aortic tissue.  
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3.6 Analysis of vascular Cyp2E1 splice variants   
3.6.1 Statistical analysis of Cyp2E1 exon-specific differences between dietary 
treatment groups  
The Cyp2E1 gene consists of 9 exons and nucleotide sequence of full-length Cyp2E1 
mRNA contains 1759 bp (NCBI Accession # BC013451) The DNA Mouse Exon 1.0 
ST Array from Affymetrix is designed that every exon of a gene is covered by at least 
one probeset (Figure 3-12). 
To assess whether Cyp2E1 is alternatively spliced, Tukey`s post hoc test based on 
one-way ANOVA results of exon microarray data was applied to identify which 
probesets (covering and representing exons) are differentially expressed between the 
5482378
Cyp2E1 (1759bp)
Probeset ID 5263914 4909450 4624914 5000510
5425945
4618728 5096737 4780542
5542302
5328457
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Figure 3-12 Schematic representation of full-length Cyp2E1 transcript 
Cyp2E1 consists of 9 exons (boxes) and contains a nucleotide sequence of 1759 bp. Scheme represents 
the location of the 5`untranslated region (5`UTR); Start, start codon of Cyp2E1, CDS (coding sequence) 
of Cyp2E1, Stop, stop codon of Cyp2E1, 3`untranslated region (3`UTR), and poly(A) tail, 
polyadenylation tail. DNA exon arrays have a following design: Every exon is covered by at least one 
probeset. To distinct which probeset covers which exon, every probe set has its own ID. Depending on 
the length, one exon can be covered by more than one probeset as in exon 7 and 9. 
Exon Probeset ID   
HFD vs. CD 4909450 0.02228 -2.071 4
5425945 0.009736 -1.443 7
5096737 0.001632 -2.192 8
5542302 0.01587 -1.939 9
HFD/CD vs. CD 5482378 0.01399 -1.214 2
5263914 0.01066 -1.825 3
4909450 0.001902 -3.043 4
4624914 0.0108 -2.807 5
4618728 0.006739 -2.449 6
5000510 0.002449 -2.953 7
5425945 0.0008094 -2.074 7
5096737 0.0004613 -2.601 8
4780542 0.01226 -3.211 9
5542302 0.001907 -2.685 9
Exon Probeset ID  
maches to Exon 
Group 
comparisons
young-fat effect   
[Tukey p-value]  
Fold Change   
[log2 ratio]
 
 
Table 3-3 Tukey`s post hoc test analysis of Cyp2E1 
Table represents specific exons of Cyp2E1 that are differentially expressed between HFD or HFD/CD and 
CD group. p value threshold was set to < 0.05 and fold change threshold to > −0.4. Negative fold change 
indicates downregulation. 
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groups. Results for Cyp2E1 are shown in Table 3-3 (HFD vs. CD group and HFD/CD 
vs. CD group). Analysis between HFD and CD group showed that 4 probe sets covering 
4 different exons of Cyp2E1 are downregulated (minimum fold change: -1.4 fold for 
exon 7; maximum fold change: -2.2 fold for exon 8), while comparison of HFD/CD and 
CD group showed that 10 probe sets covering 8 exons (2 different probe sets cover exon 
7 and exon 9) of Cyp2E1 are differentially downregulated between HFD/CD and CD 
group (minimum fold change: -1.2 fold for exon 2; maximum fold change: - 3.2 fold for 
exon 9). 
3.6.1.1 Exon-specific validation of Cyp2E1 using PCR  
To investigate whether the differentially expressed exons identified for Cyp2E1 are 
due to the existance of truncated exons of Cyp2E1, exon-spanning primers (each primer 
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Figure 3-13 “Exon-specific” PCR of Cyp2E1 exons 1-8 in mouse liver and aorta 
(A) Illustrated are PCR amplicons generated with specific exon-spanning primer pairs for exons 1 to 8 
(B) Scheme shows the position of the different primer pairs (forward and reverse primer, indicated by 
black arrows) for each exon 1-8 and corresponding PCR product sizes in red. PCR amplicons were 
separated on a 2 % agarose gel. A 50 bp DNA marker was used to estimate size of the PCR products. As 
positive control cDNA from one liver per group was used to perform PCR, while cDNA from four 
different mouse aortae per group was used. 
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pair include one exon, (Appendix Table 5-2) were designed (Modrek & Lee, 2002; 
Erkens et al., 2008). Schematic representation of PCR amplicons of Cyp2E1 exons 1-8 
are shown in Figure 3-13 “Exon-specific” PCRs revealed that exons 1-8 are expressed 
in aorta of all groups (Figure 3-13A) with variations in expression levels (verified by 
qRT-PCR, data not shown). The amplicon sizes from exons 1-8 (Figure 3-13B) 
matched to those of mouse liver cDNA which was used as a positive control. Total size 
of Cyp2E1 exon 9 is 424 bp of which 185 bp correspond to the coding sequence 
including the stop codon, and 239 bp to the 3`untranslated region (3`UTR). 
Analysis of exon 9 using reverse primer Exon 9/1_3`UTR (Appendix Table 5-2) 
binding at basepair position 196 in the 3`UTR of Cyp2E1 indicated a truncation of this 
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Figure 3-14 “Exon-specific” PCR of Cyp2E1 exon 9 in mouse liver and aorta 
PCR amplicons of exon 9 are represented generated with three different reverse primers (blue, green and 
purple arrows). Different PCR product sizes of exon 9 are indicated in red. PCR amplicons were 
separated on a 2 % agarose gel. A 50 bp DNA marker was used to estimate size of the PCR products. As
positive control cDNA from one liver per group was used to perform PCR, while cDNA from four 
different mouse aortae per group was used. Stop, stop codon of Cyp2E1, 3`untranslated region (3`UTR). 
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region in aorta of all the groups, but not in liver(Figure 3-14, blue arrow). To narrow 
the region in which the truncation of exon 9 starts, two other reverse primers, Exon 
9/2_3`UTR and Exon 9/3_Stop were designed (Appendix Table 5-2). Reverse primer 
Exon 9/2_3`UTR is indicated in Figure 3-14 with a green arrow (binds at basepair 
position 104 in the 3`UTR of Cyp2E1), and reverse primer Exon 9/3_Stop is indicated 
by a purple arrow (Figure 3-14, this primer binds to the stop codon region at basepair 
position 185 of Cyp2E1) Visualization of PCR amplicons indicate that , 81 bp 
corresponding to the 3`UTR (distance between purple, 185 bp, and green reverse 
primer, 104 bp) are present in aortic tissue of all groups but amplification rate decreases 
with HFD and HFD/CD. Interestingly, PCR products with a size of 92 bp corresponding 
to the 3`UTR of exon 9 (distance between blue, 196 bp and green reverse primer, 104 
bp) are not present in any of the dietary treatment groups (Figure 3-14). 
3.6.1.2 Exon skipping analysis of aortic Cyp2E1 
Full-length Cyp2E1 mRNA in liver consists of 9 exons and contains a nucleotide 
sequence of 1759 bp with a molecular weight of ~51 kilo Dalton (kDa) for the 
translated protein. Two Cyp2E1 splice variants in liver are identified (Zhuge & 
Cederbaum, 2006a; b). Interestingly, in both splice variants 229 bp of the 3`UTR from 
exon 9 are missing. In addition, variant 1 lacks exons 4-6 (NCBI Accession # 
DQ838976, 1012 bp, 37 kDa) while variant 2 lacks exons 1-6 and 35 bp from exon 7 
(NCBI Accession # DQ838977, 484 bp, 17 kDa). To test whether known Cyp2E1 
variants are detectable in aortic tissue, PCR was performed using a forward primer 
binding at the end of exon 3 (ForEx3) and a reverse primer binding at the beginning of 
exon 8 (RevEx8, Figure 3-15A, Appendix ) Liver cDNA was used as a positive control. 
Visualization of the amplicons from liver and aorta using agarose gel electrophoresis 
revealed an upper band corresponding to a PCR product size of approximately 850 bp 
and a lower band at ~ 400 bp in two of four aortic samples in the CD group (Figure 
3-15B). In the aortic samples of the HFD and HFD/CD group, no lower band at ~ 400 
bp was detectable. 
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PCR bands of the CD group were excised from the agarose gel, purified and 
sequenced. In Figure 3-16 aligned sequencing results are shown. Using nucleotide 
“Basic Local Alignment Search Tool” (BLAST® from NCBI) upper band was identified 
as Cyp2E1 wild type sequence with an expected product size of 850 bp including exon 
4-6 of Cyp2E1. Interestingly, the sequencing results for the lower band showed that 
exon 4-6 are skipped. 
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Figure 3-15 Representative agarose gel image of separated PCR products amplified using the 
specific primer pair ForEx3 and RevEx8 in liver and aorta of CD, HFD and HFD/CD group 
(A) Scheme represents the location of the primer pair (direction of the primers indicated by black arrows)
in Cyp2E1 full-length transcript. (B) Amplified PCR products from all groups (CD, HFD, HFD/CD) were
loaded on a 2 % agarose gel. 1 kb DNA ladder (lane 1, 5, 6, and 19) was used to estimate size of all PCR 
products. As positive control cDNA from one liver per group (lane 2, liver CD; lane 3, liver HFD; lane 4,
liver HFD/CD) was used, while cDNA from four different mouse aortae per group (lane 7-10, aorta CD; 
lane 11-14, aorta HFD; lane 15-18, aorta HFD/CD) was used to perform PCR. ForEx3 (forward primer
binding at exon 3); RevEx8 (reverse primer binding at exon 8); 5`UTR, 5`untranslated region; Start, start 
codon of Cyp2E1, CDS, coding sequence of Cyp2E1, Stop, stop codon of Cyp2E1, 3`UTR, 
3`untranslated region and poly(A) tail, polyadenylation tail. 
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3.7 Effect of DETC on vascular reactivity in dietary treatment groups  
To investigate whether Cyp2E1 contributes to vascular reactivity in aorta of mice 
from the CD, HFD and HFD/CD group, the first approach was to inhibit Cyp2E1 with 
DETC. It is important to note that DETC inhibits Cyp2E1 in liver microsomes 
(Guengerich et al., 1991) and arteries of hypertensive rats (Zhang et al., 2005), but also 
SOD in aorta in mice, rats, and rabbits (Ghanam et al., 1998; Karasu, 2000; Takenouchi 
et al., 2009).  
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Figure 3-16 Nucleotide sequence alignment of complete Cyp2E1 amplicon and Cyp2E1 splice 
variant in aorta of the CD group 
Cyp2E1 CAmp represents the nucleotide sequence of complete Cyp2E1 amplicon whereas Cyp2E1 SV 
represents the nucleotide sequence of the splice variant in which complete exon 4 (pink), exon 5 (red) and 
exon 6 (dark green) are spliced out. Numbers 369-1184 represent nucleotide basepair positions of 
complete mRNA sequence targeted by primer pair ForEx3 and RevEx8. Vertical black lines indicate 
beginning and end of a particular exon. Colours represent different exons. 
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3.7.1 Impact of DETC on responses to vasoconstrictors phenylephrine and 5-
hydroxytryptamine  
Cumulative concentrations of phenylephrine were added after rings were incubated 
without or with DETC for 30 minutes. As shown previously, without addition of 
inhibitors, contractile responses to phenylephrine at 100 nM were significantly 
increased with HFD and HFD/CD (see also Figure 3-3A). Inhibition with DETC 
significantly increased phenylephrine-mediated contractions in the CD group (21±3.7 % 
vs. 33.3±4.1 %) (Figure 3-17A) and were decreased in HFD (46.5±5.8 % vs. 26.7±4.1 
%) and HFD/CD group (56.7±6.6 % vs. 29.4±2.9 %) (Figure 3-17B,C, respectively). 
Contractions to phenylephrine due to inhibition with DETC were similar in all groups 
(CD DETC: 33.3±4.1 %; HFD DETC: 26.7±4.1 %; HFD/CD DETC: 29.4±2.9 %). 
5-hydroxytryptamine-mediated contractions were analyzed using no inhibitor or 
DETC in the thoracic aorta of the CD, HFD and HFD/CD group (Figure 3-18). At a 
concentration of 10 µM, contractions were induced in all the three groups. In the 
absence of DETC, only 5-hydroxytryptamine contraction in the HFD/CD group was 
significantly increased, but not in the HFD group (see also Figure 3-3B). Interestingly, 
addition of DETC significantly reduced 5-hydroxytryptamine-induced contractions in 
the CD (58.8±5.4 % vs. 33.5±4.1 %) and HFD/CD group (67.6±3.9 % vs. 46.5±5.2 %) 
(Figure 3-18A,C), but not in the HFD group (53.1± 4.6 % vs. 43.2± 7.9 %) (Figure 
3-18B). However, contractions to 5-hydroxytryptamine in the presence of DETC were 
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Figure 3-17 Effect of DETC on phenylephrine-mediated contraction in CD, HFD, and HFD/CD 
group 
Phenylephrine (PE)-induced contractions were determined by incubating rings either without inhibitor
(Ø) (open bar, CD; black bar, HFD; grey bar, HFD/CD) or with DETC (100 µM) (striped bars) before 
contracting the vessels with cumulative concentrations of phenylephrine (0.1-100 nM). Data represent 
phenylephrine-induced contractions at a concentration of 100 nM (A-C). Data are shown as a percentage 
of KCl-induced contraction. n=9-20 animals/group. Values represent means±SEM.* p<0.05 vs. CD group 
Ø, † p<0.05 vs. HFD group Ø, # p<0.05 vs. HFD/CD group Ø. 
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similar in all groups (CD DETC: 33.5±4.1 %; HFD DETC: 46.5±5.2 %; HFD/CD 
DETC: 43.2.±7.9 %). 
3.7.2 Effect of DETC on endothelium-dependent contractions induced by 
acetylcholine  
Endothelium-dependent contractions were induced under NO-depleted condition (as 
described in 3.2.2) at high concentration of acetylcholine (1 µM) in all the three groups 
(CD group: 15.4±3.3 %, HFD group: 40.3±5.1 %, HFD/CD group: 11±2.8 %, see also 
Figure 3-4B) Interestingly, treatment with DETC significantly reduced endothelium-
dependent contractions in the CD and HFD group (Figure 3-19A,B) but not in the 
HFD/CD group (Figure 3-19C). 
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Figure 3-18 Role of DETC in 5-hydroxytryptamine-mediated contraction in CD, HFD, and 
HFD/CD group 
Aortic rings were incubated in the absence (open bar, CD; black bar, HFD; grey bar, HFD/CD) or 
presence (striped bars) of DETC (100 µM) for 30 minutes before cumulative concentrations of 5-
hydroxytryptamine (0.1 nM-10 µM) were added. 5-hydroxytryptamine (5-HT) contraction at a 
concentration of 10 µM is represented (A-C). n=9-14 animals/group. Data are shown as a percentage of 
KCl-induced contraction. Data represent means±SEM.* p<0.05 vs. CD group Ø, † p<0.05 vs. HFD/CD 
group Ø. 
Results 
63 
3.8 Vascular reactivity in wild type and Cyp2E1-deficient mice 
To test whether Cyp2E1 plays a role in vascular reactivity, wild type and Cyp2E1-
deficient mice were analyzed. Aortic rings were treated with different vasoactive 
substances to test contractile (phenylephrine, 5-hydroxytryptamine, acetylcholine) and 
relaxant (acetylcholine) responses. Additionally, these mice were used to verify the 
results obtained with the Cyp2E1-inhibitor, DETC, and additionally to test its 
specificity for Cyp2E1 in this experimental setting. 
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Figure 3-19 Effect of DETC on endothelium-dependent contractions in thoracic aorta of CD, HFD 
and HFD/CD group 
Before pre-contraction with phenylephrine, rings were incubated only with L-NAME (300 µM) (CD, 
open bar; HFD, black bar; HFD/CD, grey bar) or with L-NAME and DETC (1 µM) (striped bars) for 30 
minutes. Then, rings were exposed to cumulative concentrations of acetylcholine (ACh). Endothelium-
dependent contractions at a concentration of 100 µM are shown in all three groups (A-C). n=8-18 
animals/group. Data are shown as a percentage of KCl-induced contraction. Data represent means±SEM.* 
p<0.05 vs. rings treated with L-NAME in the CD group, † p<0.05 vs. rings treated with L-NAME in the 
HFD group. 
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3.8.1 Responses to vasoconstrictors phenylephrine and 5-hydroxytryptamine 
Phenylephrine-and 5-hydroxytryptamine-induced contractions were investigated in 
aorta of wild type (WT) and Cyp2E1-deficient (Cyp2E1-/-) mice. Contractions induced 
by phenylephrine at a concentration of 1 µM were similar in WT and Cyp2E1-/- mice 
(WT: 54.1±6.3 % vs. Cyp2E1-/-: 57.3±2.6 %) (Figure 3-20A). However, 5-
hydroxytryptamine-induced contractions at a concentration of 10 µM were significantly 
decreased in Cyp2E1-/- mice (WT: 88.3±4.9 % vs. Cyp2E1-/-: 64.7±4.7 %) (Figure 
3-20B). 
3.8.2 Endothelium-dependent relaxation 
In aortic rings of WT and Cyp2E1-/- mice endothelium-dependent relaxation were 
analyzed using acetylcholine. Maximal acetylcholine-induced relaxation was impaired 
in Cyp2E1-/- mice compared to WT mice (WT: -73.4±5.8 %; Cyp2E1-/-: -53.4±7.4 %) 
(Figure 3-21). Inhibition of NO with L-NAME blocked endothelium-dependent 
relaxation completely in WT and Cyp2E1-/- mice (data not shown). 
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Figure 3-20 Contractile responses to phenylephrine and 5-hydroxytryptamine in wild type and 
Cyp2E1-deficient mice 
Phenylephrine- (PE, 1 µM) (A) and 5-hydroxytryptamine (5-HT, 10 µM)-induced contractions (B) in 
wild type (WT, open bars) and Cyp2E1-deficient (Cyp2E1-/-, black bars) mice are represented. n=10 WT 
animals; n= 17 Cyp2E1-/- animals. Data are shown as a percentage of KCl-induced contraction. Data 
represent means±SEM.* p<0.05 vs. WT. 
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3.8.3 Acetylcholine-induced endothelium-dependent contractions   
WT and Cyp2E1-/- mice were used to test whether Cyp2E1 plays a role in 
acetylcholine-induced endothelium-dependent contractions. Endothelium-dependent 
contractions induced by acetylcholine were increased by 2 fold in Cyp2E1-/- mice 
compared to WT mice (WT: 7.3±3.7 %; Cyp2E1-/-: 14.7±3.2 %) (Table 3-4). 
Additionally, it was tested whether the increase in acetylcholine-induced contractions in 
Cyp2E1-/- mice is initiated by COX-dependent release of prostanoids. Therefore, vessels 
were either pre-incubated with L-NAME (300 µM) alone or L-NAME + meclofenamate 
(1 µM) , a non-selective competitive inhibitor of COX-1 and COX-2 (Kretz et al., 2006) 
for 30 minutes, pre-contracted with phenylephrine and exposed to acetylcholine at a 
high concentration of 100 µM. Interestingly, acetylcholine-induced contractions in 
Cyp2E1-/- mice were abolished by addition of meclofenamate (Table 3-4). 
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Figure 3-21 Acetylcholine-relaxation in wild type and Cyp2E1-deficient mice 
To test endothelium-dependent relaxation in aortic rings of experimental mice, vessels were pre-
contracted with phenyleprhine to a 50 % contraction to KCl followed by cumulative concentration of 
acetylcholine (ACh, 0.1 nM-100 µM). WT (open squares); Cyp2E1-/- (black squares) mice. n= 5 WT 
animals; n= 6 Cyp2E1-/- animals. Data are shown as a percentage of phenylephrine (% PE)-induced pre-
contraction. Data represent means±SEM.* p<0.05 vs. WT. 
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3.9 Effect of DETC on vascular reactivity in wild type and Cyp2E1-
deficient mice 
3.9.1  Impact of DETC on phenylephrine- and 5-hydroxytryptamine-mediated 
contractions  
Aortic rings from WT and Cyp2E1-/- mice were incubated with no inhibitor (Ø) or 
different concentrations of DETC, (100 µM or 500 µM), followed by phenylephrine 
treatment. A concentration of 100 µM of DETC increased contraction to phenylephrine 
(1 µM) in WT (54.1±6.3 % vs. 74±11 %) and Cyp2E1-/- mice (56.5±2.5 % vs. 73.2±8.2 
%), (Table 3-5A) but not 5-hydroxytryptamine-induced contractions (WT: 88.3±4.9 % 
vs. 91.5±6.1 %; Cyp2E1-/-: 67.4±5.2 % vs. 63.7±7.5 %) (Table 3-5B). A concentration 
of 500 µM further enhanced phenylephrine-induced contractions (1 µM) in WT 
(54.1±6.3 % vs. 96±3.8 %) and Cyp2E1-/- mice (56.5±2.5 % vs.105±12.1 %) (Table 
3-5A). Contractions to 5-hydroxytryptamine were decreased with DETC at a 
concentration of 500 µM only in WT (88.3±4.9 % vs. 74.6±4.7 %) but not in Cyp2E1-/- 
mice (67.4±5.2 % vs. 62.6 ±10.1 %) (Table 3-5B). 
 
Table 3-4 Endothelium-dependent contractions induced by acetylcholine in wild type and Cyp2E1-
deficient mice 
Contractions to acetylcholine at a concentration of 100 µM in aortic rings of WT and Cyp2E1-/- mice are 
represented. Vessel rings of WT mice were only incubated with 300 µM of L-NAME while rings of 
Cyp2E1-/- mice were incubated with L-NAME or L-NAME+meclofenamate (1 µM) for 30 minutes before 
pre-contraction with cumulative concentrations of phenylephrine (0.1 nM-1µM). Endothelium-dependent
contractions were detected at a concentration of 100 µM of acetylcholine. n= 6 WT animals; n=6-12 
Cyp2E1-/- animals. Data are shown as a percentage of KCl (% KCl)-induced contraction. Data represent 
means±SEM.* p<0.05 vs. WT, † p<0.05 vs. Cyp2E1-/- L-NAME. NA, not analyzed. 
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3.9.2 Effect of DETC on endothelium-dependent contractions induced by 
acetylcholine  
Acetylcholine-induced contractions at a high concentration (100 µM) were 
investigated in NO-depleted condition without or with DETC (100 µM) in WT and 
Cyp2E1-/- mice. Table 3-6 represents that endothelium-dependent contractions induced 
by acetylcholine are decreased by DETC in WT (7.3±3.7 % vs. 2.1±1.4), but not in 
Cyp2E1-/- mice (14.9± 3.2 % vs. 13.3±3.4 %). 
 
 
Inhibitors DETC
100 µM
DETC
500 µM
Cyp2E1-/-
54.1±6.3%WT *
Ø
74±11% 96±3.8%
56.5±2.5% 73.2±8.2% 105.2±12.1%
A
B
*
† †
Inhibitors DETC
100 µM
DETC
500 µM
Cyp2E1-/-
88.3±4.9%WT
Ø
91.5±6.1% 74.6±4.7%
67.4±5.2% 63.7±7.5% 62.6±10.1%
*
 
 
Table 3-5 Different DETC concentrations and their effect on phenylephrine- and 5 –hydroxytrypt-
amine- induced contractions in wild type and Cyp2E1-deficient mice 
Table shows phenylephrine- (A) and 5-hydroxytryptamine-induced contractions (B) at a concentration of 1 
µM and 10 µM in aortic rings, respectively, in WT and Cyp2E1-/- mice without inhibitor (Ø) or pre-
incubated for 30 minutes with either 100 µM or 500 µM of DETC. n= 7-17 WT animals; n=8-12 Cyp2E1-/-
animals. Data are shown as a percentage of KCl (% KCl)-induced contraction. Data represent means±SEM.* 
p<0.05 vs WT, † p<0.05 vs Cyp2E1-/-. 
Inhibitors L-NAME L-NAME + DETC
Cyp2E1-/-
7.3±3.7%WT 2.1±1.4%
14.9±3.2% 13.3±3.4%
*  
 
Table 3-6 Effect of DETC on acetylcholine-induced contractions in wild type and Cyp2E1-deficient 
mice 
Represented are contractions induced by acetylcholine at a concentration of 100 µM in the presence of L-
NAME (300 µM) or L-NAME+DETC (100 µM) in aortic rings from WT and Cyp2E1-/- mice. n= 6 WT 
animals; n= 6-12 Cyp2E1-/- animals. Data are shown as a percentage of KCl (% KCl)-induced
contraction. Data represent means±SEM.* p<0.05 vs. WT L-NAME. 
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4 Discussion 
The main findings of the current study are as follows: (I) HFD causes heterogenous 
changes in vascular reactivity, increases body weight and leads to impaired glucose 
tolerance; (II) a diet switch from HFD to CD induces selective changes in vascular 
reactivity despite normal body weight and glucose tolerance; (III) transcriptomic 
analysis reveals 46 genes in which at least 2 exons show a significant expressional 
change in any of the treatment groups; (IV) identification of Dpp10, Car 3, Cidec and 
Cyp2E1 being differentially expressed by HFD and HFD/CD in aortic tissue; (V) 
characterization of aortic Cyp2E1 splice variants; (VI) Cyp2E1 plays a role in 
regulation of vascular function. 
4.1 Effect of HFD and HFD/CD on body weight and glucose tolerance  
Obesity is characterized by an imbalance between energy intake and energy 
expenditure, in which energy intake is increased and/or energy expenditure is decreased. 
This leads to an increase in body weight which can be mainly attributed to more body 
fat or adipose tissue. Adipose tissue is composed of adipocytes. Obesity increases 
number (hyperplasia) and size (hypertrophy) of adipocytes, the predominant cell type in 
adipose tissue (Jequier, 2002). Systemically, obesity is associated with various 
alterations including impaired glucose tolerance and insulin resistance in humans (Kahn 
et al., 2006; Karam & McFarlane, 2011) and animals (Woods et al., 2004; Mundy et al., 
2007b). After reduction of body weight glucose tolerance improves (Colman et al., 
1995).  
The C57BL/6J mouse strain is suitable to study diet-induced obesity (Surwit et al., 
1988; Collins et al., 2004) because these mice develop obesity and diabetes upon high- 
fat diet feeding resembling human obesity and diabetes (Buettner et al., 2007). Many 
factors such as composition of fatty acids, secretion of signaling molecules from 
adipocytes, stress, low satiating effects of fat, texture and odour of the high-fat diet, 
frequency and rate of food intake are described in rodents leading to an increase in body 
weight (Hariri & Thibault, 2010). In rodents usually high-fat diets containing 30-78 % 
kcal from fat are used to induce obesity (Buettner et al., 2007) compared to normal 
chow diet containing 3.5-12 % kcal from fat (Reliene & Schiestl, 2006; Gajda et al., 
2007). In the present study, the high-fat/high-carbohydrate diet used from Research 
Diets (D12079B) contains 41 % kcal from fat, 45 % kcal from carbohydrates and 17 % 
kcal from protein. This diet induced a significant increase in body weight after 30 weeks 
in the HFD group. In accordance to the present data, studies showed that high-fat/high-
carbohydrate diets increase body weight in C57BL/6J mice (Surwit et al., 1988; Klaus, 
2005). At 30 weeks of diet, the mean value of total body weight reached in mice of the 
HFD group was 37 grams. This was 6 grams more compared to CD and HFD/CD. 
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Another study showed a 14 grams increase in body weight in C57BL/6J mice after 30 
weeks, but the high-fat diet used contained 60 % kcal from fat (Hoffler et al., 2009). 
The mice used in this study were held in a specific-pathogen free environment in cages 
with separate air condition. As germ-free C57BL/6J mice increase less in body weight 
compared to conventionally housed mice (Rabot et al., 2010) this might be a possible 
explanation for the overall lower weight gain in mice of the present study. Furthermore, 
body weight in diet-induced obesity mice is not as high as in genetically-modified mice 
(Woods et al., 2004; Murphy et al., 2010). Surprisingly, body weight of mice in the 
different treatment groups was similarly increased after 15 weeks. Another study 
showed that the same high-fat diet (D12079B) induces a significant increase in body 
weight gain of 6 grams in C57BL/6J mice after 15 weeks of high-fat diet compared to 
control diet (Mundy et al., 2007b). Ito et al. even showed that C57BL/6J mice fed for 
15 weeks with the high-fat diet (D12079B) had an increased body weight gain of 16 
grams (Ito et al., 2006). It suggests that in the present experimental set-up (i) weight 
gain is highly variable in the first 15 weeks of age and that (ii) body weight gain is 
independent of dietary fat content for the first 15 weeks of diet. It is possible that body 
weight in all treatment groups was similar after 15 weeks because mice were only 4 
weeks old when the dietary treatment started. The energy from the first 15 weeks of 
HFD feeding was exclusively used for growth of the animals. Important to note is also 
that total weight gain in all dietary treatment groups was highest after 15 weeks 
(approximately 15 grams of weight gain). Mice in the HFD group increased their body 
weight after 30 weeks to 6 grams whereas in the CD and HFD/CD group an increase of 
only 2 grams was observed. It suggests that longer feeding of this diet is relevant for 
HFD-dependent increase in body weight. Therefore it was not surprising that total 
weight gain in the HFD/CD group was lower compared to the HFD group and similar to 
the CD group. The control diet used in the CD and HFD/CD group contained 12 % kcal 
from fat, 65 % kcal from carbohydrates, and 22 % kcal from proteins. Studies with 
animals showed that diets low in fat can induce weight loss after 16 weeks of feeding a 
high-fat diet and switching to a low-fat diet for 16 weeks (Parekh et al., 1998). Other 
studies showed that C57BL/6J mice develop hyperplastic and hypertrophic fat cells 
upon HFD feeding (Surwit et al., 1995). Hill and colleagues reported that hyperplasia of 
fat cells induced by 17 weeks of high-fat diet intake was reversed after diet was 
switched to low fat diet. Interestingly, if the diet switch was only carried out after 30 
weeks hyperplasia of fat cells was not reversible (Hill et al., 1989).  
Not only the amount of energy from fat is important to develop obesity but rather the 
composition of fatty acids is crucial (Storlien et al., 2001; Moussavi et al., 2008). Fat in 
the high-fat diet (D12079B) from Research Diets derives mainly from milk fat. Usually, 
70 % of fatty acids in milk fat are saturated, 25 % are monounsaturated, and 
approximately 2 % are polyunsaturated (Mansson, 2008). Nutrition rich in saturated 
fatty acids (SFAs) increase the risk to develop obesity in humans (van Marken 
Lichtenbelt et al., 1997). Wang et al. showed that a diet high in SFAs also increases 
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body weight in C57BL/6J mice (Wang et al., 2002). SFAs are usually not used for 
energy expenditure, but stored as triglycerides in adipose tissue. However, 
polyunsaturated and monounsaturated fatty acids are used for energy expenditure and 
stored less in adipose tissue (Storlien et al., 2001). It is also known that SFAs from 
animal fat mainly contain long-chain fatty acids compared to plant fat which contains 
medium-chain fatty acids and that this is related to the development of obesity (Hariri & 
Thibault, 2010). The high content of SFAs in the diet may contribute to the higher 
weight gain in mice fed with HFD in the present study. 
High dietary fat intake leads to impaired glucose tolerance and reduces the effect of 
insulin to lower glucose levels in the blood (Lichtenstein & Schwab, 2000). A study 
performed by Takahashi and coworkers showed that a higher percentage of fat in a 
high-fat diet is correlated with glucose intolerance (Takahashi et al., 1999). The dietary 
treatment used in this study not only had an effect on body weight but also had an 
impact on glucose tolerance in these mice. A GTT performed with mice fed for 30 
weeks with HFD showed that glucose tolerance in these mice was impaired after 2 
hours but not in HFD/CD group. Glucose concentration in the blood of mice in the 
HFD/CD group was reduced after 2 hours compared to the HFD group and similar to 
the CD group. Parekh et al. showed that plasma glucose and insulin levels (analyzed 
with a Beckman Glucose Analyzer 2 (Taylor & Pennock, 1981) and double antibody rat 
insulin radioimmunoassay kit, respectively) were decreased after switching from 16 
weeks of high-fat diet feeding to a low fat diet for 16 weeks (Parekh et al., 1998). The 
reduced weight gain in the HFD/CD group compared to the HFD group might be the 
reason why glucose tolerance is normal in these mice. Similarly, weight loss in severely 
obese humans by bariatric surgery and dietary intervention by reduction in dietary fat 
intake improves glucose tolerance (Long et al., 1994; Fruchter, 2001).  
This study has some limitations in regard to phenotypic and metabolic analysis: 
Daily food intake was not measured in these experimental groups. An irregular food 
intake might explain why animals had similar weights after 15 weeks and the mean total 
body weight of mice in the HFD group was only 37 grams. Furthermore, fat pads 
(subcutaneous and epididymal) of these animals were not weighed which would have 
indicated whether adipose tissue amount is different between the dietary treatment 
groups. It would have been also important to measure plasma lipids such as cholesterol 
(Do et al., 2011) and common adipokines or cytokines such as leptin (Ahren et al., 
1997) and TNFα (Mito et al., 2000) which are secreted by adipose tissue. Leptin, for 
example, is an important adipokine regulating food intake and body weight (Zhang et 
al., 1994). It is elevated in obese humans (Saad et al., 1998) and also in mice (Frederich 
et al., 1995). This in fact indicates that high levels of leptin cause leptin resistance. 
Dysfunction of leptin receptors in the hypothalamus lead to uncontrolled food intake 
and behavior (Frederich et al., 1995). In addition to the GTT, an insulin tolerance test 
should have been performed to test whether secretion of insulin and its action on 
lowering blood glucose is affected, especially in the HFD group. Furthermore, 
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pancreatic β-cells, skeletal muscle, liver and adipocytes play an important role in 
regulating glucose metabolism. Additional experiments using these cells and organs 
would be needed to explain why glucose tolerance is impaired by HFD and normal after 
HFD/CD. It is known that pancreatic β-cells synthesize and secrete insulin to maintain 
blood glucose level homeostasis. In obese humans, a dysfunction of pancreatic β-cells 
can lead to a diminished insulin secretion. The cells are not able anymore to release 
insulin quickly upon high glucose levels in the blood (Kahn, 2001). In this study, 
impaired glucose tolerance after HFD might be explained in part by damage in β-cell 
function not able to release insulin. Mundy and colleagues showed that an impaired 
glucose tolerance was already present after 15 weeks of feeding with high-fat diet 
(D12079B) (Mundy et al., 2007b). This implicates that a disturbance in glucose 
tolerance already occurs after 15 weeks of high-fat diet treatment and sustains after 
longer feeding of 30 weeks. The data of the present study show that a reduction in 
dietary fat content after 15 weeks can normalize an impaired glucose tolerance. 
4.2 Influence of HFD and HFD/CD on vascular reactivity 
An intact endothelial function is important to maintain healthy vascular homeostasis 
(Caballero, 2003). Regulation of vascular tone by release of vasoactive molecules such 
as vasoconstrictors and vasodilators is one of the main functions of the endothelium. 
Obesity leads to an imbalance between secretion of vasoconstrictors and vasodilators, 
favoring the release of vasocontractile molecules but also of inflammatory and growth-
promoting molecules. A consequence can be endothelial dysfunction and development 
of vascular diseases (Quyyumi, 1998; Caballero, 2003). Weight loss improves 
endothelial dysfunction (Caballero, 2003) but other studies also showed that if 
endothelial function is once damaged, for example by obesity, it is not possible to 
completely restore its function even after normalization of body weight (Brook et al., 
2004). A possibility to assess functional or dysfunctional endothelium is measurement 
of vascular reactivity. 
4.2.1 Phenylephrine and 5-hydroxytryptamine-induced contractions 
Phenylephrine causes vasoconstriction in isolated thoracic aorta of C57BL/6J mice 
(Russell & Watts, 2000), mainly by direct binding to the G-protein coupled α1-
adrenergic receptor on VSMCs (Piascik et al., 1996). HFD feeding in mice increases 
vascular contractions to phenylephrine (Molnar et al., 2005). In the present study, 
treatment with HFD and HFD/CD for 30 weeks increased phenylephrine-mediated 
contractions in thoracic aorta of mice. The increased response to HFD could be due to 
an increased expression of α1-adrenergic receptors and phenylephrine-induced 
downstream signalling stimulated by HFD. Additionally, expression and release of 
dilatory molecules might be decreased which increases phenylephrine-mediated 
contractions. In the present study, inhibition with L-NAME showed that basal NO 
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availability is reduced by HFD and HFD/CD in comparison to CD (data not shown). 
This is also shown by other studies (Bourgoin et al., 2008). Smith et al. showed that 
body weight is increased, glucose tolerance is impaired and phenylephrine-mediated 
contraction to phenylephrine is enhanced in aorta of rats fed a high-fat diet (35 % from 
fat) for 10 weeks (Smith et al., 2006). Increased contractile responses to the 
vasoconstrictor phenylephrine could be also explained by the increased body weight and 
the impaired glucose tolerance in mice of the present study. It might be possible that 
HFD affected phenylephrine-mediated contractions by an increased number of α1-
adrenergic receptors on VSMCs and promoting an increase in contractile responses. A 
study performed by Hodgkin et al. showed that total number of α1-adrenergic receptors 
in aorta of rats is increased due to dietary fat treatment (Hodgkin et al., 1991). The 
increased phenylephrine-mediated contractile response in the HFD/CD group could be 
due to a memory effect of VSMCs. Increased expression of α1-adrenergic receptors 
probably cannot be reversed after reducing the fat content in the diet after 15 weeks 
even though body weight and glucose tolerance are similar to CD. This might also 
explain that changes in vasoconstriction responses already occur early possibly even 
after 15 weeks of HFD feeding. Furthermore, these data suggest that a switch to CD 
after 15 weeks of HFD only normalizes body weight and glucose metabolism which is 
partly independent from changes in the vasculature. Surprisingly, contractile responses 
to 5-hydroxytryptamine were not affected by HFD even though it has been shown that 
diet-induced obesity augments 5-hydroxytryptamine-induced contraction in isolated 
mesenteric arteries (Boustany-Kari et al., 2007) and aorta of rats (Ghatta & Ramarao, 
2004). It is possible that smaller vessels such as mesenteric arteries are more prone to 
increased vasoconstriction than aorta. However, Ghatta et al. showed that contractile 
responses to 5-hydroxytryptamine were higher in aortic rings from rats fed a high-fat 
diet containing 58 % from fat suggesting species-specific effects (Ghatta & Ramarao, 
2004). 5-hydroxytryptamine-induced contractions are mainly mediated by activation of 
S2-receptors on VSMCs (Vanhoutte et al., 1984). Expression of these receptors might 
not be changed by HFD. On the other hand, changes in adrenergic receptor expression 
might be more susceptible and sensitive to HFD than serotonergic receptors. Important 
to note is that contractions to 5-hydroxytryptamine are higher compared to 
phenylephrine-induced contractions in the CD group. It is possible that under normal 
conditions the number of expressed S2-receptors is higher compared to α1-adrenergic 
receptor on VSMCs. HFD is not able to increase expression of S2- receptors because of 
saturation which might not be the case for α1-adrenergic receptors. Interestingly, HFD 
did not increase 5-hydroxytryptamine-contractions, but a slight and significant increase 
in these contractions was observed with HFD/CD. Based on the results of the HFD 
feeding it could be that not HFD feeding but a switch to CD feeding is responsible for 
the increase in 5-hydroxytryptamine contractions. Overall, 5-hydroxytryptamine-
induced contractions are more resistant to dietary interventions independent of changes 
in body weight and glucose metabolism than contractile responses to phenylephrine.  
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Taken together, HFD and HFD/CD increases contractions to phenylephrine strongly, 
while contractions to 5-hydroxytryptamine were only slightly increased after HFD/CD 
diet. 
4.2.2 Acetylcholine-induced relaxation and contraction 
Acetylcholine causes endothelium-dependent relaxation in isolated thoracic aorta of 
C57BL/6J mice (Russell & Watts, 2000) by the release of NO (Feletou et al., 2008). In 
the present study, endothelium-dependent relaxation in aorta induced by acetylcholine 
was unaffected by HFD. Unchanged vascular relaxation by dietary interventions 
indicates that eNOS activity and NO availability are intact. Other researchers showed 
that HFD feeding for 15 weeks using the same type of diet (D12079B from Research 
Diets) also did not impair endothelium-dependent relaxation (Mundy et al., 2007b). 
Similarly, feeding of C57BL/6J mice with a HFD from Harlan Teklan, containing 42 % 
kcal from milk fat for 26 and 30 weeks showed that acetylcholine-induced endothelium-
dependent relaxation in isolated aorta and mesenteric arteries was normal (d'Uscio et 
al., 2001; d'Uscio et al., 2002). The results of this study together with findings from the 
above mentioned publications indicate that (i) neither short-term nor long-term feeding 
of HFD alters endothelium-dependent relaxations in different vascular beds which could 
be due to normal NO availability. Despite normal dilatory response induced by 
acetylcholine after HFD the source of relaxant molecules can change: Obesity can 
activate expression of inflammatory genes such as iNOS (Noronha et al., 2005). iNOS 
releases up to 1000-fold more NO than eNOS (Nathan, 1997). Noronha et al. showed 
that diet-induced obesity in C57BL/6J mice increases expression of iNOS in aorta 
raising NO production (Noronha et al., 2005). It suggests that endothelium-dependent 
relaxation in the CD group is mediated by NO release from eNOS while relaxation in 
the HFD groups might be mediated by NO produced by increased expression of iNOS.  
On the other hand, it is known that ECs generate high amounts of ROS during 
obesity (Traupe et al., 2002; Taniyama & Griendling, 2003; Mundy et al., 2007b). 
Uncoupling of eNOS forms O2- and NO. This leads to scavenging of NO by O2- 
resulting in ONOO- formation which decreases NO availability and NO-mediated 
relaxation (Vanhoutte et al., 2009). Additionally, O2- is converted by SOD to H2O2 
which causes relaxation (Shimokawa, 2010). In the present study, it is possible that 
HFD feeding increases formation of O2- leading to H2O2 which would explain the 
normal relaxation. Additionally, H2O2 can be further converted by catalase into H2O and 
O2 or to •OH (Taniyama & Griendling, 2003). Interestingly, •OH enhances 
endothelium-dependent relaxation in mice fed a high-fat diet (Mundy et al., 2007a). To 
note is that acetylcholine can also stimulate the production of ROS (Yao et al., 1999; 
Oldenburg et al., 2002; Noronha et al., 2005). These observations indicate that 
acetylcholine-induced endothelium-dependent relaxation during HFD is mediated by 
the release of ROS. In rats, high-fat diet feeding decreases acetylcholine-induced 
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relaxation after a feeding period of 28 weeks (Roberts et al., 2005). It is possible that 
impact of high-fat diet feeding on endothelium-dependent relaxation varies between 
species. On the other hand, Ketonen et al. showed that endothelium-dependent 
relaxation is impaired in aorta of C57BL/6J mice after 20 weeks of high-fat diet 
(Ketonen et al., 2010). These authors showed that decreased endothelium-dependent 
relaxation is associated with dysregulation of eNOS phosphorylation and eNOS 
uncoupling because of increased superoxide production (Ketonen et al., 2010). The 
impairment in vascular relaxation observed by Ketonen et al. might be due to higher fat 
content (61 % kcal from fat) in the diet used. In this study, endothelium-dependent 
relaxation was unaffected by HFD/CD. Ketonen et al. showed that caloric restriction 
after high-fat diet feeding normalizes endothelium-dependent relaxation because of 
reduced release of reactive oxygen species (Ketonen et al., 2010). Endothelium-
dependent relaxation in the HFD/CD group probably occurs via reduced release of 
reactive oxygen species or by NO either generated by iNOS or eNOS. Furthermore, 15 
weeks of feeding with the high-fat diet (D12079B) has no impact on vascular relaxation 
as shown by Mundy et al. (Mundy et al., 2007b). Therefore, it was not surprising that 
endothelium-dependent relaxation in the HFD/CD group was similar to the CD group. 
The data of the present study also show that relaxant responses to dietary interventions 
are more resistant to changes compared to vasoconstrictor responses mediated by 
phenylephrine. 
Inhibition of NO-synthase blocks the release of NO in isolated arteries (Vanhoutte & 
Tang, 2008). This evokes endothelium-dependent contractions by conversion of AA by 
COX-1 to endoperoxides and prostaglandins which bind to TP receptors on VSMCs to 
mediate contractions (Feletou et al., 2008; Vanhoutte & Tang, 2008). In the present 
study, acetylcholine-induced endothelium-dependent contractions were increased by 
HFD but not by HFD/CD. An increase in endothelium-dependent contractions by HFD 
might involve an increased COX-1 activity and enhanced release of endoperoxides and 
prostaglandins. Additionally, expression of TP-receptors is enhanced due to increased 
release of endoperoxides and prostanoids. Interestingly, Mundy et al. showed that HFD 
feeding in C57BL/67 mice for 15 weeks did not significantly increase endothelium-
dependent contractions upon NO-synthase inhibition with L-NAME (Mundy et al., 
2007b). This indicates that a longer duration of HFD feeding facilitates endothelium-
dependent contractions. Furthermore, generation of ROS by HFD promote an increase 
in endothelium-dependent contractions in mice which is related to increased expression 
of TP receptors (Gollasch, 2002; Traupe et al., 2002). Specifically, O2- can scavange 
NO leading to ONOO- favoring endothelium-dependent contractions (Vanhoutte et al., 
2009). HFD fed animals of this study showed increased body weight and glucose 
tolerance. Increased body weight leads to endothelium-dependent contractions in aorta 
of mice fed a HFD for 30 weeks (Traupe et al., 2002). Due to the literature high glucose 
levels and obesity facilitate an increase in ROS availability in the vasculature, especially 
O2- and increase the expression of COX-1 which leads to endothelium-dependent 
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contraction (Vanhoutte et al., 2009). Furthermore, O2- stimulates COX-1 metabolizing 
AA to endoperoxides and prostaglandins (Vanhoutte, 2002). Endothelium-dependent-
contractions in the HFD group might be due to increased release of O2-. Endothelium-
dependent contractions in the HFD/CD group were similar to those observed with CD. 
This might be due to the beneficial effect of the diet switch, reduced production of O2-, a 
normalized COX-1 activity and reduced release of endoperoxides and prostaglandins.  
 
Only HFD increased endothelium-dependent contractions possibly by increased 
release of O2- while endothelium-dependent-relaxation remained unaffected by HFD 
and HFD/CD. 
4.3 Vascular gene expression profiling after different dietary 
interventions  
Since 1995 DNA microarray technology is a powerful tool to identify differences in 
gene expression patterns (Schena et al., 1995), and is successfully used to determine 
obesity-associated changes in gene expression (Mzhavia et al., 2008; Joo & Yun, 2011). 
Many studies have shown that high-fat diet and obesity affect gene expression in 
adipose tissue (Urs et al., 2004; Baranova et al., 2005; Rodriguez-Acebes et al., 2010; 
Ichioka et al., 2011), liver (Kim et al., 2004), and skelatal muscle (Sparks et al., 2005). 
Soukas and colleagues were the first performing DNA microarray experiments related 
to obesity in 2000 (Soukas et al., 2000). The effect and improvements of weight loss 
due to caloric restriction on gene expression was mainly investigated in adipose tissue 
in rodents and humans using transcriptomics tools (Viguerie et al., 2005). Only few 
studies exist in which the effect of high-fat diet feeding on gene expression profiling in 
aorta is explored (Mzhavia et al., 2008; Dejeans et al., 2009; Mak et al., 2010; Rull et 
al., 2010). The impact of dietary fat restriction on vascular gene expression is not yet 
investigated. Furthermore, most of the studies mentioned here used 3`based gene 
expression arrays. Since 2005, Affymetrix offers exon microarrays (Affymetrix., 2005b) 
for humans, mouse and rats which allow implementation of gene expression analysis of 
the whole gene and the identification of alternatively spliced genes (Whistler et al., 
2010; Paloschi et al., 2011). This is possible because probes are located at each exon 
over the entire length of the transcript (detailed description of the Affymetrix exon 
arrays is described in Materials and Methods 2.2.4) This is different to the 3`based gene 
expression arrays in which the probes only target the 3`end of the gene. The Affymetrix 
exon array was successfully used in various disease-related studies to identify gene 
expression changes and splice variants (Gardina et al., 2006; Thorsen et al., 2008; 
Bemmo et al., 2010). Therefore, in the present study, Affymetrix DNA exon microarray 
was chosen to assess gene expression changes by dietary treatments but also exon 
expression changes to distinguish between different isoforms of a gene. Gene 
expression analysis revealed that dietary treatments with HFD and HFD/CD only 
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affected the expression of few genes in aortic tissue with a total of 37 genes. Exon 
expression analysis identified 46 genes in which at least 2 exons of a gene showing to 
be differentially expressed. In addition, only small expressional changes with a maximal 
log2 fold change of 2.2 were identified. This indicates that long-term dietary treatment 
affects only few genes in aortic tissue with small expressional changes. Dejeans and 
colleagues performed a DNA microarray experiment with aortic tissue from C57BL/6J 
mice fed a high-fat diet for only 3 weeks. Surprisingly, these researchers showed that 
448 genes were differentially expressed upon high-fat diet treatment (Dejeans et al., 
2009). This might indicate that a short-term dietary treatment of 3 weeks affects 
expression of more genes than a long-term treatment of 30 weeks. Interestingly, the 
expressional changes were also not very high (maximal log2 fold change of 4, but most 
genes showed a log2 fold change of 0.5-2.5) (Dejeans et al., 2009) which is in line with 
our findings. An additional study by Mzhavia et al. performed a microarray of aortic 
tissue from C57BL/6J mice which were fed with a high-fat diet containing 35 % from 
fat for 16-20 weeks identified Cyp2E1 as one of the significant differentially expressed 
genes (Mzhavia et al., 2008) which is in line with findings of this study.  
Gene Ontology analysis revealed that identified genes are associated with processes 
due to cytoskeleton and extracellular matrix alterations (Dejeans et al., 2009) whereas in 
the present study identified genes were assigned to processes involved in regulation of 
vasoconstriction, circulatory system process, blood circulation, and positive regulation 
of vasodilatation. It indicates that short-term dietary treatment affects genes which are 
important for vessel architecture and structure whereas a long-term dietary treatment 
has an impact on vessel function. An artery mainly contains ECs and VSMCs (Pugsley 
& Tabrizchi, 2000). Both cell types are important to modulate vascular function. Using 
ECs (Beyer et al., 2008) or VSMCs as starting material for array analysis would have 
probably led to different results. A separate microarray analysis of ECs and VSMCs 
would avoid nivellation problems which means that a particular gene is not identified in 
a whole aortic tissue approach if the gene is upregulated in ECs and downregulated in 
VSMCs. Another possibility could be that the observed changes in vascular reactivity 
due to HFD and HFD/CD are not exclusively mediated by expressional changes of 
genes in aortic tissue. Expressional changes of genes in liver, skeletal muscle and 
adipose tissue are evenly important in modulating changes in vascular reactivity. Gene 
expression of peroxisome proliferator-activated receptors (PPARs) in liver of mice was 
shown to be affected by long-term high-fat diet treatment of 12 weeks (Kim et al., 
2004). PPAR-γ was shown to be involved in modulation of angiotensin II and 
thromboxane A2 -mediated renal vasoconstriction in rats (Newaz et al., 2006). 
Furthermore, high-fat diet treatment in mice reduces expression of genes involved in 
oxidative phosphorylation in mitochondria of skeletal muscle (Sparks et al., 2005). 
Oxidative phosphorylation is an important process to provide energy in form of ATP 
from oxygen (Madamanchi et al., 2005). Under pathophysiological conditions, possibly 
initiated through high fat diet, oxidative phosphorylation is partially uncoupled leading 
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to production of O2-. As outlined in 1.4 ROS, and specifically O2- are implicated to 
affect vascular reactivity and leading to endothelial dysfunction (Cai & Harrison, 2000). 
Several adipokines such as leptin and adiponectin as well as inflammatory cytokines 
such as TNF-α and IL-6 released from adipocytes during obesity are known to have an 
impact on vascular reactivity (Kougias et al., 2005; Vila & Salaices, 2005).  
4.3.1 Validation and regulation of target gene expression 
In order to ensure whether data obtained from DNA microarray experiments are 
biologically valid, data sets are usually validated using qRT-PCR and Western Blot 
(Chuaqui et al., 2002). Often data from microarray and quantitative RT-PCR do not 
correlate based on biological and/or technical variations, and different analysis tools 
(Chuaqui et al., 2002). A microarray experiment is a multi-step procedure in which it is 
important to keep variability (biological and technical) low in order to obtain good data. 
A biological variability of the sample is difficult to control. It is important to carefully 
prepare the sample as well as include a solid number of replicates. Technical variabilty 
can involve steps from isolation of RNA, reverse transcription, labeling of cDNA, 
hybridization of cDNA to the chip platform, and analysis of the data (Novak et al., 
2002; Bryant et al., 2011). Therefore, care has to be taken while performing a 
microarray experiment to avoid irregularities which can affect the quality of the data. 
Sources for errors using qRT-PCR and Western Blots are amplification errors, 
mispriming and primer dimers, and antibodies which may affect the results negatively. 
In the present study, based on statistical analysis 12 genes being differentially 
expressed by HFD and HFD/CD were chosen for validation with qRT-PCR. Four genes 
(Dpp10, Car3, Cidec, and Cyp2E1) could be validated by qRT-PCR to be differentially 
expressed by HFD and HFD/CD. This is in line with the results obtained by microarray 
analysis (see also 3.3.4). It suggests that the microarray experiment was technically 
performed well because data of qRT-PCR correlate with data obtained from microarray. 
Furthermore, primer pair design and binding location was chosen appropriate for those 
genes.  
Validation of target genes Lepr and Dgkg showed that both genes are only 
differentially expressed after HFD and not by HFD/CD as suggested by the microarray 
data. This indicates that the results of the qRT-PCR are not in line with the microarray 
data. On the other hand, it is important to note that primers designed for qRT-PCR 
validation only detected short sections of the sequence (max. 150 bp, mainly located in 
one exon or exon boundaries of the whole gene) to achieve good amplification 
efficiency (Wong & Medrano, 2005). This means that data obtained with qRT-PCR 
only could validate expression of maximal 2 exons of a gene. Further studies would be 
needed to find out whether expression of exons are differentially affected by dietary 
treatments which is suggested by line graphs (see 3.3.4) For Cyp2E1 primer pairs were 
designed for each exon of the gene to validate exon expression levels with qRT-PCR. 
The results showed that expression of each exon was downregulated by HFD and 
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HFD/CD (data not shown). The data obtained for Lepr and Dgkg also indicate that some 
exons of the genes are only affected by HFD and others probably by both HFD and 
HFD/CD. To test this primer pairs for each exon of the gene should have been designed 
and expression validated by qRT-PCR.  
Target genes Lyve1, Pdk4, P2rx1, Fkbp5, FMO3 and Nrg1 were not, differentially 
expressed by HFD and HFD/CD as shown with qRT-PCR even though a tendency was 
observed. This might be due to very small differences observed and standard errors of 
the mean are relatively high indicating a strong variability. The results for these genes 
indicate that the primer pair used detects an exon which is not differentially expressed 
by neither HFD nor/and HFD/CD.  
It is not known whether these four genes biologically interact with each other. 
Cyp2E1 protein levels in liver can be induced by obesity (Raucy et al., 1991). 
Interestingly, mRNA and protein expression of aortic Cyp2E1 was increased in 
streptozotocin-induced diabetic rats (Schafer et al., 2010). mRNA expression of 
Cyp2E1 was also increased in C57BL/6J mice fed for 16-20 weeks with a high-fat diet 
containing 35 % from fat (Mzhavia et al., 2008). In the present study, Cyp2E1 was 
downregulated by HFD and HFD/CD after 30 weeks of feeding. Indeed, other 
researchers showed that Cyp2E1 protein expression is downregulated in interlobar 
arteries of spontaneous hypertensive rats at the age of 10-12 weeks. (Zhang et al., 2005) 
This would be in line with our finding. Taken together, this indicates that expression of 
Cyp2E1 is affected by (i) tissue-specific regulation, (ii) various diseases, and (iii) short-
term vs. long-term high-dietary feeding.  
Car3 is one of 14 known carbonic anhydrase isozymes (Swenson, 2000) which was 
found to be expressed in low amounts in vascular smooth muscle cells of bovine aorta 
(Berg et al., 2004). Carbonic anhydrases are usually involved in acid-base balance, ion 
transport, and gas exchange but it was also implicated to play a role in the regulation of 
vascular tone, even though concentrations are low (Berg et al., 2004). Interestingly, a 
gene expression profiling analysis using adipose tissue from C57BL/6J mice fed a high-
fat diet (21 % from fat) showed that expression of Car3 is increased after 3 weeks of 
high-fat diet feeding and decreases after 5 weeks of feeding (Van Schothorst et al., 
2005). In the present study, HFD and HFD/CD decreased expression of Car3 in aortic 
tissue after 30 weeks of dietary feeding. It might suggest that longer dietary treatment 
decreases expression of Car3 in various tissues.  
In the present study, Cidec mRNA expression levels in aortic tissue were 
downregulated by HFD and HFD/CD. Cidec belongs to the cell-death-inducing DFF45-
like effector gene familiy and was implicated to play a role in adipocyte lipid 
metabolism (Magnusson et al., 2008) and apoptosis (Keller et al., 2008). Interestingly, 
Keller et al. showed that Cidec expression in subcutaneaous adipose tissue from obese 
patients (BMI ≥30 kg/m2) is decreased. Another study from Magnusson and collegues 
reported that Cidec expression in subcutaneaous adipose tissue from obese patients 
(BMI of 36 kg/m2) undergoing a very low calorie dietary treatment for 12 weeks was 
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decreased (Magnusson et al., 2008). Together this suggests that Cidec expression is 
similar regulated in adipose and aortic tissue.  
To my knowledge, nothing is known about the expression of Dpp10 in aortic tissue 
and impact of dietary treatments. Dpp10 belongs to the S9B prolyl oligopeptidase class 
of serine proteases which is highly expressed in brain and modulates voltage-gated K+ 
channels (Kvs) especially Kv4-mediated A-type K+ channels (Zagha et al., 2005). Kvs 
are expressed in vascular smooth muscle cells (Korovkina & England, 2002) and play 
an important role in regulating vascular tone under normal and pathophysiological 
conditions (Brayden, 1996; Thorneloe et al., 2001). The Kv4 subfamily is also 
expressed in vascular smooth muscle cells (Cox, 2005). Therefore it is not surprising 
that Dpp10 was identified in aortic tissue. It is possible that downregulation of Dpp10 
expression by HFD and HFD/CD has an impact on Dpp10-mediated modulation of 
Kv4-mediated A-type K+ channels in aortic tissue.  
 
In order to test whether protein expression levels of Dpp10, Car3, Cidec and Cyp2E1 
are differentially expressed by HFD and HFD/CD Western Blot analysis was 
performed. Detection of Dpp10 protein was unsuccessful, because of unspecific binding 
of antibody against Dpp10. A Dpp10 blocking peptide could not resolve the problem 
(data not shown).  
Car3 was detected at 28 kDa. Its expression is downregulated by HFD and HFD/CD 
which matches to the results obtained with qRT-PCR. This indicates that both diets 
impair mRNA synthesis leading to decreased expression of the protein. Another 
explanation would be that mRNA is posttranscriptional modified. It could be that one 
part of the mRNA is degraded and only a small part is transferred to the cytosol for 
protein translation. This would explain why protein expression of Car3 is generally 
lower in all three treatment groups compared to qRT-PCR data.  
Cidec has a molecular weight of 27 kDa. Cidec mRNA is downregulated by HFD 
and HFD/CD whereas protein expression is downregulated by CD and upregulated by 
HFD and HFD/CD. This indicates that CD stabilizes mRNA of Cidec but translation of 
Cidec is repressed possibly by specific microRNAs (miRNAs) or Cidec is degraded 
posttranslational. The decrease in Cidec mRNA levels by HFD and HFD/CD could be 
due to a negative feedback inhibition leading to a degradation of Cidec mRNA initiated 
when Cidec protein is translated and stabilized.  
Interestingly, full-length Cyp2E1 at 51 kDa could not be detected in aortic protein 
lysates, but 2 other bands could be detected at 39 and 45 kDa. Quantification of these 
two bands showed that expression of Cyp2E1 at 39 kDa is downregulated by HFD and 
HFD/CD and expression of Cyp2E1 at 45 kDa showed a tendency to be downregulated 
by both diets. This indicates the generation of at least 3 different mRNA transcripts. 
There are several different possibilities why Cyp2E1 full-length is not detected by 
Western Blot in aortic tissue: (i) Cyp2E1 gene is not formed after splicing or (ii) it is 
formed but degraded or (iii) not translated into protein. The other two mRNA transcripts 
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are translated and expressed but different posttranscriptional and posttranslational 
regulations might play a role. From the qRT-PCR results, it is impossible to figure out 
from which mRNA transcript, mRNA expression levels are detected. In liver, Cyp2E1 
expression is regulated posttranscriptional by stabilization of mRNA and 
posttranslational by protecting against protein degradation (Song et al., 1987; Roberts et 
al., 1995; Lieber, 1997). Mohri et al. showed that human Cyp2E1 is regulated by the 
miRNA miR-378 which needs to bind to the 3`UTR leading to translational repression 
thereby decreasing Cyp2E1 protein expression (Mohri et al., 2010). 
 
Interestingly, mRNA expression of Car3, Cidec and Cyp2E1 were downregulated by 
HFD and HFD/CD whereas mRNA expression of Dpp10 was upregulated by both diets 
which could also suggest that transcription of Car3, Cidec and Cyp2E1 is decreased and 
transcription of Dpp10 is increased by HFD and HFD/CD. Transcriptional regulation 
controls whether and how much mRNA is synthesized. Epigenetic processes can cause 
alterations in gene expression without altering DNA sequence. Such processes include 
DNA methylation or histone deacetylation which can lead to a decrease in transcription 
and gene expression (Gibney & Nolan, 2010). Diet-induced and genetically caused 
obesity in mice was reported to affect gene expression by epigenetic regulation 
(Takahashi et al., 2005; Stoger, 2008). Additionally, activation of repressors binding to 
silencer regions in the promoter region of a gene does not allow RNA-polymerase to 
bind to the promoter thereby impairing transcriptional process (Lodish et al., 2007). 
Certain transcription factors, called general transcription factors, are needed to start 
transcription because they help RNA polymerase to bind to the promoter (Lodish et al., 
2007). Therefore, a disruption in this transcription initiation complex can effect 
expression of a gene. It may be possible that HFD and HFD/CD affects the transcription 
machinery for Car3, Cidec and Cyp2E1 to reduce their expression while it activates 
transcription for Dpp10. 
 
Taken together, in aortic tissue high dietary fat intake leads in at least four genes to 
gene and protein expression changes that sustain after high-dietary fat is reduced.  
4.4 Vascular Cyp2E1 splice variants 
Alternative splicing of eukaryotic genes is important since it increases the variety of 
transcripts leading to various protein isoforms (Tazi et al., 2009). Approximately 70-90 
% of human genes are alternatively spliced (Johnson et al., 2003; Wang et al., 2008). 
Splicing is the process in which introns are removed from the transcribed pre-mRNA 
which can result in joining of exons in multiple ways. Products are alternatively spliced 
mRNAs leading consequently to different protein isoforms (Black, 2003). Alternative 
splicing events can be various: (I) exons can be included or excluded, known as cassette 
exon or exon skipping, (II) exclusion of exon mutually means that one exon of two will 
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be retained in the mRNA, but not both at the same time resulting in two alternatively 
spliced mRNAs (III) alternative 5` (a) and 3` (b) splice sites occur which may lead to a 
shorter or longer exon (IV) an alternative promoter (a), poly(A) region (b) and the 
removal of the stop codon (c) can have an impact on transcription and translation, (V) 
part of an intron or the whole intron can be retained in the generated mRNA (Black, 
2003). The splicing process is very complex and includes multiple steps (Black, 2003). 
A defect in the splicing process in form of mutations can lead to diseases (Faustino & 
Cooper, 2003). 
In this study, statistical analysis using Tukey`s post hoc test revealed gene that 4 
exons (4, 7, 8, 9) of Cyp2E1 are downregulated by HFD compared to CD, and 8 exons 
(2-9) are downregulated by HFD/CD compared to CD (see Table 3-3) Based on this 
analysis, an exon specific PCR was performed to test whether differentially expressed 
exons are due to the existence of truncated exons. Results showed that exons 1-8 are 
detectable in all dietary treatment groups, but their expressions are downregulated by 
HFD and HFD/CD in aortic tissue but not in liver as verified with qRT-PCR (data not 
shown). This is not in line with the Tukey`s post hoc data. Additionally, it indicates that 
differential exon expression is not necessarily related to truncation of an exon. 
Furthermore, data suggest that HFD and HFD/CD have an impact on expression of 
exons which is independent of their amplification. This means that the amount of cDNA 
amplified representing the amount of mRNA produced is independent of its expression. 
Interestingly, only exon 9 including the stop codon is amplified in all groups whereas 81 
bp downstream of the stop codon in the 3`UTR is amplified in the CD group but 
amplification rate diminishes with HFD and HFD/CD. Furthermore, additional 92 bp in 
the 3`UTR are not amplified at all in any of the groups. This implicates that the end part 
of the 3`UTR is truncated in aortic tissue of all dietary treatment groups and suggests a 
spliced isoform independently of HFD and HFD/CD. 3 `UTR plays a role in mRNA 
stability, its localization in the cytoplasm and is involved in the regulation of translation 
(Mignone et al., 2002; Mazumder et al., 2003). It may suggest that mRNA of full-length 
Cyp2E1 is degraded or not functional because of partial truncated 3`UTR therefore full-
length Cyp2E1 is not translated. Important to note is that even though exons 1-8 are 
detectable it does not mean that splice variants do not exist. In liver, two truncated 
isoforms of Cyp2E1 were identified (Zhuge & Cederbaum, 2006a; b). Interestingly, in 
both truncated versions 229 bp of the 3`UTR from exon 9 are missing. This is partly in 
line with our data. In addition, variant 1 lacks exons 4-6 corresponding to 1012 bp and 
37 kDa (Zhuge & Cederbaum, 2006a) while variant 2 lacks exons 1-6 and 35 bp from 
exon 7 corresponding to 484 bp and 17 kDa (Zhuge & Cederbaum, 2006b). In the 
present study, exon skipping analysis using a primer pair detecting exon 4-7 identified 
an isoform of Cyp2E1 in which exons 4-6 were skipped in aortic tissue. This would 
suggest that aortic Cyp2E1 isoform lacks exons 4-6 as shown for Cyp2E1 variant 1 in 
liver. Lack of exons 4-6 would account for an isoform length of ~1280 bp (full-length 
Cyp2E1 nucleotide sequence: 1759 bp subtracted by 479 bp (exon 4-6) and a molecular 
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weight of ~47 kDa. This isoform was only detected in the CD group but not in the HFD 
and HFD/CD group. This might be due to decreased Cyp2E1 mRNA expression levels 
in the HFD and HFD/CD group (verified with qRT-PCR). Western Blot analysis 
detected two protein isoforms at 39 and 45 kDa in aorta of the HFD and HFD/CD 
group. Overall it is difficult to assess whether the two identified Cyp2E1 protein bands 
at 39 and 45 kDa can be correlated with the results of the exon-specific and exon 
skipping PCR analysis but it is possible that aortic Cyp2E1 splice variant lacking exons 
4-6 corresponds to the Western Blot band at 45 kDa. To test this, identified transcript 
should have been cloned separately into an expression vector to further be transfected 
into a cell line to overexpress this isoform. Overexpressed Cyp2E1 isoform could be 
detected with Western Blots and be compared to the bands obtained in aortic tissue.  
 
Taken together, the results indicate that two different Cyp2E1 mRNA transcripts 
could be identified. Additionally, two new Cyp2E1 protein isoforms in aortic tissue are 
detected in all dietary treatment groups with reduced expression induced by HFD and 
HFD/CD. Full-length Cyp2E1 mRNA transcript is detectable by PCR but probably not 
translated into protein. 
4.5 Effect of DETC and role of Cyp2E1 in vascular reactivity 
Cyp2E1 acts as a ω- hydroxylase catalyzing the formation of 18 (R)-, 19 (R)-and 
19(S)-HETEs from AA in the vasculature (Laethem et al., 1993). Zhang et al. showed 
that inhibition of Cyp2E1 by DETC decreases levels of 18- and 19-HETE in interlobar 
arteries of SHR. These researchers also showed that a decrease in 18-and 19- HETE 
enhances Cyp4A-derived 20-HETE-mediated contractions and that 20-HETE itself 
enhances phenylephrine-mediated contractions (Zhang et al., 2005) indicating that 18- 
and 19-HETE act as vasodilators. These findings are further strengthened by a recent 
publication demonstrating that streptozotocin-induced diabetes in rats increases the 
expression of Cyp2E1 and 18- and 19-HETE levels in aorta which decreased 20-HETE 
levels and phenylephrine-mediated contractions. These data indicate that up regulation 
of Cyp2E1 increases 18-and 19-HETE formation which decrease phenylephrine-
mediated contractions by inhibition of 20-HETE. (Schafer et al., 2010) Additionally, 
Cyp2E1 can generate ROS such as O2- and H2O2 (Lu & Cederbaum, 2008) during the 
“decoupling reaction” (Loida & Sligar, 1993). It is also important to note, that DETC is 
not only inhibiting Cyp2E1 but also is reported to inhibit SOD (Ghanam et al., 1998; 
Karasu, 2000). SOD catalyzes O2- to H2O2. H2O2 is known to be a vasodilator. It can be 
further converted by catalase to H2O and O2 or to •OH by the Fenton (Dikalova et al., 
2001) or Haber-Weiss reaction (Ingelman-Sundberg & Johansson, 1984; Taniyama & 
Griendling, 2003; Kyaw et al., 2004). Additionally, DETC is able to scavenge NO in 
the presence of exogenous and endogenous iron in cells and tissues which leads to an 
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impaired vasorelaxant response due to NO-releasing agonists such as acetylcholine 
(Vedernikov et al., 1992). 
In this present study, vascular function experiments using Cyp2E1-/- mice showed 
that DETC is not a specific Cyp2E1 inhibitor for aortic Cyp2E1, but rather inhibits 
SOD. This suggests that the results obtained with DETC should be interpreted with 
caution.  
4.5.1 Effect of DETC in vascular reactivity of mice fed with diets of different fat 
content 
Inhibition with DETC in aorta of the dietary treatment groups increased 
phenylephrine-induced contractions in the CD group and decreased contractions in the 
HFD and HFD/CD group. It can be speculated that in the CD group O2- is generated and 
immediately converted into H2O2 which possibly dilates phenylephrine-mediated 
contractions. Increased contractions to phenylephrine in the HFD and HFD/CD group 
might be due to decreased O2- production and conversion to H2O2.  
Contrariwise, 5-hydroxytryptamine-induced contractions upon inhibition with DETC 
were decreased by CD and HFD/CD and were unaffected by HFD. It could be that O2- 
is converted into H2O2 and further into •OH. •OH has vasoconstrictor properties in aorta 
of rats (Li et al., 2004). It is possible that increased contractile responses to 5-
hydroxytryptamine in the CD and HFD/CD group involve •OH.  
Endothelium-dependent contractions were reduced in aorta by inhibition with DETC 
in the CD and HFD group but not in the HFD/CD group. It is known that O2- is involved 
in endothelium-dependent contractions and that those contractions can be decreased by 
DETC (Vanhoutte, 2002) The results might implicate that O2- is involved in 
endothelium-dependent contractions in CD and HFD group and that probably high 
amounts of O2- are present in the HFD group. 
 
In this study, changes in vascular reactivity due to dietary treatments are probably 
regulated by involvement of ROS.  
4.5.2  Vascular reactivity in wild type and Cyp2E1-deficient mice 
Results of vascular function experiments obtained with WT and Cyp2E1-/- mice 
showed that phenylephrine-induced contractions are uneffected. This suggests that 
Cyp2E1 plays no role in phenylephrine-mediated contractions in the analyzed 
experimental setting. Schäfer et al. showed that in aorta of diabetic rats Cyp2E1 
expression is upregulated leading to increased levels of 18-and 19-HETE decreasing 
phenylephrine-mediated contractions by inhibition of 20-HETE. (Schafer et al., 2010) It 
is possible that Cyp2E1 is only important in regulation of phenylephrine-induced 
contraction in diseased condition. Interestingly, inhibition with DETC increased 
contractions to phenylephrine in WT and Cyp2E1-/- mice which suggests that O2- levels 
are similar in both groups. It could be speculated that possibly O2- is converted to 
Discussion 
85 
similar levels of H2O2 and that phenylephrine-mediated contractions are controlled by 
dilatory properties of H2O2 in both groups.  
Contractile responses to 5-hydroxytryptamine were decreased in Cyp2E1-/- mice. 
This indicates that Cyp2E1 has an influence on 5-hydroxytryptamine contractions but 
probably not by the involvement of dilatory metabolites. Inhibition of 5-
hydroxytryptamine-induced contractions by DETC decreased only slightly, but 
significant in aorta of WT mice, whereas inhibition in the Cyp2E1-/- mice had no effect. 
This might explain that 5-hydroxytryptamine-mediated contractions are induced by 
generation of O2- through Cyp2E1 which is first converted into H2O2 and finally into 
•OH. •OH may contribute to an increased response to 5-hydroxytryptamine in WT mice.  
Interestingly, acetylcholine-dependent relaxation was impaired in Cyp2E1-/- mice 
compared to WT mice indicating that Cyp2E1 contributes to acetylcholine-induced 
relaxation. A possible explanation would be that acetylcholine not only stimulates the 
release of NO but also activates Cyp2E1 to release 18-and 19-HETE which potentiate 
NO-induced endothelium-dependent relaxation. Interestingly, inhibition with DETC 
impaired acetylcholine-induced relaxation in WT mice (Omar et al., 1991; Vedernikov 
et al., 1992; Karasu, 2000) but no effect was observed in Cyp2E1-/- mice, suggesting 
that DETC either scavenges NO or inhibits SOD thereby increasing O2- levels which 
can also scavenge NO leading to decreased relaxant responses in WT-mice. Since L-
NAME inhibits acetylcholine-induced relaxation in WT and Cyp2E1-/- mice (data not 
shown), it indicates that relaxant responses are NO-dependent in the presence and 
absence of Cyp2E1.  
Endothelium-dependent contractions were enhanced in Cyp2E1-/- mice and were 
completely blocked by non-specific COX-inhibitor meclofenamate. These findings 
implicate that Cyp2E1 decreases endothelium-dependent contractions possibly by 
releasing 18-and 19-HETE which due to their dilatory properties decrease those 
contractions in WT mice. Furthermore, inhibition of endothelium-dependent 
contractions by DETC in WT mice suggests that O2- also contributes to those 
contractions. Moreover, it can be speculated that Cyp2E1 through 18-and 19-HETE 
decreases COX-activity in WT mice, because endothelium-dependent contractions in 
Cyp2E1-/- mice are COX-dependent. Interestingly, endothelium-dependent contractions 
in Cyp2E1-/- mice are not affected by DETC. It proposes that in the absence of Cyp2E1 
endothelium-dependent contractions are not mediated by O2- but that these contractions 
are probably mediated by other factors which stimulate COX.  
 
Taken together, Cyp2E1 modulates vascuar reactivity of aorta from mice possibly 
via ROS and NO availability. 
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4.6 Further directions 
One of the most pivotal follow-up question of the present study is whether in 
Cyp2E1-/- mice vascular function is changed after HFD or HFD/CD compared to control 
mice. Intriguingly, data of an abstract presented by Armoni et al. in June 2011 (Armoni 
et al., 2011) at the American Diabetes Association 71st Scientific Sessions showed that 
Cyp2E1-/- mice fed with a high-fat diet for 8 weeks were protected against obesity and 
had no impaired glucose tolerance compared to wild type mice fed a high fat diet. 
Furthermore, these researchers showed that Cyp2E1 induces insulin resistance via 
oxidative stress and inhibition of Glut4 expression.  
 
To mechanistically understand the role of the oxidoreductase Cyp2E1 in the 
vasculature it will be important to determine in which conditions (i) its vasorelaxent 
products 18- or 19-HETEs are formed or, alternatively, (ii) uncoupling of the catalytic 
process generates ROS. 
 
Another avenue of investigation could be to test whether identified Cyp2E1 splice 
variants are functional. To this end Cyp2E1 splice variants should be cloned to perform 
functional enzyme activity assays. It remains to be determined why Cyp2E1 splice 
variants and not full length version are expressed at protein level in the vasculature. An 
interlocking question could be to test the contribution of the two different isoforms (39 
and 45 kDa) in the regulation of vascular reactivity.  
 
Apart of Cyp2E1 other genes (Car3, Cidec, and Dpp10) were shown to be 
differentially expressed by HFD and HFD/CD feeding. These molecules may also be of 
importance in regulation of vascular reactivity. It warrants further studies to delineate 
their impact on vascular reactivity. 
 
4.7 Conclusion and clinical implications 
In this dissertation, a vascular transcriptome analysis of mice fed with diets 
containing different fat contents was performed. Genes were identified with 
expressional changes that sustain after high-dietary fat content is reduced. One of the 
target genes was Cyp2E1, shown to play a role in regulating vascular reactivity. 
Possible mechanisms by which Cyp2E1 regulates vascular reactivity in aorta involve 
ROS and NO. Based on these data it could be speculated that a downregulation of gene 
and protein expression of aortic Cyp2E1 by HFD and HFD/CD implicates that a 
compensatory mechanism protects from diet-induced changes in the vasculature. An 
upregulation of Cyp2E1 in aortic tissue by HFD and HFD/CD would probably damage 
the vasculature heavily since it is known that increased expression of Cyp2E1 by 
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chronic ethanol consumption leads to generation of oxidative stress which is strongly 
associated with liver injury and subsequently development of alcoholic liver disease 
(Lieber, 1997). Therefore, the results would implicate that alterations in vascular 
reactivity due to HFD and HFD/CD are caused by other ROS producing enzymes than 
Cyp2E1. Furthermore, this interpretation would be strengthened by results of Armoni et 
al. showing that Cyp2E1-/- mice fed with a high-fat diet for 8 weeks were protected 
against obesity and had no impaired glucose tolerance compared to wild type mice fed a 
high fat diet (Armoni et al., 2011). It can be speculated that Cyp2E1-/- mice fed a high-
fat diet would be protected against diet-induced changes in vascular reactivity.  
Obesity is usually associated with a decrease in antioxidant enzymes (Ozata et al., 
2002). Researches showed that impaired endothelium-dependent relaxation in aorta of 
rats due to high-fat diet feeding for 6 months could be preserved after high-fat diet 
feeding supplemented with antioxidants vitamin A and E (Sato et al., 2002). However, 
clinical trials showed that longer treatment with antioxidant vitamins did not improve 
cardiovascular diseases (Forstermann, 2008). On the other hand, treatment with statins 
inhibits endothelial O2- formation and increases expression of eNOS (Forstermann, 
2008). Anti-obesity drugs such as orlistat and sibutramine are successfully used in 
reduction of body weight in obese patients and in improvement of endothelial function 
(Sekuri et al., 2003; Shechter et al., 2006). Important to note is that side effects occur 
using those drugs. For example, sibutramine treatment increases blood pressure 
(McNeely & Goa, 1998). Interestingly, Ozcelik et al. reported that obese patients 
maintained on a hypocaloric diet combined with orlistat treatment and exercise training 
for 12 weeks reduced body weight but also levels of malonaldehyde, a marker for lipid 
peroxidation (Ozcelik et al., 2005). It would be important to develop anti-obesity drugs 
that decrease oxidative stress and specifically target enzymes that produce oxidative 
stress in the vasculature. Another possible therapeutic approach to improve diet-induced 
changes in vascular reactivity due to increased ROS in obese patients and in those who 
were obese would be proteasome inhibition. It is known that proteasome inhibition 
increases expression of antioxidative enzymes and protects against oxidative stress 
(Yamamoto et al., 2007). Recently, it was shown that proteasome inhibitor PS-341 
(Bortezomib, Velcade®) is effective in the treatment of alcohol liver disease (Bardag-
Gorce, 2011). In liver of rats fed with ethanol, antioxidative enzymes were 
downregulated. After treatment with proteosome inhibitor PS-341 expression of 
antioxidant enzymes increased. This suggest that PS-341 is a potential drug for 
treatment of alcoholic liver disease induced by oxidative stress. It would be important to 
test, whether PS-341 treatment in obese patients and those who were obese improves 
diet-induced changes in vascular reactivity.  
An alternative interpretation of the data is as follows: Downregulation of gene and 
protein expression of aortic Cyp2E1 by HFD and HFD/CD is not due to a compensatory 
mechanism to protect the vasculature but rather responsible for diet-induced changes in 
vascular reactivity. This would implicate that aortic Cyp2E1 under physiological 
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condition has a protective role against diet-induced changes in the vasculature. 
Following this interpretation it would be important to increase expression of aortic 
Cyp2E1 in obese patients and in those who were obese. Drugs have to be developed to 
block diet-induced downregulation of Cyp2E1 by manipulation of the transcription 
machinery. This approach might be difficult to implement because Cyp2E1 is a 
multifunctional enzyme and its expression is differently regulated by diseases.  
 
Taken together, these data could provide important information for the development 
of new strategies to treat or prevent obesity-associated pathophysiological changes in 
the vasculature in humans. 
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5 Appendix 
5.1 Oligonucleotide primers used in qRT-PCR for amplification of 
mouse cDNA  
 
Gene Oligonucleotide Forward Primer
Oligonucleotide Reverse Primer
Product Size
(bp)
Car3
Cidec
Cyp2E1
Dgkg
Dpp10
Fkbp5
Fmo3
Lepr
Lyve1
Nrg1
5‘-GGGGGAAAAGTTCAAATGGT-3‘
5‘-CCTGGGATCCTTGAGAAACA-3‘
5‘-CACACTTTGACCCATCATGC-3‘
5‘-AGCTCACAGTCATGGGCTCT-3‘
5‘-GACCTCCTGAACAAGGTCCA-3‘
5‘-ATTGTGCCATCTTCCTCCAG-3‘
5‘-CTCTGAGATATGGGCTCCTGA-3‘
5‘-CAACTGTACCCTTGGGGATG-3‘
5‘-TGAGCACACACCTCTTCCTG-3‘
5‘-CATCTGCTTTGGCAGCATTA-3‘
5‘-GAGGCCAAATGGTGACAGAT-3‘
5‘-CTGGAATCCACTTCCTCTGC-3‘
5‘-GCTGTGGTGGAAGGACATTT-3‘
5‘-CATCTTCACCAGGGCTTTGT-3‘
5‘-GGGAATGAGCAAGGTCAAAA-3‘
5‘-TCAAGTCCCCTTTCATCCAG-3‘
5‘-CATCCCTCGGATTTTCTCAA-3‘
5‘-TCGGATGAGTTGTGGCAATA-3‘
5‘-GAATACGAAACGACCCAGGA-3‘
5‘-GAACTTGGGTTGCTGTCCAT-3‘
129
111
139
134
130
244
80
132
107
104
Actb 5‘-CGTGCGTGACATCAAAGAGA-3‘
5‘-CCCAAGAAGGAAGGCTGGA-3‘
180
Pdk4
P2rx1
5‘-TGACTCAAAGACGGGAAACC-3‘
5‘-ACTGGTCGCAGAGCATCTTT-3‘
5‘-ACTGGGAGTGTGACCTGGAC-3‘
5‘-CAGGTTCTTCTCCCCGTACA-3‘
83
110
NCBI mRNA
Accession Number
NM_007393
NM_007606 
NM_178373  
NM_021282
NM_138650 
NM_199021
NM_010220 
NM_008030
NM_053247
NM_178591 
NM_013743
NM_008771 
NM_001122899 
Exon
Covered by
Primer Pair
Exon 6
Exon 3-4
Exon 7
Exon 4-5
Exon 20
Exon 6
Exon 8-9
Exon 3
Exon 3
Exon 2-3
Exon 5-6
Exon 8
Exon 3
Table 5-1 Oligonucleotide primers used for validation of target genes using qRT-PCR 
Gene symbols, NCBI mRNA accession numbers, nucleotide sequences of the gene specific 
oligonucleotide forward and reverse primers, product sizes of the gene amplicons in basepairs (bp), 
binding position of primer pairs at exons of specific genes are listed. Primer pairs of Cidec, Dgkg, Fmo3, 
Nrg1, and Pdk4 bind between end and start of two exons. 
Appendix 
90 
5.2 Oligonucleotide primers used in Cyp2E1“exon-specific PCR” 
 
 
Cyp2E1
Exon Region
Oligonucleotide Forward Primer
Oligonucleotide Reverse Primer
Product Size
(bp)
5‘-CGTGTTCCGAGGATATGTCA-3‘
5‘-AGGCCTTCTCCAACACACAC-3‘
5‘-TTTCAGCTGGATTTGAAGGA-3‘
5‘-CCTTCCATGTGGGTCCATTA-3‘
5‘-GGGACATTCCTGTGTGTTCCAG-3‘
5‘-GCACAGCCAATCAGAAAGGT-3‘
5‘-CTGGTGGAGGAGCTCAAAAA-3‘
5‘-CTTTTCTGTGGCTTCCAGGT-3‘
5‘-TGGAGCTCATGAGTTTGTTCA-3‘
5‘-ACATGGGTTCTTGGCTGTGT-3‘
5‘-GGGATGTGACTGACTGTCTCC-3‘
5‘-GGCCCAATAACCCTGTCAAT-3‘
5‘-CTCTGAGATATGGGCTCCTGA-3‘
5‘-CAACTGTACCCTTGGGGATG-3‘
5‘-CCTGAGCATTTTCTGAATGAA-3‘
5‘-GGTCTCATGAACGAGGAATGA-3‘
5‘-CCTGAGCATTTTCTGAATGAA-3‘
5‘-GAGCAGTCGGGTGCTCTTAC-3‘
5‘-CCTGAGCATTTTCTGAATGAA-3‘
5‘-GCTGTCTTCAGACACTCCAGAA-3‘
235
435
337
198
244
223
261
217
244
256
5‘-GACCCAGGTGCAGTGTGAA-3‘
5‘-CATCACCGTTGCCTTGCT-3‘ 207
Exon 2
Exon 3
Exon 4
Exon 5
Exon 6
Exon 7
Exon 8
Exon 9/3_Stop
Exon 9/2_3`UTR
Exon 9/1_3`UTR
Exon 1
Table 5-2 Cyp2E1 exon-spanning oligonucleotide primers for identification of Cyp2E1 splice vaiants 
in aorta using PCR 
Table contains Cyp2E1 exon regions, nucleotide sequences of oligonucleotide forward and reverse 
primers and expected PCR product sizes in basepairs (bp). Oligonucleotide forward and reverse primers 
are designed as exon-spanning primers where each primer pair covers one exon. For analyzing exon 9 
three different primer pairs were designed. The forward primer is the same in all three primer pairs. Exon 
9/3_Stop reverse primer binds to the stop codon of Cyp2E1, Exon 9/2_UTR and Exon 9/1_UTR reverse 
primers bind at different positions in the 3`untranslated region of Cyp2E1. 
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5.3 Experimental set up: Investigation of aortic function in mice ex 
vivo 
 
 
ascending aorta
aortic arch
thoracic aorta
descending aorta
abdominal aorta
common iliac
artery
aortic ring
(3 mm)
aortic ring (3 mm)
mounted on tungsten wires
excision of aorta from mouse
and removement of adherent tissue
dissection of thoracic aorta
horizontally into segments
Tissue bath set up
force transducer
Rikadenki recorder
mounting hook
carbogen
(95% O2 + 5% CO2
tissue bath
37°C
H2O
aortic ring
Krebs buffer
pH 7.4, 37°C
wire hooks
drain
37°C
H2O recordings
Figure 5-1 Course of vascular function experiments 
First, the experiment begins with euthanasia of the mouse before aorta is excised and cleaned from 
attached adherent tissue. Then, thoracic aorta is dissected horizontally into aortic rings of 3 mm in size 
before mounted onto tungsten wires and transferred to tissue baths containing pre-warmed Krebs buffer. 
Rings are connected to force transducers which are connected to Rikadenki recorders to plot changes in 
vascular reactivity. 
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5.3.1 Representative recordings of vascular contraction and relaxation curves 
Figure 5-2 Representative recording for contractile and relaxant responses in thoracic aorta 
(A) This graph represents a typical protocol used to investigate phenyleprine-mediated contractions and 
acetylcholine-induced relaxation (B). Contractile responses to phenylephrine and acetylcholine-induced 
endothelium-dependent contraction indicated by a * (C). Contractile response to 5-hydroxytryptamine is 
shown. z indicates the direction of the protocol, x corresponds to 10 min, y to 0.5 g. Vertical arrows 
indicate cumulative concentrations of phenylephrine and acetylcholine (A), (B) , and 5-
hydroxytryptamine (C). 
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5.4 Coverage of exons by probe sets 
 
Table 5-3 Coverage of exons of a gene by probe sets 
Represented are number of probe sets and total number of exons per gene. One exon can be covered by 
more than one probe set. Arrows indicate 5`to 3`direction of the gene. 
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